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CHAPTER 1-INTRODUCTION 
 
1.1 Breast cancer general introduction 
Breast cancer is the most commonly diagnosed cancer and the second leading cause of 
cancer-related mortality among women of all racial and ethnic groups [1]. In 2016, this disease 
accounted for 14.6% of all new cancer cases and 6.8% of all cancer-related deaths [1].  Four 
molecular subtypes of breast cancer have been identified by gene expression analysis. Luminal A 
breast cancers express estrogen receptor (ER) and progesterone receptor (PR), and are negative for 
the human growth factor-neu receptor (HER2/neu). This subtype accounts for 40% of all breast 
cancer and is associated with good  prognosis [2]. Luminal B breast cancers express ER, PR and 
HER2/neu, whereas HER2-enriched breast cancers express only HER2/neu [2]. Both luminal B 
and HER2-overexpressing breast cancers have high expression of proliferation-related genes [2]. 
Lastly, basal-like/triple negative breast cancers do not express ER, PR and HER2/neu, and are 
characterized by high expression of basal cytokeratins [1-3]. Since  breast cancer subtypes 
expressing  ER, PR or HER2/neu  rely on their respective activities for cellular growth, this permits 
the use of receptor targeting therapies  such as tamoxifen and trastuzumab [4]. With the addition 
of targeted therapies, breast cancer death rates have fallen by 1.9% per year for the last three years 
and the overall 5-year survival for breast cancer patients is ~90% [1]. However, basal-like/triple 
negative breast cancers do not express these receptor targets and thus are not suitable for targeted 
therapy. 
1.2 Triple negative breast cancer (TNBC) 
1.2.1 TNBC development and clinical characteristics 
TNBCs comprise 15-20% of all breast cancers [5]. TNBCs have less than 1% of tumor 
cells expressing ER and PR and lacking Her2/neu expression by immunohistochemistry [2, 6]. 
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This subtype of cancer is inherently aggressive and has the worst prognosis. Approximately 80-
90% of TNBCs are poorly differentiated invasive ductal carcinomas [7]. TNBCs are associated 
with a 4-fold increase in risk for distant metastasis, increased lymphocytic infiltration and shorter 
median survival with a 5-year survival rate of only 14% [8]. Unlike non-TNBCs, which commonly 
metastasize to the bone and liver, TNBCs frequently metastasize to the lungs and central nervous 
system [2, 8]. It has also been noted that TNBC patients are diagnosed at a younger mean age and 
are more likely to have large, grade III tumors with high proliferation rates [2, 7]. TNBC is 
associated with obesity, high waist-to-hip circumference ratio, increased parity, and shorter 
breastfeeding duration [2]. This characteristically aggressive disease is also more prevalent in pre-
menopausal African-American women and is the second most common subtype of breast cancer 
in black women of all ages [2]. Additionally, black women have the highest lifetime risk for 
developing TNBC. While a strong association between genetically defined African ancestry and 
TNBC has been established, no genetic alterations or specific loci contributing to this association 
have been identified [2].  
1.2.2 Involvement of breast cancer susceptibility gene in TNBC 
A key event involved in the development of TNBC/basal-like breast cancer is alterations 
in the breast cancer susceptibility (BRCA) genes. Breast cancer susceptibility 1 (BRCA1) gene 
and breast cancer susceptibility 2 (BRCA2) gene mutations account for 20%-25% of hereditary 
breast cancers and 5-10% of all breast cancers [9]. Though both BRCA1 and BRCA2 contribute 
to TNBC development, it has been found that more than 80% of BRCA1 mutation carriers develop 
TNBC while only 15% of BRCA2 mutation carriers develop TNBC [7]. BRCA1 is a 
phosphoprotein that functions as a tumor suppressor. It plays a role in normal breast development 
and is required for conversion of ER-negative cells to ER-positive cells [7]. BRCA1 is involved 
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in DNA repair (via its role in the BRCA-dependent homologous recombination (HR) repair 
pathway) and chromosome segregation during mitosis (via its role in centrosome function) [9-14]. 
Thus, mutations in BRCA1 result in increased genomic instability. Patients with TNBCs harboring 
BRCA1 mutations are often younger at diagnosis and present with higher-grade and higher-stage 
tumors than those without BRCA1 mutations [15, 16]. Patients who present with BRCA1 
mutations are also more likely to have breast cancers with high nuclear grade, invasive ductal 
carcinoma, and a triple negative phenotype [17, 18]. Further, it has been shown that sporadic 
TNBCs show BRCA1 protein dysfunction despite a lack of BRCA1 mutation, resulting in a 
BRCAness phenotype [7].  These data implicate a critical role for BRCA1 in TNBC/basal-like 
breast cancer. 
1.2.3 TNBC subtypes 
While TNBC and basal-like breast cancers share clinicopathological features, including 
aggressive characteristics and mutated BRCA1, these cancers do not completely overlap. Indeed, 
an estimated 20-30% of TNBCs are not basal-like breast cancers [3] and ~54% of basal-like breast 
cancers are not TNBCs [6]. Moreover, gene expression analysis has demonstrated that basal-like 
breast cancers form a homogenous group with similar gene expression profiles whereas this is not 
the case with TNBCs. To date, seven distinct subtypes of TNBC with differential clinical 
characteristics and drug responses have been identified by gene expression analysis of 587 TNBC 
cases in 21 breast cancer datasets [19]. These subtypes include the basal-like 1 (BL1), basal-like 2 
(BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), luminal 
androgen receptor (LAR), and unstable (UNS) subtype. The BL1 and BL2 subtypes are highly 
proliferative with high expression of genes and pathways related to cell cycle and DNA damage 
response (such as the ATR/BRCA1 and Fanconi Anemia pathway). The IM subtype is enriched in 
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gene ontologies for immune cell processes and overlaps with gene signatures in medullary breast 
cancer. The M and MSL subtypes are enriched for genes associated with epithelial to mesenchymal 
transition and stem cell phenotypes, respectively.   The LAR subtype is ER- but is enriched for 
genes linked to androgen receptor-regulated pathways. The UNS subtype is composed of TNBCs 
that do not fall into any category [19]. Under this classification, it was found that most TNBC 
subtypes were composed primarily of the basal-like and mesenchymal intrinsic subtypes (30.8% 
and 28.4%, respectively). It should be noted that although TNBCs and basal-like breast cancers 
are fundamentally different in their gene expression, TNBC takes the place of basal-like breast 
cancers during clinical diagnosis as immunohistochemical analysis of ER, PR, and HER2/neu 
receptor status is more cost effective than gene expression analysis. 
1.2.4 Therapeutic options in TNBC 
As TNBCs lack the traditional therapeutic targets found in breast cancer they are currently 
treated with broad range chemotherapies. The standard chemotherapeutic regimens for TNBC 
patients include taxanes (microtubule stabilizers) and/or anthracyclines (topoisomerase II 
inhibitors) [3]. While this regimen achieves a pathologically complete response in 20-45% of 
TNBC patients, it is also associated with increased incidences of leukopenia, anemia, 
thrombocytopenia, nausea, pharyngitis and cardiotoxicity when compared to monotherapy in 
metastatic breast cancer patients [3, 20]. Additionally, it has been found that TNBCs demonstrate 
significantly higher clinical response rates to neoadjuvant therapy when compared to luminal type 
breast cancers. However, the incidence of residual disease, relapse, and death is also increased 
[21].  Interestingly, it has been noted that TNBCs with BRCA1 mutations or BRCAness 
demonstrate significantly lower response rates to taxanes than TNBCs with wild type BRCA1, 
implicating a role for BRCA1 in TNBC drug response [22]. 	
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In addition to taxanes and anthracyclines, therapies targeting the specific weaknesses of 
TNBCs are currently being investigated. It has been noted that TNBCs are highly vascularized to 
support their rapid proliferation rate. Thus, expression of angiogenesis-related genes and vascular 
endothelial growth factor are common in this subtype [3]. The addition of the angiogenesis 
inhibitor bevacizumab to the standard TNBC treatment regimen improved the pathologically 
complete response rates in TNBC patients but did not improve long-term outcomes [3].  Further, 
systemic toxicity resulted in the withdrawal of approval for bevacizumab treatment in advanced 
breast cancer [2]. Another weakness of TNBCs is the expression of the androgen receptor. As the 
luminal androgen receptor (LAR) subtype of TNBC constitutes about 25-35% of TNBCs anti-
androgens are being investigated as a therapeutic option [3]. Studies have shown monotherapy 
with the anti-androgens bicalutamide and enzalutamide moderately impacted TNBC outcome, 
reaching a clinical benefit rate (CBR; complete response, partial response, and stable disease) of 
35% and 16% respectively [3, 23]. About 10% of TNBCs display activating mutations in 
phosphoinositide 3-kinase (PIK3CA). While inhibition of mTOR, a critical component of the 
PIK3CA pathway, showed synergy with the platinum-based compound carboplatin in TNBC cell 
lines, clinical studies show a modest CBR of 36% and associated systemic toxicity [24]. The 
epidermal growth factor receptor (EGFR) is found to be expressed in 54% of TNBCs leading to 
the clinical investigation of EGFR inhibitors. However, in phase II clinical trials, the response rate 
to the EGFR inhibitor cetuximab was only 6% and was modestly increased to 17% in combination 
with carboplatin [25].   
Therapies targeting the observed DNA repair defects due to BRCA1 mutations or 
BRCAness in TNBCs are also being investigated under the premise of synthetic lethality. 
Synthetic lethality is observed when two drugs alone modestly impact viability but in combination 
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result in death. TNBCs with BRCA1 mutations or BRCAness show decreased double strand break 
(DSB) repair via homologous recombination repair (HR). Thus, poly ADP-ribose polymerase 
(PARP) inhibitors are of interest. PARP functions to repair single strand breaks (SSB) in the DNA 
through the base excision repair pathway and inhibition of PARP results in DSB formation. Cells 
with BRCA1 mutations or BRCAness are unable to repair these DSBs and undergo cell death [2]. 
While in vitro experiments demonstrated that TNBC cells were more sensitive to PARP inhibition 
both singly and in combination, a phase II clinical study of the PARP inhibitor olaparib as a 
monotherapy in pretreated metastatic TNBC showed no response [2]. Additionally, the specificity 
and mechanism of action of PARP inhibitors are not well established leading to skepticism.  
Platinum-based compounds are also of interest in TNBCs with BRCA1 mutations or 
BRCAness. Platinum-based compounds induce DSBs by generating interstrand crosslinks that 
result in replication fork stalling. In phase II clinical studies with the platinum drugs cisplatin and 
carboplatin, an overall response rate of 25% was achieved [6]. This was increased to 54% when 
examining the response of BRCA1 mutated patients alone [6]. It has been noted that platinum 
agents should be administered in combination to improve response and survival [8].  
Though broad range chemotherapies have been shown to have some therapeutic benefit in 
TNBCs, their therapeutic spectrum is constrained by systemic toxicity, heterogeneous gene 
expression, and BRCA1 status.  
1.3 Rad6: A fundamental component of postreplication DNA repair or translesion DNA 
synthesis 
1.3.1 Role of Rad6 in DNA damage tolerance	 
Rad6 (UBC2) is one of the several genes found to increase ultraviolet (UV) light sensitivity 
and reduce sporulation in Saccharomyces cerevisiae [26]. Rad6 is a member of an epistatic group 
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of proteins including Rad8, Rad9, Rad15, Rad18, Rev1, Rev2, and Rev3 [27, 28]. Analysis of UV 
sensitivity and UV-induced mutagenesis in yeast mutated in these genes revealed that these 
proteins function in error-prone DNA repair. Yeast carrying defective Rad6 also exhibited 
hypersensitivity to UV light and had the lowest frequency of UV-induced mutagenesis [29],  
implicating an epistatic relationship between these repair genes and  a central role for Rad6 in 
error-prone DNA repair.  
Sedimentation of UV-irradiated DNA pulse-chased with either radioactive or non-
radioactive uracil from Rad1 mutant yeast defective in nucleotide excision revealed a conversion 
of low molecular weight DNA to high molecular weight DNA by 4 h post irradiation [30]. This 
implicates a DNA damage tolerance pathway capable of the completing replication in the presence 
of pyrimidine dimers referred to as postreplication repair. Treatment with cycloheximide reduced 
the extent of repair, indicating this pathway is inducible and requires the production of newly 
synthesized proteins for activity [30]. In contrast to Rad1 mutants, Rad6/Rad1 double mutants 
were blocked in this repair, revealing a role for Rad6 in the bypass of DNA lesions in a damage 
induced survival mechanism [30]. In contrast, when yeast mutant in Rev3, a gene epistatic to Rad6 
and deficient in UV-induced mutagenesis, was crossed with Rad1 mutants postreplication repair 
still occurred [30].  These data suggest that the mutagenic capacity of Rad6 is not required for 
DNA damage tolerance and thus most of this repair is error free. 
1.3.2 Functional role for Rad6 in recombination 
In addition to the role of Rad6 in UV light response via its role in error-free and error-prone 
DNA damage tolerance, Rad6 mutants also demonstrated an inability to sporulate. Rad6 null yeast 
expressing genetic markers for the study of meiotic recombination and haploidization were used 
to investigate the role of Rad6 in sporulation [31]. Exponentially growing yeast cultures were 
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transferred to liquid sporulation medium and plated on selective growth plates at different intervals 
during sporulation. Using this system Rad6 wild type yeast produced colonies expressing the 
genetic markers for meiotic recombination and haploidization while Rad6 null yeast were unable 
to sporulate and could not produce these colonies in selective medium  [31]. Together these data, 
indicate loss of Rad6 blocks sporulation via its role in meiotic recombination [31].  
In contrast to the role of Rad6 in meiotic recombination, Kern et. al. found that loss of 
Rad6 enhanced both spontaneous and mutagen-induced mitotic recombination again using 
selective growth plates [32]. Support for a role of Rad6 in recombination was further obtained 
using alkaline sucrose gradients and neutral sucrose gradients for DNA sedimentation assays to 
detect MMS-induced SSB and DSB, respectively [33]. It was shown that Rad6 mutants exhibited 
extreme sensitivity to MMS and this sensitivity was not associated with DSBs, as MMS did not 
induce DSBs at the doses used. These data indicate an inability of Rad6 mutant yeast to repair 
SSBs resulting in increased sensitivity [33]. Further, sedimentation of pulse labeled DNA at 
various time points post-MMS treatment revealed that loss of Rad6 prevented the conversion of 
low molecular weight DNA to high molecular weight DNA  in the presence of DSBs [33].  
Together these data show that Rad6 mutant yeast are unable to facilitate single-strand rejoining 
and DSB repair, both processes involved in recombinational events.  Moreover, this implicates a 
requirement for Rad6-dependent SSB repair prior to DSB repair [33].  
The roles for Rad6 in mitotic and meiotic recombination were validated by examining the 
effects of Rad6 loss on spontaneous and UV-induced homologous and unequal sister chromatid 
mitotic and meiotic recombinations using selective growth plates [34]. These analyses showed that 
while the loss of Rad6 resulted in an enhancement of spontaneous and UV-induced homologous 
and sister chromatid mitotic recombination, meiotic recombination and sporulation were abrogated 
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[34]. These data demonstrate that the Rad6 pathway and recombination pathway are intimately 
connected. This supports the role of Rad6 in repair and suggests a role for Rad6 function in 
recombination during the G1 phase of the cell cycle [34].  
1.4 Rad6 and the cell cycle	 
The role of Rad6 in cell cycle progression was analyzed by measuring the incorporation of 
radioactive precursors into the DNA of yeast cells synchronized in G1 [35]. This analysis revealed 
that while radioactive incorporation in wild type cells occurs immediately post synchronization 
and last 40 minutes, Rad6 mutant cells demonstrated a 40-minute lag period before initiation of 
DNA synthesis which lasted 80 minutes [35]. The length of G2/M phase was observed to be 40 
and 20 minutes for Rad6 wild type and Rad6 mutant yeast, respectively, [35]. These analyses 
revealed that Rad6 mutant yeast experienced prolonged G1- and S-phases and a reduced G2/M 
phase when compared to wild type cells, implicating cell cycle control of Rad6 [35]. Additionally, 
Rad6 deleted yeast resulted in slowed growth, reduced plating efficiency, and an increased 
proportion of cells showing characteristics indicative of defective nuclear division and DNA 
synthesis [36]. These data suggest an elongation of the cell cycle, particularly late-S phase [36].  
Rad6 mRNA expression during the cell cycle was investigated using cell division cycle 
mutant yeast known to arrest at various stages in the cell cycle at a restrictive growth temperature 
or wild type yeast treated with hydroxyurea or MMS [37]. This analysis revealed an increase in 
Rad6 mRNA levels at the beginning of S-phase, peaking in late S-/G2-phase of the cell cycle [37].  
Additionally, a drastic drop in the Rad6 mRNA level was observed between samples, indicating 
Rad6 mRNA has a short half-life [37].  
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1.5 Rad6 protein characteristics 
 Nucleotide sequencing of the yeast Rad6 gene revealed that Rad6 protein is 172 amino 
acids long (predicted molecular weight of 19.7 kDa ) and consists of 20 basic residues (9 lysine, 8 
arginine, and 3 histidine residues) and 40 acidic residues (28 aspartic acids and 12 glutamic acid 
residues), with 20 of the 23 terminal amino acids being acidic, including 13 consecutive aspartates 
[38]. 	Using deletion mutations, the function of the acidic tail was determined. Yeast with a 
truncated Rad6 protein, lacking the acidic tail, demonstrated equivalent levels of UV sensitivity 
and UV-induced mutagenesis as Rad6 wild type yeast [39]. However, yeast lacking the acidic tail 
of Rad6 were blocked in meiotic function, as measured by sporulation, identifying a specific role 
for the polyacidic tail in sporulation [39].  
1.6 Human homologs of Rad6 
 Using extracts from human placenta a 17 kDa protein was isolated [40]. 
Comparison of a deduced portion of the 17 kDa  protein nucleotide sequence with known protein 
sequences identified the yeast Rad6 protein as having 69% identical amino acids [40].  This 
increased to 84% with the inclusion of conservative amino acid replacements [40].  
The most conserved region between yeast and human Rad6 is the N-terminal sequence in 
which the first 15 residues are identical [40]. This region is found to be conserved among all the 
homologs of Rad6 [40]. Taking advantage of the homology of Rad6 seen in eukaryotes, a human 
lambda cDNA library was screened with Rad6 probes prepared from Drosophila melanogaster 
and Schizosaccharomyces pombe yeast [41]. This screening identified two Rad6 genes, 
HHR6A/UBE2A/Rad6A (Human homolog of Rad6) and HHR6B/UBE2B/Rad6B [41]. 
Interestingly, northern blot analysis using HeLa cell RNA and representative Rad6A and Rad6B 
cDNAs revealed that the Rad6A probe detected two transcripts of 1.7 and 0.8 kB, while the Rad6B 
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probe detected a transcript of 4.4 kB. Sequence analysis of the two Rad6A transcripts determined 
that the transcripts were identical and the difference seen was due to alternative polyadenylation 
site selection [41].  
Comparison of the coding sequences of Rad6A and Rad6B showed both proteins are 152 
amino acids long with molecular weights of 17.2 kDa and 17.3 kDa, respectively [41]. 
Additionally, the two proteins share 95% identity in their amino acid sequence [41]. At the 
nucleotide level, the proteins share 80% identity with the difference being found in the 5’ and 3’ 
untranslated regions [41]. While Rad6A and Rad6B share 80% nucleotide sequence identity and 
95% amino acid sequence identity, they are localized to different regions of the genome and 
display different mutant phenotypes [42-44]. Rad6A is localized to Xq24-25 and Rad6B is 
localized to 5q23-31 [42]. Both Rad6A and Rad6B lack the polyacidic tail seen in Saccharomyces 
cerevisiae, and share approximately 70% sequence identity with yeast Rad6 [41]. Rad6 mutant 
yeast expressing Rad6A or Rad6B displayed UV resistance and UV-induced mutagenesis like that 
of Rad6 wild type yeast [41]. However, Rad6A and Rad6B expression had no impact on 
sporulation [41]. This indicates that while there are functional similarities between the human and 
yeast Rad6 protein, all yeast data cannot be strictly extrapolated.  
Much like humans, mice are found to have two copies of the Rad6 gene [42]. Additionally, 
the amino acid sequence of Rad6A and Rad6B are completely conserved between mouse and 
human [43].  Mouse embryo fibroblasts from mHR6A knockout mice displayed normal DNA 
repair, presumably from the redundant function of mHR6B, however, these mice had overall 
reduced body weight compared to wild type and mHR6B knockout mice [43]. Male mHR6A -/- 
mice were fertile, whereas female mHR6A-/- mice were unable to produce offspring [43]. While 
there was no dysfunction in the ovaries or one-cell embryos of mHR6A-deficient mice compared 
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to wild type mice, the embryos isolated from mHR6A-deficient mice experienced developmental 
arrest after the first embryonic cell division and were unable to mature to the blastocyst stage [43]. 
Similarly, fibroblasts derived from mHR6B knockout mice did not display DNA repair defects, 
likely due to the redundant function of mHR6A [44]. In contrast to the mHR6A knockout mice, 
loss of mHR6B did not affect female fertility but impaired male fertility [44]. Specifically, at least 
70% of the spermatozoa had abnormal head morphology and the remaining spermatozoa 
demonstrated severely retarded motility [44]. In conjuntion with the role of mHR6B in 
spermatogenesis, mHR6B protein levels were elevated in elongated spermatids and spermatozoa 
[45]. 
Mouse studies also revealed that a double knockout of mHR6A and mHR6B proved 
embryonically lethal, as there is no compensatory expression of the remaining gene  [43].  Together 
these studies show that while there is some functional redundancy between Rad6A and Rad6B, 
there are also differences in function as well as gene regulation.  
1.7 Rad6: an E2 ubiqutin-conjugating enzyme 
Rad6 is  an E2 ubiquitin-conjugating enzyme that shows selectivity for  ubiquitination of 
histones H2A and H2B [46]. This discovery provides the first connection between the 
ubiquitination system and DNA repair. 
 1.7.1 Ubiquitination cascade	 
Ubiquitin is an 8.5 kDa protein whose covalent attachment can alter protein stability, 
function, and localization [47, 48].  The ubiquitination process (Figure 1.1) begins with the 
adenylation of ubiquitin by an E1 ubiquitin-activating enzyme. The E1 and ubiquitin then form a 
thioester bond between the thiol group of an active site cysteine residue on the E1 and the carbonyl 
group of the C-terminal glycine residue of ubiquitin. The activated ubiquitin is then transferred to 
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FIGURE 1.1 Ubiquitination cascade. In an ATP dependent process E1 ubiquitin-activating 
enzymes adenylate ubiquitin and form a thioester bond between the thiol group of a cysteine 
residue on the E1 and the carbonyl group of the C-terminal glycine residue of ubiquitin. The 
activated ubiquitin is then transferred to an E2 ubiquitin-conjugating enzyme and forms a 
thioester intermediate with the E2 enzyme. The E2 enzyme either transfers the ubiquitin to an 
enzymatically active HECT-domain E3 ubiquitin ligase or directly transfers the ubiquitin to the 
target substrate, in complex with an enzymatically inactive RING finger E3 ubiquitin ligase. 
Notably, monoubiquitination and Lys63 linked polyubiquitination (>4 ubiquitin moieties)  
facilitate protein involvement in DNA repair, signal transduction, and trafficking/sorting of 
membrane proteins, while Lys48 linked polyubiquitination promotes proteosomal degradation. 
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an E2 ubiquitin-conjugating enzyme via a trans-thioesterification reaction and forms a thioester 
intermediate with the E2 enzyme. The E2 enzyme either transfers the ubiquitin to an enzymatically 
active HECT-domain E3 ubiquitin-ligase, which then ubiquitinates the target substrate, or directly 
transfers the ubiquitin to the target substrate, with support from an enzymatically inactive RING 
finger E3 ubiquitin-ligase [47, 49]. The ubiquitin moiety is covalently attached to the target 
substrate through a peptide bond between the carbonyl group of the terminal glycine on ubiquitin 
and the amino group of the target lysine in the substrate [50]. It should be noted that most 
ubiquitination occurs on lysine residues, as these residues possess an epsilon-amino group that can 
bind with ubiquitin. Additionally, ubiquitin itself possesses seven lysine residues (Lys6, Lys11, 
Lys27, Lys29, Lys33, Lys48 and Lys63) that can be further ubiquitinated [49]. Substrates can be 
monoubiquitinated (attachment of a single ubiquitin), multi-monoubiquitinated (attachment of a 
single ubiquitin to multiple substrate lysine residues), or polyubiquitinated (formation of a 
ubiquitin chain on a single substrate lysine residue) [49]. Polyubiquitin chains can either be an 
open conformation chain, in which the ubiquitin moieties do not interact with each other aside 
from their covalent peptide bond, or a closed conformation chain, in which ubiquitin moieties have 
interfaces with interacting residues [47].  The effect of ubiquitination on a target substrate is 
determined by the type of ubiquitination and chain conformation, as well as the ubiquitin lysine 
residue on which the polyubiquitin chain is formed [47]. Notably, monoubiquitination and Lys63 
linked polyubiquitination facilitate protein involvement in DNA repair, signal transduction, and 
trafficking/sorting of membrane proteins, while Lys48 linked polyubiquitination (>4 ubiquitin 
moieties) promotes proteosomal degradation [49]. 
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1.7.2 Rad6 enzymatic activity is critical for its cellular function 
To investigate the importance of ubiquitination in the function of Rad6 the sole cysteine 
(Cys-88) residue was mutated to an alanine or valine, residues that cannot accept ubiquitin and are 
least likely to disrupt the protein conformation of Rad6 [51]. Comparison of the ubiquitin 
conjugating activity of Rad6 Ala-88, Rad6 Val-88, and wild type Rad6 revealed an inability of 
Rad6 Ala-88 and Rad6 Val-88 mutants to form ubiquitin-conjugates as well as catalyze the 
ubiquitination of histones H2A and H2B [51].  Using Rad6 depleted yeast engineered to 
overexpress either wild type Rad6, Rad6 Ala-88, or Rad6 Val-88 it was demonstrated that yeast 
overexpressing ubiquitin null Rad6 mutants displayed similar phenotypes to Rad6 null yeast in 
regards to defects in DNA repair, mutagenesis, and sporulation, indicating the role of Rad6 in these 
cellular processes is due entirely to its E2 ubiquitin-conjugating activity [51]. Thus, the ability of 
Rad6 to regulate multiple cellular functions is attributed to its role in ubiquitination and its 
interaction with different E3 ubiquitin-ligases. 
1.8 Rad6 E3 ubiquitin-ligase binding partners     
1.8.1 Ubr1: ‘N-end’ rule 
An important determinant for recognition of proteolytic substrates by the ubiquitin-
conjugating system is the ‘N-end’ rule, which relates the metabolic stability of a protein to the 
identity of its amino-terminal residue [52]. Using Escherichia coli b-galactosidase derivatives with 
known N-terminal degradation signals (N-degrons), it was found that loss of Rad6 stabilized these 
normally short-lived proteins, implicating a role for Rad6 in ‘N-end’ rule proteolytic degradation 
[52]. The N-end rule in Saccharomyces cerevisiae is mediated by the RING finger E3 ubiquitin-
ligase Ubr1 [52]. The high similarity between the yeast and human Rad6, particularly in the N-
terminal region, dictates a role for human Rad6 in ‘N-end’ rule degradation. Indeed, studies on 
16	
	
human Rad6 revealed phosphorylation of Rad6 mitigated its ability to complete ‘N-end’ rule 
degradation in a Ubr1 dependent process [53]. 
1.8.2. Bre1: histone ubiquitination 
Histone ubiquitination has been shown to modify chromatin structure permitting 
transcription and other chromosomal processes, such as meiosis. Due to the role of the Rad6 acidic 
tail in meiosis/sporulation, the ability of the polyacidic tail to mediate histones H2A and H2B 
ubiquitination was examined [54]. Using yeast engineered to express wild type Rad6 or Rad6 
mutants lacking various lengths of the polyacidic tail it was found that wild type Rad6 is capable 
of mono- and poly-ubiquitinating histones H2A and H2B. However, loss of the polyacidic tail 
greatly reduced monoubiquitinations of histones H2A and H2B and completely abolished 
polyubiquitination of these histones [54]. To identify the E3 ubiquitin-ligase required for histone 
H2B ubiquitination Wood et. al. tested non-essential yeast gene deletion mutants for methylation 
of histone H3. This analysis uncovered the RING finger E3 ubiquitin-ligase Bre1. Physical 
interaction of Bre1 with Rad6 in vivo was determined by affinity purification with tandem affinity 
purification-tagged Bre1 and tagged-Rad6. It was found that Rad6 co-purified with Bre1 and this 
interaction was required for histone H2B monoubiquitination as deletion of Rad6 or Bre1 resulted 
in the loss of H2B monoubiquitination [55].   
Though neither Rad6A nor Rad6B possess the polyacidic tail seen in yeast Rad6, pull-
down experiments revealed that Bre1 associated with both Rad6A and Rad6B [56]. Additionally, 
ubiquitin-conjugating assays using oligonucleosomes revealed Rad6 mediated ubiquitination of 
histone H2B solely in the presence of human Bre1 [56]. 
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1.8.3 Rad18: DNA damage repair 
Rad18 is a member of the Rad6 epistatic family and Rad18 mutant yeast display UV 
sensitivity and reduced postreplication repair. Nucleotide sequence analysis revealed the Rad18 
gene encoded a protein with three zinc finger domains capable of binding DNA [57]. This suggests 
that Rad18 may function to localize Rad6 to the site of DNA damage. In concordance with this 
model, coimmunoprecipitation analysis determined that Rad18 and Rad6 directly interact [58].  In 
yeast overexpressing Rad6 and Rad18, these proteins could be co-purified, indicating they exist as 
a heterodimer [59].  Dot blotting technique was used to examine the ability of purified Rad18 and 
Rad6 proteins to bind 32P-labeled linear double-stranded or single-stranded DNA [58]. While 
neither Rad6 nor Rad18 could bind double-stranded DNA, Rad18 was efficient in binding single-
stranded DNA [58]. This implicates a requirement for Rad18 in localizing Rad6 to the site of DNA 
damage. Ubiquitin conjugation assays demonstrated that while Rad6 is capable of ubiquitinating 
histone H2B alone, the interaction of Rad18 with Rad6 did not disrupt this function and the 
Rad6/Rad18 heterodimer was able to conjugate ubiquitin to histone H2B [59]. Together these data 
indicate that the repair function of Rad6 is associated with its interaction with Rad18.  
1.9. Rad6/Rad18-mediated regulation of postreplication repair 
Initiation of postreplication repair relies on the ubiquitination of Pol30 (proliferating cell 
nuclear antigen; PCNA) by Rad6/Rad18. Pulldown with anti-PCNA antibody and probing with 
anti-ubiquitin antibody showed that PCNA mono- and poly-ubiquitination was MMS-inducible 
and was absent in Rad6 mutants [60]. Additionally, experiments performed with PCNA mutants 
for various lysine residues showed that the ubiquitin modification occurred on Lys164 [60]. 
Phenotypic analysis revealed that PCNA-Lys164R mutants are sensitive to UV and MMS [60], 
and that PCNA mutation  is epistatic to Rad6, as PCNA/Rad6 double mutants are not more UV-
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sensitive than Rad6 single mutants [61]. These data indicate that Rad18 recruits Rad6 to the site 
of DNA damage, through its single strand DNA binding ability, and facilitate Rad6 mediated 
mono- and poly-ubiquitination of PCNA and subsequent postreplication repair. Further 
investigation into Rad6/Rad18 mediated modification of PCNA revealed that the type of PCNA 
ubiquitination regulated activation of the Rad6 error-prone and error-free repair pathways. 
1.9.1 PCNA polyubiquitination: error-free DNA repair 
 It was found that PCNA polyubiquitination is facilitated by Mms2, a ubiquitin-conjugating 
enzyme-like protein, in complex with Ubc13 [60]. Mms2, Ubc13 and Rad5 have all been shown 
to be epistatic to Rad6 in UV-sensitivity, however mutation in these genes did not impair UV-
induced mutagenesis in yeast, indicating a role for these genes in error-free repair [62-64]. 
Additionally, the Mms2/Ubc13 complex is required to mediate Lys63 linked PCNA 
polyubiquitination, a post-translational modification that enables error-free repair [62]. Similarly, 
to the Rad6/Rad18 relationship, Mms2/Ubc13 is guided to the site of DNA damage by the RING 
finger E3 ubiquitin-ligase Rad5 [65]. These data support a model in which Rad6/Rad18 interact 
with Mms2/Ubc13/Rad5 to cooperatively polyubiquitinate PCNA and initiate error-free repair.  
This model is supported by the finding that while Rad6 and Rad18 deletion inhibited both mono- 
and poly-ubiquitination of PCNA, deletion of Ubc13, Mms2, and Rad5 prevented only poly-
ubiquitination of PCNA [60]. 
1.9.2. PCNA monoubiquitination: translesion synthesis (TLS) 
Interestingly, the Rad6 error-prone repair pathway also relies on the ubiquitination of 
PCNA. However, this pathway is regulated by PCNA monoubiquitination and involve Rev3 and 
polymerase eta (Pol h), both of which are epistatic to Rad6  [66]. Rev3 dimerizes with Rev7 to 
form polymerase zeta (Pol z), with Rev3 encoding for the catalytic subunit [63]. Unlike replicative 
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DNA polymerases, which are high fidelity due to their 3’-5’ proofreading activity, Pol z and Pol 
h are low fidelity and low speed TLS polymerases [67].  Pol z has been shown to replicate past 
thymidine dimers more efficiently than replicative polymerases, during TLS. However, this repair 
is error prone, as Rev3 mutant yeast demonstrate a reduction in both spontaneous and DNA 
damage-induced mutagenesis with no loss of postreplication repair [63]. During this repair, Pol z 
functions by error-prone extension from the nucleotide opposite a variety of lesions or mismatches 
[66].  
Pol h, in contrast to Pol z, participates in error-free postreplication repair. Similarly, to 
Rev3 mutant yeast, yeast with Pol h mutation demonstrates modest UV-sensitivity, indicating 
epistasis with Rad6 [68]. However, there is no reduction in mutagenic capacity indicating that 
polymerase eta operates in an independent error-free repair pathway [68]. Further characterization 
of Pol h revealed its ability to efficiently and accurately replicate past certain lesions, such as cis-
syn thymine-thymine dimers. However, it was shown that in response to other lesions, Pol h 
requires Pol z for lesion bypass [69]. In this mechanism, Pol h can insert a nucleotide opposite the 
damage and DNA extension occurs in a Pol z  dependent manner [69]. Thus, TLS is carried out 
by low fidelity polymerase and the monoubiquitination of PCNA increases its affinity for these 
low fidelity polymerases at the damage site allowing for a polymerase switch [70].  
Two models have been proposed to describe the mechanism of polymerase switching. In 
the first model, high fidelity polymerases stall at the DNA damage site, which facilitates PCNA 
monoubiquitination and recruitment of low fidelity TLS polymerases at the site to fill the gap [71]. 
These polymerases continue replication through the DNA lesion. Once the damaged portion is 
replicated, the low fidelity polymerases are switched back to replicative polymerases [71]. In the 
gap filling model, the high fidelity PCNA-replicative complex dissociates at the site of damage 
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and reassembles after the DNA lesion. These processes are not mutually exclusive and both may 
be used during TLS. 
1.10. Rad6-mediated post replication repair in humans	 
 In addition to Ubr1 and Bre1, a human Rad18 homolog was found [72]. The human 
Rad18 gene encodes a protein ~54kDa and shows 26% amino acid identity with yeast Rad18 [72]. 
Further, yeast two-hybrid experiments reveal that human Rad18, much like Bre1, interacts with 
both Rad6A and Rad6B [72]. Rad18 is ubiquitously expressed in human tissues [72]. As Rad6 and 
Rad18 both participate in TLS in yeast, the identification of these genes in humans revealed the 
potential for these repair pathways to be active in human cells. This speculation is supported by 
the fact that many yeast proteins involved in these processes have human homologs, including Pol 
h, Rev3, Mms2-Ubc13, and the human homologs of Rad5, HTLF and SHPRH.  
However, there are differences between the yeast repair mechanism and that of human 
cells. In humans, Rad6/Rad18 mediated monoubiquitination of PCNA is the major modification 
of PCNA in mammals (Figure 1.2). PCNA polyubiquitination has been reported in response to UV 
irradiation and other DNA damaging agents, however, it occurs at a rate ~20-fold lower than 
PCNA monoubiquitination [71].  PCNA polyubiquitination predominantly occurs via en bloc 
transfer of pre-formed ubiquitin chains rather than by extension of the ubiquitin chain on 
monoubiquitinated PCNA [73]. Here HTLF initially forms a thiol-linked ubiquitin chain on 
Ubc13, which is then transferred to Rad6~ubiquitin to form Rad6~ubiquitinn+1. The resultant chain 
is subsequently transferred en bloc to PCNA by Rad18 [73]. In humans, as seen in yeast, 
polyubiquitinated PCNA is implicated in error-free damage avoidance pathway, although the 
details of the mechanism remain to be established [71]. It is, however, believed that it involves the 
release of the stalled primer end from the damaged template and annealing with the newly 
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FIGURE 1.2. Rad6-mediated postreplication repair. In response to DNA damage 
Rad6/Rad18 facilitate the mono- and poly-ubiquitination of PCNA promoting either TLS 
or template switching, respectively. It should be noted that in human cells 
monoubiquitination of PCNA (and subsequent TLS activation) is the major PCNA 
modification. Additionally, polyubiquitination of PCNA require the activities of 
Ubc13/HTLF/SHPRH. 
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synthesized daughter strand of the sister chromosome [74]. This use of sister duplex information 
ensures an error-free process by preventing accumulation of mutations in the replicated strand  
[71]. 
Additionally, it was found that human Xeroderma pigmentosum variant (XP-V), a genetic 
disorder associated with increased risk of melanoma, was dissimilar to other characterized 
xeroderma pigmentosum disorders as these variant cells are capable of nucleotide excision, but 
lacked a functional Pol h [75]. This disease revealed a prominent role for translesion synthesis in 
DNA repair and cancer development.   
1.11 Rad6 expression in breast cancer 
In our laboratory, we used a genetically related mouse mammary metastasis model system 
to examine differentially displayed cDNAs associated with disease aggression [76]. This model is 
comprised of five genetically related sister sub lines (67, 168FAR, 66cl4, 4T07, and 4T1) that 
differ in their metastatic propensities [76]. Isolation and sequence analysis of the transcript 
upregulated in the most metastatic subline 4T1 identified Rad6B [76]. RT-PCR analysis showed 
15-fold higher levels of Rad6B mRNA in 4T1 cells as compared to the nonmetastatic derivatives 
[76].  To evaluate expression of Rad6 protein, we developed a Rad6 antibody that recognizes an 
amino acid sequence that is 100% conserved in Rad6B and 91% conserved in Rad6A [76]. Thus, 
this antibody cannot distinguish between the two paralogs.  To translate these findings to human 
breast cancer, we analyzed Rad6 protein expression in normal (MCF10A), premalignant 
(MCF10AT), DCIS (MCF10ADCIS.com), tumorigenic (MCF-7) and metastatic (MDA-MB-231) 
breast cells [76]. Immunostaining of Rad6 in clinical breast tissues revealed intense nuclear Rad6 
staining in DCIS and invasive lesions compared to weak cytoplasmic staining in normal breast 
epithelium [76]. Rad6B overexpressed in breast cancer cells is wild type and efficiently 
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ubiquitinates histone H2A or H2B demonstrating its functional activity [76]. These data 
demonstrate that expression of Rad6B correlates with aggressive breast cancer phenotype.  
To evaluate the role of Rad6B in breast cancer, we stably transfected MCF10A breast 
epithelial cells with a Rad6B expression construct engineered to constitutively overexpress Rad6B. 
Rad6B overexpressing cells exhibited increased nuclear pleomorphism, including multinucleation 
(potentially resulting from abnormal mitosis and cell-cell fusion), and aneuploidy [76]. Due to the 
intimate relationship between Rad6B overexpression and mitotic defects, the effect of Rad6B 
overexpression on centrosomes (cellular organelles which function during mitosis to ensure equal 
DNA division) was investigated. Centrosome-specific immunolabeling with anti-g-tubulin 
antibodies showed overexpression of Rad6B induced centrosome amplification [76]. Parental 
MCF10A cells (98%) were found to have two or three centrosomes, while Rad6B overexpressing 
cells (~25%) displayed more than four centrosomes [76].  Further analysis revealed that Rad6 co-
localized with g-tubulin at all phases of the cell cycle, implicating a strong association between 
Rad6 expression and centrosome function [76]. The ability of Rad6B overexpression to promote 
anchorage-independent growth, an indicator of transformation from a normal cell to a 
paraneoplastic cell, in MCF10A was determined with soft-agar assays [76]. Whereas parental 
MCF10A cells failed to form anchorage-independent colonies in soft agar, Rad6B overexpressing 
MCF10A cells could form colonies with 10-40% efficiency [76]. These data demonstrate a role 
for Rad6B in genomic stability and malignant transformation in breast cancer. 
To determine if Rad6 has a chemoprotective role, Rad6B was overexpressed in MCF10A 
cells. The overexpression of Rad6B enhanced cisplatin and Adriamycin (ADR) resistance in 
MCF10A cells, a phenomenon that was reversed with transfection of antisense Rad6B [77]. That 
this enhanced chemoresistance was due to the role of Rad6 in postreplication repair was verified 
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by DNA sedimentation assays.  These assays showed that DNA in parental MCF10A and Rad6B 
overexpressing MCF10A clones were converted to  high density fractions post-cisplatin treatment 
(indication of postreplication repair) whereas cells engineered to overexpress antisense Rad6B 
were postreplication repair compromised as the cisplatin exposed DNA remained in the low 
density fraction indicating [77]. Together these data establish a role for human Rad6 in 
chemoresistance and drug tolerance.  
1.12. Rad6 regulation in breast 
The role of Rad6 in normal breast cells was investigated in the MCF10A breast epithelial 
cells. MCF10A cells were synchronized in the G1/S-phase by 5-hydroxyurea and cells were 
harvested at various times post-synchronization for cell cycle and protein analysis. These analyses 
showed that Rad6 was maximally expressed in late S/G2-phase, corroborating yeast data and the 
role for Rad6 in postreplication repair [77]. To investigate the repair capacity of Rad6, MCF10A 
cells were treated with vehicle or ADR and collected at various time points post-treatment. RNA 
was isolated from vehicle and ADR treated cells and used for reverse transcriptase-polymerase 
chain reaction. This analysis revealed a 4-fold increase in the Rad6B cDNA of ADR treated cells 
compared to vehicle treated cells [77]. These data were corroborated at the protein level. The 
addition of actinomycin D to prevent transcription abolished the ADR-induced increase in Rad6B 
mRNA levels, indicating that Rad6B gene expression is regulated by ADR at the transcriptional 
level [77]. This was further validated by the addition of cycloheximide (a  protein synthesis 
inhibitor), which showed that addition of cycloheximide prevented the ADR-induced Rad6 protein 
expression [77].  
Additionally, the subcellular translocation of Rad6 in response to ADR was examined. 
Vehicle and ADR treated cells were treated in vivo with formaldehyde to form crosslinks between 
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proteins or between proteins and DNA. The crosslinked samples were sheared and fractions were 
collected by density gradient ultracentrifugation [77]. Whereas Rad6 was found in the low density 
fractions in control cells,  Rad6  was located in the high density fractions along with DNA in ADR 
treated cells [77]. These data indicate that whereas much of Rad6 is found in cytoplasmic fractions 
of control cells, ADR treatment induced Rad6 association with DNA. The association of Rad6 
with DNA in response to damage corroborates the role of Rad6-mediated TLS in breast cells. 
 1.13. Development of a novel Rad6-selective small molecule inhibitor  
Recently, we have described the development of the first Rad6-selective small molecule 
inhibitor [78]. Using Molecular Operating Environment (MOE) 2010.10, a drug discovery 
software, an E2 ubiquitin-conjugating consensus binding site was constructed based on the nuclear 
magnetic resonance structure of the E2 ubiquitin-conjugating enzyme Ubc1. Key residues 
conserved across the human E2 family and involved in the stabilization of the E2-ubiquitin 
thioester intermediate were used to develop a pharmacophore model detailing the key hydrogen 
donor and hydrogen acceptors points necessary to ensure optimal inhibitor interactions. This model 
was then virtually screened against the ZINC database, a free database of commercially available 
compounds, and a substituted diamino-triazine (TZ) core structure was identified [78]. The 
identified TZ core was modified and a panel of 12 TZ variants were investigated in vitro for the 
ability to inhibit Rad6-mediated histone H2A ubiquitination. Recombinant human Rad6B, histone 
H2A, ubiquitin, E1 ubiquitin-activating enzyme, and ATP were incubated alone or in the presence 
of a TZ variant [78]. Ubiquitination assays showed that Rad6 efficiently transferred ubiquitin to 
histone H2A in control conditions [78]. However, treatment with the TZ variants reduced Rad6-
ubiquitin thioester formation as well as the transfer of ubiquitin to histone H2A to various degrees, 
with TZ#8 and TZ#9 having the best inhibition [78]. Concordantly, in silico molecular docking of 
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TZ variants to Rad6 revealed TZ#8 and TZ#9 had the highest geometric shape complementary 
score. Further, in silico molecular docking suggested that TZ#8 and TZ#9 form noncovalent 
interactions with threonine 69, asparagine 119, alanine 122, aspartic acid 90 and glutamine 93 
(latter two residues are adjacent to the Rad6 catalytic cysteine) [78].  
Using MDA-MB-231 and MCF10A cells the effects of Rad6B inhibition on cell 
proliferation and migration were assessed. MTT proliferation assays showed that  both TZ#8 and 
TZ#9 were able to inhibit MDA-MB-231 proliferation while having no effect on MCF10A cells, 
TZ#9 had a greater effect [78]. Similarly, while both TZ variants inhibited migration of MDA-
MB-231 cells, TZ#9 was more proficient in this action [78]. The specificity of TZ#9 (further 
referred to as SMI#9) was tested in ubiquitination assays using recombinant human UbcH5, (an 
E2 ubiquitin-conjugating enzyme sharing the greatest identity with Rad6B) and the UbcH5 
substrate BCA2. This analysis showed that SMI#9 had no effect on the ability of UbcH5 to 
ubiquitinate BCA2, and that Rad6 was unable to ubiquitinate BCA2 [78]. SMI#9 selectivity for 
Rad6 is further supported by the fact that substitution of any one of the amino acids in the binding 
pocket disrupt SMI#9 binding [78].  
Differential uptake of the fluorescence dyes acridine orange and ethidium bromide were 
used to determine whether the effects of SMI#9 in MDA-MB-231 cells was cytostatic or cytotoxic 
[78]. Dye uptake demonstrated that cells intercalated acridine orange into their DNA, indicating 
early apoptosis, 8 h post SMI#9 treatment and incorporated ethidium bromide into their DNA, 
indicating late stage apoptosis, at 24 and 48 h post SMI#9 treatment [78]. To determine whether 
the effect of SMI#9 was associated with cell cycle arrest, MDA-MB-231 were subjected to cell 
cycle analysis by flow cytometry. MDA-MB-231 cells were synchronized by serum starvation for 
48-72 h.  Cells were then replated in complete medium for 8 h prior to SMI#9 treatment and then 
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collected 24-72 h posttreatment for flow cytometry. Flow cytometry analysis revealed SMI#9 
treatment increased the proportion of cells in G2/M phase by 2-fold compared to vehicle treatment, 
implicating SMI#9 induced G2/M arrest [78].   Immunostaining of MDA-MB-468 cells for cyclin 
B1 revealed that SMI#9 treatment resulted in accumulated cyclin B1, indicating G2/M arrest [78]. 
Additionally, these cells exhibited intense a-tubulin immunolabeling at the dividing plane of late 
mitotic cells and contained pleomorphic/multiple nuclei [78]. In concordance with the role of Rad6 
at the centrosome, these data implicate an inability of SMI#9 treated cells to exit mitosis and 
strongly suggest G2/M arrest. Together, these data demonstrate both the specificity and inhibitory 
effect of SMI#9. 
It should be noted that the SMI#9 binding pocket is conserved in both Rad6A and Rad6B, 
and hence SMI#9 inhibition is not selective to either Rad6A or Rad6B. However, SMI#9 will not 
phenocopy every aspect of Rad6 double knockout because of tissue-selective expressions of 
Rad6A and Rad6B proteins, and unlike genetic knockout which deletes the protein entirely, SMI#9 
will only disrupt the catalytic activity related functions of Rad6.  
Recent literature describes the synthesis of several additional Rad6 inhibitors. These 
inhibitors are SMI#9 derivatives and were shown to inhibit conjugation of ubiquitin to Rad6B and 
the transfer of ubiquitin to histone H2A more effectively than SMI#9 [79]. However, in vitro cell 
survival assays did not show enhanced efficacy, particularly in breast cancer cell lines [79]. 
Furthermore, the authors did not verify the specificity of their inhibitors. To date, SMI#9 is a novel 
Rad6-selective small molecular inhibitor.  
1.14. Rad6 as a potential therapeutic target in TNBC: central hypothesis 
Rad6 is known to play a role in DNA damage repair and centrosome function in breast 
cancer, both of which are targets of the investigational platinum-based drugs and the mainstay 
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taxane-based drugs, respectively, in TNBC. Rad6 has also been found to be overexpressed in 
invasive and metastatic breast cancer tissues and cells lines. Additionally, the constitutive 
overexpression of Rad6 in normal behaving MCF10A breast epithelial cells reveals a role for Rad6 
in transformation. This implicates a critical role for Rad6 in the development and progression of 
aggressive breast cancers. Based on this, we hypothesize (Figure 1.3) that Rad6 overexpression 
influences the drug response of TNBCs to DNA damaging agents and microtubule stabilizing 
agents by regulating DNA damage repair pathways and centrosome function, respectively. 
Therefore, targeting Rad6 in these breast cancers will offer sustained therapeutic benefit to TNBC 
patients. 
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FIGURE 1.3. Central hypothesis. Rad6 overexpression influences the drug response of 
TNBCs to DNA damaging agents and microtubule stabilizing agents by regulating DNA 
damage repair pathways and centrosome function, respectively. Therefore, targeting Rad6 
with SMI#9 will offer sustained therapeutic benefit to TNBC patients. 
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CHAPTER 2-RAD6-MEDIATED TRANSLESION SYNTHESIS IS REQUIRED TO 
OVERCOME RESISTANCE TO PLATINUM-BASED DRUGS 
 
2.1 Introduction 
 
Chapters 2 and 3 of this dissertation address the role of Rad6 in repair of platinum drug 
induced damage. Specifically, in this chapter we address the role of Rad6 in mediating crosstalk 
of TLS pathway and Fanconi Anemia (FA) network as well as the therapeutic benefit of inhibiting 
Rad6 to reverse platinum resistance. In chapter 3 of this dissertation we will examine the role of 
Rad6 in mediating TLS and FA crosstalk with HR in BRCA1 wild type and BRCA1 mutant 
TNBCs. 
2.1.1 Platinum based therapies: mechanism of action 
Platinum-based drugs are DNA damaging agents capable of inducing toxic DNA lesions 
[80], and  can be segregated into 5 main classes: platinum drugs  that bind covalently to DNA,  
bind noncovalently to DNA,  bind bifunctionally to DNA,  act as prodrugs, and  multinuclear 
platinum complexes which contain two or more linked platinum centers [80]. Among these classes, 
the most commonly used platinum based compounds  in cancer treatment are those that  bind 
covalently to DNA, such as cisplatin, carboplatin, and oxaliplatin [80].   
Cisplatin functions by crosslinking genomic DNA, and is commonly used in treatment of 
testicular, ovarian, and non-small cell lung cancers [81-83]. This process is dependent upon the 
hydrolysis of the labile chloride group in cisplatin. While the high chloride ion concentration in 
the bloodstream suppresses this process, the lower chloride ion concentration inside  the cell assists 
with this hydrolysis [80]. Once inside of the cell, typically accomplished by passive diffusion 
through the plasma membrane or active transport mediated by membrane proteins [82], the 
chloride group in cisplatin is replaced with a water molecule resulting in a positively charged 
cisplatin complex with a 2 h half-life [80-82]. Once aquated, cisplatin can enter the nucleus where 
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it is attracted to negatively charged biomolecules including DNA, RNA, and proteins, with DNA 
being the major functional target [80-82].  The most nucleophilic sites of DNA are the N7 atoms 
of the purine residues guanine and adenine, with guanines being preferentially platinated [80-82]. 
First, aquated cisplatin forms a single covalent bond on DNA. A second independent process then 
occurs in which the remaining cisplatin chloride is substituted with a second guanine base, forming 
a crosslink on the DNA [80, 82]. This second reaction can occur with a guanine reside on the same 
strand of DNA or on the opposite strand of DNA, forming either intra- or inter-strand DNA 
crosslinks respectively [80, 82]. While intra-strand crosslinks are the most prevalent (~95%), inter-
strand crosslinks (ICLs) are the most deleterious as they block DNA replication, and if left 
unrepaired, can lead to SSBs, DSBs and chromosomal rearrangements [84]. Additionally, it has 
been found that it only requires about 20-40 ICLs to kill repair-deficient mammalian cells [85]. 
Though cisplatin is the most clinically successful DNA covalent binder, acquired resistance and 
systemic toxicity, particularly neurotoxicity and nephrotoxicity [80] pose major  clinical 
challenges. 
Carboplatin is a second-generation platinum compound with a bidentate dicarboxylate 
instead of the cisplatin chlorides, resulting in a slower substitution by water and increased drug 
stability, as carboplatin has a half-life of about 30 h [80, 82]. Further, the reduced rates of 
hydrolysis leads to reduced side-effects [80]. While side effects are reduced, the induction of toxic 
ICLs is also reduced to 3-4% of total lesions [86, 87]. Carboplatin is predominately used in ovarian 
cancers but has been found to be useful in the treatment of retinoblastomas, neuroblastomas, 
nephroblastomas, brain tumors, and cancers of the head and neck, endometrium, cervix, testes, 
breast, lung and bladder [80, 82, 83].  
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Oxaliplatin is a third generation platinum compound and possesses a bidentate  1,2- 
diaminocyclohexane stable ligand and an oxalate leaving group [80]. Similarly to carboplatin, this 
leaving group reduces the rate at which oxaliplatin is hydrolyzed, increases the stability of 
oxaliplatin and reduces oxaliplatin associated toxic side effects [82]. However, in contrast to 
carboplatin, ~14% of the lesions produced by oxaliplatin are ICLs [88]. Oxaliplatin has been 
shown to have therapeutic benefits in colorectal cancer and is routinely used in the treatment of 
these cancers [80]. 
2.1.2 Repair of platinum-induced damage	 
Repair of platinum-induced ICLs requires the concerted efforts of Rad6-mediated TLS, FA 
and BRCA dependent HR pathways [86, 89]. Processes that allow cancer cells to persist in the 
face of ICLs such as upregulation of these DNA damage response (DDR) pathways are 
advantageous to cancer cells [90-92]. 
As described, TLS is a major component of the DDR mechanism. Briefly, in response to ICLs, 
Rad6 in complex with Rad18 monoubiquitinates PCNA at Lys164 [60]. PCNA 
monoubiquitination triggers the recruitment of low fidelity TLS polymerases Pol h, Pol k, Pol i or 
REV1 [71, 93]. These polymerases have decreased fidelity due to their relaxed active sites [94], 
and have varied efficiencies to tolerate DNA distortions and insert nucleotides opposite the damage 
site, resulting in either error-free or mutagenic repair [60]. Monoubiquitinated PCNA facilitates 
recruitment of TLS polymerases via interactions with the ubiquitin binding motifs in the TLS 
polymerases [95]. In addition to its role in activation of TLS, Rad6 has been implicated in FA 
network and homologous recombination pathway activity [89]. 
 Fanconi Anemia is a rare autosomal recessive genetic disease caused by mutations in the 
Fanconi Anemia protein cluster. Fanconi Anemia is characterized by hypersensitivity to DNA ICL 
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agents, chromosomal instability, and predisposition to various cancers including leukemia, breast 
cancer and head and neck cancers [96]. The FA pathway functions in the S-phase and is implicated 
in repair of ICL lesions as cells defective for the FA pathway exhibit hypersensitivity to ICL 
inducing agents [93, 97-100]. In response to DNA damage and replication stress, the Fanconi 
Anemia core complex proteins FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL 
and FANCM assemble at the site of the ICL, phosphorylate FANCI followed by 
monoubiquitination of FANCD2 and FANCI (surrogate markers of FA activation), and subsequent 
formation of FANCI/FANCD2 complex at the site of damage [101]. Ubiquitinated 
FANCI/FANCD2 then bind to the ICL and recruit endonucleases for the removal of the ICL. 
However, the exact sequence of events concerning the FA pathway and TLS are still not well 
understood. It is possible that the FANCI/FANCD2 complex promotes incision at the site of the 
ICL and TLS subsequently fills in the gap at the lesion. Alternatively, the TLS activity may precede 
the incision, and that the FANCI/FANCD2 complex promotes TLS activity near the ICL [102].  
 The Rad6/Rad18 complex has also been implicated in activation of the FA network as 
silencing of Rad6 results in decreased FANCD2 monoubiquitination, whereas overexpression of 
Rad6 leads to an increase in FANCD2 ubiquitination [103]. Further, silencing of Rad18 decreased  
FANCD2 ubiquitination and increased sensitivity to ICL inducing agents [104, 105]. Evidence 
also suggests that PCNA and FANCD2 interact via the FANCD2-PCNA interacting peptide (PIP)-
box motif and that a mutation in this motif abrogates FANCD2 monoubiquitination [106]. These 
data suggest that Rad6-mediated TLS impacts FA network activation via its role in FANCD2 
ubiquitination. 
 DSBs are produced as an intermediate of ICL removal. HR utilizes the undamaged sister 
chromatid as a template for repair of DSBs. Repair by HR requires three major steps: end resection, 
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strand invasion, and resolution [107]. During strand invasion, a transient structure known as the 
D-loop structure is formed [107]. It is currently unclear as to what replication machinery is used 
for this elongation, however the TLS polymerase Pol h has been implicated.  
The extensive crosstalk between TLS, FA and HR is mediated, in part, by Rad6 and thus 
inhibition of Rad6 could disrupt this crosstalk and restore chemosensitivity. In this chapter, we 
show a direct role for the Rad6 ubiquitin-conjugating activity in coordinated activation of FA and 
TLS pathways in cisplatin or oxaliplatin treated TNBC or colon cancer cells, respectively. 
Inhibition of Rad6 enzymatic activity with our novel Rad6-selective small molecule inhibitor 
SMI#9 [78] or Rad6B silencing suppresses FANCD2 and PCNA monoubiquitinations, as well as 
cisplatin-induced gH2AX, PCNA, Pol h, FANCD2, and Rad6 foci formation. Further, Rad6 is 
required for overcoming cisplatin-induced replication fork stalling as restart of cisplatin stalled 
replication forks are impaired in SMI#9 pretreated and Rad6B silenced cells. Consistent with these 
results, in vitro and in vivo assays show that SMI#9 treatment inhibits proliferation of MDA-MB-
231 TNBC cells, and enhances their in vitro and in vivo sensitivity to cisplatin. Using an isogenic 
colon cancer cell model of oxaliplatin resistance, we demonstrate that oxaliplatin induces PCNA 
and FANCD2 monoubiquitination in parental HCT116 colon cancer cells while oxaliplatin-
resistant (HCT116-OxR) colon cancer cells exhibit constitutive monoubiquitination of these 
proteins. SMI#9 treatment enhances sensitivity of HCT116-OxR cells to oxaliplatin. These data 
implicate a pivotal role for Rad6/Rad18 mediated TLS in platinum-induced ICL repair and 
highlight the therapeutic benefit of targeting Rad6 to overcome platinum resistance in TNBC and 
colon cancer cells.   
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2.2 Materials and methods 
2.2.1 Cell lines and culture  
MDA-MB-231 human TNBC cells and HCT116 human colon cancer cells were purchased 
from American Type Culture Collection (ATCC) and authenticated by ATCC by short tandem 
repeat DNA profiling. Cells were maintained in Dulbecco’s Minimal Essential Medium/F12 
(DMEM/F12; Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine serum. An isogenic 
model of acquired oxaliplatin resistance was generated by exposing parental HCT116 cells to 
gradually increasing concentrations of oxaliplatin to select HCT116-OxR cells capable of 
tolerating 10 µM oxaliplatin. MDA-MB-231, HCT116, and HCT116-OxR cells were expanded 
and multiple aliquots were cryopreserved. Cells were used within 10-15 passages or within 3 
months.  
 2.2.2 Cell survival assays 
MDA-MB-231, parental HCT116 or HCT116-OxR cells were seeded at 2.5-5 x 103 
cells/well in 96-well dishes. MDA-MB-231 cells were treated with cisplatin and HCT116 and 
HCT116-OxR cells were treated with oxaliplatin at the indicated doses to assess cell sensitivity. 
In experiments examining the effect of Rad6 inhibition on cisplatin or oxaliplatin responses, cells 
were pretreated overnight with 5 µM of the Rad6 selective small molecule inhibitor SMI#9 [78] 
or vehicle prior to addition of cisplatin (MDA-MB-231) or oxaliplatin (HCT116-OxR). To 
determine the effect of Rad6B depletion, cells were transfected with 20 pmol SMARTpool 
containing four Rad6B-specific siRNAs (described below) or nontarget siRNA (Dharmacon) and 
treated with cisplatin. Cell viability was assessed at 72 h by standard MTT protocol and Rad6 
knock-down was verified by western blot analysis. Experiments were done in quadruplicates and 
results expressed from at least two independent experiments. 
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2.2.3 Colony formation assays 
MDA-MB-231 cells were treated with vehicle, SMI#9 (5 µM), and cisplatin (0.5 or 1 µM). 
For combination treatment MDA-MB-231 cells were pre-treated with SMI#9 for 24 h prior to 
cisplatin treatment. Cells were then replated at 100 single cells per well in 24-well plates for colony 
formation. HCT116-OxR cells maintained in 10 µM oxaliplatin were treated with vehicle or 
SMI#9 (1 µM), and reseeded at 400, 200, 100 or 10 single cells per well in 24-well plates. Colony 
formation was quantified with the GelCountTM  Oxford Optronix, capable of detecting crystal violet 
stained colonies and providing colony diameter, area, density and volume per colony detected. 
Colony forming efficiency was expressed relative to control cells.  
2.2.4 DNA damage response assays  
MDA-MB-231 cells were treated with cisplatin (10 µM) for 4 h, washed and allowed to 
recover in drug free media for 0 – 24 h. To assess the involvement of Rad6 in cisplatin-induced 
damage response, cells were either pretreated with 5 µM SMI#9 (or vehicle) or transfected with 
20 pmol SMARTpool Rad6B siRNAs or nontarget siRNA prior to cisplatin treatment. Cells were 
lysed at various times post-treatment for immunoblot analysis. 
2.2.5 Rad6B knockdown with siRNA	 
siRNA targeting Rad6B/UBE2B (20 µM stock; On-Target Plus SMARTpool mixture of 
four siRNA duplexes: GGAAUGCAGUUAUAUUUGG; GAACCGAAUCCUAACAGUC; 
GAGUUUCGGCCAUUGUUGA; UAGAUAUCCUUCAGAAUCG) was obtained from 
Dharmacon (Lafayette, CO). Control siRNA (20 µM stock; 
r(UUCUCCGAACGUGUCACGU)dTdT and r(ACGUGACACGUUCGGAGAA)dTdT strands) 
was obtained from QIAGEN, Inc. (Valencia, CA). Transfections were performed in six-well plates 
(for fiber and western blot analysis) or 8-well chamber slides (foci analysis) with 20 pmol of 
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siRNA per transfection and Metafectene SI+ (Biontex Laboratories GmbH, Germany) according 
to the manufacturer’s directions. Medium was replaced at 48 h posttransfection with fresh culture 
medium and incubated for another 24 h for a total of 72 h posttransfection at which time the 
experiments were performed.  
2.2.6 Immunoblot analysis		 
MDA-MB-231, HCT116-OxR and HCT116 parental cells were lysed in Triton X-100 lysis 
buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl pH 7.4 supplemented with protease 
inhibitor cocktail (Roche) and 1 mM PMSF, sodium orthovanadate and sodium pyrophosphate. 
Protein-matched aliquots were subjected to SDS-PAGE and immunoblot analysis of Rad6 [76], 
PCNA (Dako, CA), FANCD2 (Novus Biologicals, CO), a-tubulin (Sigma-Aldrich Chemicals, 
MO), gH2AX (BioLegend, CA), and Rad18 (Imgenex Corp., CA). We previously demonstrated 
that the Rad6B gene is overexpressed in breast cancer by transcript sequencing and Rad6B shRNA 
transfections [76, 108]. However, since the peptide we used to generate Rad6B antibody is 91% 
conserved in human Rad6A, the Rad6 proteins detected by our antibody will not distinguish 
Rad6A and Rad6B proteins [76]. Hence the immunoreactive Rad6 detected from immunoblot and 
immunostaining is referred to as Rad6 rather than Rad6A or Rad6B. To analyze cell subfractions, 
cells were lysed using a cytosolic/nuclear protein fractionation kit (MBL International) according 
to the manufacture protocol. For PCNA ubiquitination analysis, appropriate lysates were subjected 
to immunoprecipitation with anti-PCNA or corresponding normal IgG antibodies, and captured 
immune complexes were analyzed by immunoblotting with anti-ubiquitin antibody. The 
membranes were stripped (62.5 mM Tris-HCl pH 6.8, 2% SDS, and 1 µL/mL b-mercaptoethanol) 
and reprobed with anti-PCNA antibody to verify equal PCNA pulldown among samples. 
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2.2.7 Immunofluorescence staining  
MDA-MB-231 cells were transfected with 20 pmol SMARTpool Rad6B siRNAs (or 
nontarget siRNA) or treated overnight with 5 µM SMI#9 (or vehicle) prior to cisplatin treatment. 
Cells were then fixed in 10% buffered formalin and permeabilized with methanol/acetone (1:1, 
v/v). Slides were incubated with anti-Rad6/anti-PCNA, anti-FANCD2/anti-PCNA, anti-
PCNA/anti-Pol h (Abcam, MA), anti-FANCD2/anti-Pol h or anti-gH2AX antibodies followed by 
FITC- and Texas Red-conjugated rabbit and mouse secondary antibodies, respectively (Molecular 
Probes, OR). Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI). Slides were 
also stained in the absence of primary antibody or with isotype matched nonimmune IgG to assess 
nonspecific reactions. Images were collected on an Olympus BX40 microscope equipped with a 
Sony high resolution/sensitivity CCD video camera and SlideBook software. The results shown 
are representative of data collected from ~ 30-75 cells in three to five fields and two independent 
experiments. 
2.2.8 DNA fiber assay for DNA replication restart studies  
Exponentially growing MDA-MB-231 cells were pulsed with 100 µM 5-iododeoxyuridine 
(IdU) for 45 min at 37ºC, washed with phosphate buffered saline (PBS) and allowed to recover for 
1 h prior to being pulsed with 100 µM 5-chlorodeoxyuridine (CldU) for 45 min [109]. To 
determine the impact of cisplatin on replication fork restart, IdU labeled cells were treated with 5 
µM cisplatin (or vehicle) for 1 h, washed, allowed to recover and pulsed with CldU. The role of 
Rad6 in replication fork-restart following cisplatin-induced damage was determined by pretreating 
cells with 1 µM SMI#9 or vehicle for 12 h prior to IdU/CldU labeling and cisplatin treatment. To 
prepare slides, cells were trypsinzed and washed and resuspended in cold PBS. Cell suspensions 
were spotted onto  glass microscope slides and mixed with 7 µl of DNA lysis buffer (100 mM 
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Tris-HCl, pH 8, 50 mM EDTA, 1% SDS) for 5 min at room temperature [109]. Slides were tilted 
to spread the suspension, and the air-dried DNA spreads were fixed in methanol/acetic acid (3:1, 
v/v). For immunostaining, slides were rinsed with PBS and DNA was denatured with 1.5 N HCl 
for 45 min at room temperature. Slides were washed and incubated in 5% BSA blocking buffer for 
30 min prior to incubation with mouse anti-IdU (Pierce, IL) and rat anti-CldU (Pierce, IL) 
antibodies and corresponding Texas Red- or FITC-conjugated secondary antibodies, respectively. 
Images were taken from randomly selected fields of untangled DNA fibers on an Olympus BX40 
and IdU, CldU, and IdU/CldU replication forks were analyzed by Image J software. 
Approximately 35-75 individual fibers were analyzed for each experiment and the average of three 
independent experiments presented.  
2.2.9 Immunofluorescence staining of replication foci 
 MDA-MB-231 cells were labeled with 100 µM IdU and CldU as described above for DNA 
fiber analysis. Cells were transfected with 20 pmol SMARTpool Rad6B siRNAs (or nontarget 
siRNA) or treated with SMI#9 prior to IdU/CldU labeling and cisplatin treatment. Cells were fixed 
in methanol/acetone (1:1, v/v), and DNA denaturation and immunostaining were performed as 
described for DNA fiber analysis. Approximately 35-75 cells were analyzed for each experiment 
and the average of three independent experiments presented. For localization of gH2AX with CldU 
nucleotide, cells treated with vehicle, SMI#9, cisplatin, or SMI#9 pretreatment followed by 
cisplatin were CldU labeled. Cells were then fixed in methanol/acetone, blocked with 5% BSA 
and incubated with anti-gH2AX antibody. Slides were washed and incubated with Texas Red-
conjugated anti-rabbit antibody. To stain CldU nucleotide, slides were fixed in 4% 
paraformaldehyde/0.2% Triton-X 100, DNA denatured, and stained with anti-CldU antibody as 
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described above. Approximately 30 cells from five to nine fields were analyzed for CldU/gH2AX 
foci colocalization by Image J. 
2.2.10 Measurement of cisplatin DNA adduct removal 
The repair kinetics of cisplatin DNA adducts was assessed by ELISA using an anti-cisplatin 
modified DNA antibody (clone CP9/19, Abcam). Genomic DNA isolated at various times of 
recovery from MDA-MB-231 cells exposed to cisplatin with or without SMI#9 pretreatment was 
coated on 96-well DNA-BIND ELISA plates in triplicates and blocked with 2% rabbit serum prior 
to incubation with CP9/19 antibody. Plates were washed, incubated with HRP-conjugated goat 
anti-rat antibody and developed with Ultra TMB (3,3′,5,5′-tetramentylbenzidine, Pierce). 
Absorbance was measured at 450 nm. The percentages of DNA adducts were calculated relative 
to the 0 h time point that was set at 100%. 
2.2.11 Orthotopic tumor growth assays 
MDA-MB-231 cells were treated overnight with vehicle, SMI#9 (5 µM), cisplatin (10 µM), 
or pretreated with SMI#9 24 h prior to cisplatin, and 5 × 106 cells suspended in 100 µl of Matrigel 
were injected orthotopically into the fatpads of fourth and fifth inguinal mammary glands of female 
nude mice. Tumors were measured with calipers twice a week and tumor volumes calculated using 
the formula (length x width2/2). Mice were sacrificed at 41 days postimplantation. Tumors were 
excised and weighed prior to being fixed in buffered formalin and paraffin-embedded. Four micron 
sections of paraffin-embedded MDA-MB-231 xenografts were stained with hematoxylin and eosin 
(H&E) for morphological analysis, or incubated with anti-Rad6 [76] or anti-PCNA antibodies 
followed by the appropriate biotinylated secondary antibody and HRP-conjugated streptavidin 
(Vector Labs, CA). Nuclei were counterstained with hematoxylin. Control sections were stained 
with corresponding normal IgG or secondary antibody only.  
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To assess the therapeutic responses of tumors to SMI#9, cisplatin or a combination of 
SMI#9 and cisplatin, 5 × 106 MDA-MB-231 cells were orthotopically implanted into the axillary 
or inguinal mammary gland fatpads. When the tumors reached ~ 150 mm3, mice were randomly 
assigned to the following groups: vehicle control, cisplatin (4 mg/kg body weight, once/week, 
intraperitoneal), SMI#9 (2.5 mg/kg body weight, twice/week, intratumoral), or a combination of 
SMI#9 and cisplatin.  Tumors were measured and tumor volumes calculated as described above. 
Mice were sacrificed at 24 days post-implantation two days after the last administration, and tumor 
growth inhibition (a measure of anti-tumor effectiveness) was calculated using the mean tumor 
burden mass for each group. Excised tumors were either sonicated in lysis buffer supplemented 
with protease and phosphatase inhibitors for western blot analysis of Rad6, Rad18, PCNA, 
FANCD2 and b-actin, or fixed and paraffin-embedded for histological analysis The in vivo studies 
were conducted in accordance with the institutional animal care and use committee (IACUC) 
guidelines of Wayne State University. 
2.2.12 Statistical analysis 
Statistical analysis was performed with GraphPad Prism. Results are presented as the mean 
± S.D. or S.E.M., and were analyzed by two-tailed Student's t test and one-way analysis of variance 
(ANOVA). Statistical significance was accepted at a P value of < 0.05.  
2.3 Results 
2.3.1 SMI#9 sensitizes platinum-resistant cancer cells  
To investigate the impact of Rad6 inhibition on the response of cells to platinating agents, 
we examined the effect of the Rad6-selective inhibitor SMI#9 [78]  on cell survival in two platinum 
resistant cancer cell models. MDA-MB-231 TNBC cells exhibit intrinsic resistance to cisplatin 
(IC50 12.2 µM), and pretreatment with SMI#9 decreased the IC50 of cisplatin to 2.4 µM (Figure  
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FIGURE 2.1 Rad6 inhibition or depletion sensitizes cancer cells to cisplatin and 
oxaliplatin. MDA-MB-231 cells pretreated with SMI#9 (A) or Rad6B siRNA (B) or their 
corresponding controls, were exposed to various concentrations of cisplatin. C) Western blot 
verification of Rad6B knockdown from two independent transfections with SMARTpool 
Rad6B siRNAs or nontarget (NT) siRNA. D) Sensitivities of parental HCT116 and isogenic 
HCT116-OxR cells to oxaliplatin. E) HCT116-OxR cells were pretreated with SMI#9 followed 
by exposure to the indicated doses of oxaliplatin. MTT assay was used to measure cell 
proliferation. Data are expressed relative to control cells as mean ± S.D. of triplicate 
experiments. Figure contributed by Matthew Sanders, Ph.D.. 
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2.1; Panel A). Similarly, Rad6B depletion by Rad6B siRNA transfection decreased the IC50 of 
cisplatin to 4.0 µM as compared to 13 µM in nontarget siRNA transfected cells (Figure 2.1; Panels 
B and C). Determination as to whether SMI#9-induced effects were selective to cisplatin or 
represented a universal response to platinum compounds, was conducted by generating oxaliplatin-
resistant colon cancer cells (HCT116-OxR). HCT116-OxR cells were developed by exposing 
HCT116 colon cancer cells to gradually increasing doses of oxaliplatin as described under 
Methods. HCT116-OxR exhibited an 11-fold increase in oxaliplatin IC50 as compared to their 
parental counterparts (13.2 µM for HCT116-OxR vs. 1.2 µM for HCT116 parental; Figure. 2.1; 
Panel D). SMI#9 pretreatment of HCT116-OxR cells resulted in ~40% reduction in cell viability. 
Thus, when results were expressed relative to control cells, the oxaliplatin sensitization effects of 
SMI#9 were only marginally discernible due to elimination of SMI#9-sensitive oxaliplatin 
resistant HCT116 subpopulations (Figure. 2.1 Panel E). Colony forming assays were performed to 
confirm SMI#9 induced cisplatin sensitization. Pretreatment with SMI#9 was found to decrease 
the clonogenic potentials of MDA-MB-231 cells grown in the presence of 0.5 (P = 0.0078) or 1 
µM (P = 0.0011) cisplatin (Figure. 2.2; Panel A). Similarly, HCT116-OxR cells seeded in media 
containing 10 µM oxaliplatin showed inhibition of colony forming potential when exposed to 1 
µM SMI#9 regardless of the seeding densities (P = 0.009; Figure 2.2; Panel B). These data suggest 
a general role for Rad6 in survival and tolerance of platinum-induced damage. 
 2.3.2 Rad6 loss and depletion attenuates cisplatin-induced increases in ubiquitinated PCNA 
and FANCD2 protein levels		 
Rad6/Rad18 mediated PCNA monoubiquitination is an essential step for TLS of  damaged 
DNA [93, 95, 110, 111]. The Rad6/Rad18 pathway has also been implicated in FANCD2 
monoubiquitination, an essential event in repair of ICLs by the FA pathway [103, 112, 113]. To  
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FIGURE 2.2 SMI#9 reduces the clonogenic potential of cancer cells in response to 
cisplatin (CDDP) and oxaliplatin. A) MDA-MB-231 cells were treated with vehicle, SMI#9 
(1 µM), CDDP (0.5 or 1 µM) or a combination of SMI#9 + CDDP and then reseeded in 
triplicate at 100 cells per well for colony formation assay. P<0.0001, one-way ANOVA. B) 
HCT116-OxR cells were maintained in 10 µM oxaliplatin in presence or absence of SMI#9 (1 
µM) and reseeded at indicated densities for colony formation. P = 0.009, one-way ANOVA. 
Results in A and B are mean ± S.D. percent colony formation efficiency from three independent 
experiments. 
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determine the role of Rad6 in cisplatin-induced DNA damage response, vehicle or SMI#9 
pretreated MDA-MB-231 cells, and nontarget or Rad6B siRNA transfected MDA-MB-231 cells 
were treated with cisplatin for 4 h, and allowed to recover for 0-24 h after cisplatin washout (Figure 
2.3; Panel A and B). The steady state levels of Rad6, Rad18, PCNA, FANCD2 and gH2AX were 
assessed by western blotting. While steady state levels of Rad6, Rad18 and nascent PCNA were 
not notably altered by cisplatin, bands corresponding to mono- and poly-ubiquitinated PCNA were 
detectable starting at 2 h that intensified at 24 h post cisplatin treatment. SMI#9 pretreatment 
diminished these cisplatin-induced increases in monoubiquitinated PCNA and partially decreased 
PCNA polyubiquitination (Figure 2.3; Panel A). These data are concordant with the observation 
that Rad6 is completely responsible for PCNA monoubiquitination, while it is only partially 
involved in PCNA polyubiquitination as the latter modification is also mediated by other E2 
ubiquitin-conjugases (Ubc13/Mms2) and E3 ubiquitin-ligases (Rad5, SHPRF, HLTF) [114-116]. 
To authenticate cisplatin-induced monoubiquitinated PCNA and its inhibition by SMI#9, 
immunoprecipitation of lysates with anti-PCNA antibody and western blotting with anti-ubiquitin 
antibody was performed (Figure 2.3; Panel C). The membranes were then stripped and probed 
with anti-PCNA antibody to estimate the levels of monoubiquitinated PCNA relative to PCNA 
input. SMI#9 treatment caused a ~ 2-fold decrease in the levels of cisplatin-induced 
monoubiquitinated PCNA levels at 24 h (Figure 2.3; Panel C and bar graph). In Figure 2.3 Panel 
C, the 39 kDa anti-ubiquitin reactive PCNA is located at the upper edge of the broad 
immunoprecipitated PCNA band and hence not discernible as a distinct species when the blot is 
reprobed with anti-PCNA antibody. Cisplatin treatment induced conversion of the lower molecular 
weight FANCD2 band to a higher molecular weight species, indicative of monoubiquitination  
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FIGURE 2.3 Loss of Rad6 decreases PCNA ubiquitination and FANCD2 steady-state 
levels. Whole cell lysates prepared from MDA-MB-231 cells treated with cisplatin (CDDP) 
with or without SMI#9 pretreatment (A) or two independent transfections with SMARTpool 
Rad6B siRNAs or nontarget (NT) siRNA (B) were subjected to western blot analysis of the 
indicated proteins. C) Indicated MDA-MB-231 lysates were immunoprecipitated with anti-
PCNA antibody. Immunoprecipitates and depleted supernatants were western blotted with anti-
ubiquitin antibody and subsequently stripped and reprobed with anti-PCNA antibody to verify 
the efficacy of PCNA pulldown. Arrow indicates monoubiquitinated PCNA. Accompanying 
graph on the right shows the relative levels of monoubiquitinated PCNA in CDDP and SMI#9 
+ CDDP treated samples. Simultaneous analysis of the indicated proteins from 4-20%, 7-18% 
(PCNA blot in Figure 2.3; Panel A), and 4-12% (Figure 2.3; Panel C) gradient gels was used to 
evaluate all protein profiles. Panels A and B contributed by Matthew Sanders, Ph.D.. 
47	
	
[113, 117]. While SMI#9 treatment did not affect the ubiquitination of FANCD2, it did decrease 
the steady state levels of ubiquitinated FANCD2 (Figure 2.3; Panel A). Cisplatin-induced gH2AX 
paralleled PCNA kinetics, becoming noticeable at 2 h of recovery post-cisplatin treatment with 
continued increases at 24 h indicating the presence of DSBs and DNA repair. Interestingly, SMI#9 
pretreatment induced gH2AX (0 h time point, Figure. 2.3; Panel A), suggesting DNA damage 
induction by SMI#9. However, the continued induction of gH2AX by cisplatin was weakened by 
SMI#9 pretreatment as a 60% reduction in gH2AX levels was observed at 24 h in SMI#9 pretreated 
cells as compared to the cisplatin treated group (Figure 2.3; Panel A). Similarly, analysis of two 
independent Rad6B siRNA-transfected MDA-MB-231 cells showed dramatic declines in mono- 
and poly-ubiquitinated PCNA, and FANCD2 and gH2AX steady state levels as compared to 
nontarget siRNA control cells, whereas Rad18 and nascent PCNA levels were again minimally 
affected (Figure 2.3; Panel B). These data further support the involvement of Rad6 in the cisplatin-
induced DNA damage response.    
Next, we determined whether the SMI#9 induced effects on PCNA, FANCD2 and gH2AX 
were associated with changes in their subcellular distribution. MDA-MB-231 cells with or without 
SMI#9 pretreatment were treated with cisplatin for 4 h, washed and allowed to recover for 0, 4 or 
24 h, prior to preparation of cytoplasmic and nuclear subfractions. Interestingly, SMI#9 
pretreatment did not affect the kinetics of Rad6, Rad18, PCNA, FANCD2 and gH2AX proteins in 
the cytoplasmic fraction compared to cisplatin treatment alone (Figure 2.4). While cisplatin-
induced increases in gH2AX, monoubiquitinated PCNA and monoubiquitinated FANCD2 were 
observed in both the cytoplasmic and nuclear fractions, SMI#9 pretreatment only affected the 
cisplatin-induced responses in the nuclear compartment (Figure 2.4). The steady state levels of 
Rad6 and Rad18 in the nuclear fractions were lower than those in the cytoplasm, and pretreatment 
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with SMI#9 decreased the cisplatin-induced increases in nuclear Rad6 at 4 and 24 h. Whereas the 
cytoplasm contained a Rad18 immunoreactive band with a molecular weight of 55 kDa, the 
corresponding nuclear fractions contained Rad18 with molecular weights of ~52 and 60 kDa.  
Although the nuclear specific Rad18 forms were present at very low levels, the cisplatin-mediated 
increase in the 52 kDa Rad18 band at 4 h was attenuated by SMI#9 pretreatment (Figure 2.4). 
Consistent with these data, SMI#9 pretreatment preferentially decreased the peak levels of nuclear 
monoubiquitinated PCNA relative to total PCNA at 24 h post cisplatin treatment (ratio of 
monoubiquitinated PCNA/total PCNA: 0.117 (control) vs. 0.0557 (SMI#9 pretreatment) but had 
no effect on cytoplasmic PCNA. SMI#9 pretreatment similarly inhibited cisplatin-induced 
accumulation of gH2AX in the nucleus but not in the cytoplasm. Whereas both unmodified and 
monoubiquitinated forms of FANCD2 were detectable in the cytoplasmic fractions, only the upper 
band corresponding to monoubiquitinated FANCD2 was detected in the nuclear fractions, its levels 
peaking at 4 h post-cisplatin treatment. Consistent with the data in Figure 2.3 Panels A and B, 
SMI#9 pretreatment reduced the nuclear cisplatin-induced monoubiquitinated FANCD2 (Figure 
2.4). The integrity of the subfractions were confirmed by cytoplasmic and nuclear specific markers 
GAPDH and lamin A/C, respectively (Figure 2.4). Compared to the cisplatin group, lamin A/C 
levels were low at 0 and 4 h in SMI#9 pretreated fractions but showed delayed profound 
accumulation at 24 h with ~12-fold higher levels in SMI#9 pretreated cells as compared to cisplatin 
group (Fig. 2.4). However, despite the abundant levels of lamin A/C at 24 h in SMI#9 pretreated 
cells, the levels of monoubiquitinated PCNA and FANCD2, and gH2AX are clearly reduced in the 
24 h SMI#9 pretreated cells as compared to cisplatin alone. If normalized for lamin A/C, this would 
only confirm further decreases in these proteins in the SMI#9 pretreated group. At this time, the  
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FIGURE 2.4 SMI#9 affects nuclear expression of DDR proteins. Cytoplasmic and nuclear 
subfractions from MDA-MB-231 cells treated with cisplatin (CDDP) with or without SMI#9 
pretreatment were analyzed by western blot for the indicated proteins. Simultaneous analysis 
of the indicated proteins from 4-20%, gradient gels was used to evaluate all protein profiles. 
Figure contributed by Matthew Sanders, Ph.D.. 
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reason for differential levels of lamin A/C in SMI#9 pretreated cells as compared to cisplatin alone 
is not clear but suggest potential alterations in the nuclear envelope.  
We next determined whether oxaliplatin resistance is also associated with Rad6 and Rad18 
regulated PCNA and FANCD2 ubiquitinations to validate the role of the Rad6/Rad18 pathway in 
general platinum resistance. HCT116 and HCT116-OxR isogenic cells were exposed to 1 or 10 
µM oxaliplatin, respectively, for 0-24 h and whole cell lysates were analyzed by western blotting. 
Whereas Rad18 was minimally expressed in parental (oxaliplatin-sensitive) HCT116 cells and 
only marginal increases were induced by oxaliplatin treatment, Rad18 was constitutively 
overexpressed in HCT116-OxR cells. Rad6 was marginally induced by oxaliplatin in parental 
HCT116 cells whereas Rad6 was expressed at ~ 2-fold higher levels in HCT116-OxR cells as 
compared to the parental cells (Figure 2.5). Consistent with Rad6 pathway activation, mono- and 
poly-ubiquitinated PCNA was detected at 4 h post oxaliplatin treatment in parental HCT116 cells. 
FANCD2 and gH2AX levels were similarly induced by oxaliplatin in parental HCT116 cells. 
Mono- and polyubiquitinated PCNA were constitutively expressed in HCT-116-OxR cells and 
persisted throughout oxaliplatin exposure. gH2AX was also constitutively expressed in HCT116-
OxR cells and persisted throughout oxaliplatin exposure, mirroring the PCNA ubiquitination 
profile. Monoubiquitinated FANCD2 was constitutively expressed in HCT116-OxR cells; 
however, prolonged oxaliplatin treatment caused a sharp decline in FANCD2 levels in HCT116-
OxR cells (Figure 2.5). Induction of and constitutive upregulation of Rad6/Rad18 pathway 
proteins in oxaliplatin sensitive and resistant HCT116 isogenic cells, respectively, imply a role for 
the Rad6/Rad18 ubiquitination pathway in oxaliplatin resistance and importantly a general role for 
the Rad6 pathway in tolerance to platinating agents. 
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FIGURE 2.5 Constitive expression of TLS proteins is associated with oxaliplatin (OxPt) 
resistance. Western blot analysis of the indicated proteins in whole cell lysates prepared from 
HCT116 or HCT116-OxR cells exposed to 1 or 10 µM OxPt, respectively.  Simultaneous 
analysis of the indicated proteins from 4-20% gradient gels was used to evaluate all protein 
profiles. Figure contributed by Matthew Sanders, Ph.D.. 
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2.3.3 SMI#9 inhibits cisplatin-induced Rad6, PCNA, FANCD2 and gH2AX nuclear foci 
formation in MDA-MB-231 cells 
Western blot data in Figure 2.4 showed that SMI#9 pretreatment selectively affects the 
regulation and levels of ubiquitinated FANCD2 and PCNA in the nucleus. To verify these data, 
we examined the intracellular localization of Rad6, PCNA, FANCD2, and gH2AX in MDA-MB-
231 cells treated with cisplatin with or without SMI#9 pretreatment. As shown in Figure 2.6  panel 
A, FANCD2 is present in both the nucleus and cytoplasm of untreated cells and cisplatin treatment 
resulted in FANCD2 relocalization and foci formation in the nucleus. With SMI#9 pretreatment, 
the majority of anti-FANCD2 immunoreactivity was localized to the cytoplasm, and SMI#9 
pretreatment compromised cisplatin-induced FANCD2 nuclear localization and foci formation 
(Figure 2.6; Panels A and D). Treatment with cisplatin similarly promoted Rad6 nuclear 
localization compared to untreated control cells, and SMI#9 pretreatment hindered cisplatin-
induced nuclear distribution as cells showed perinuclear localization of Rad6 as observed for 
FANCD2 (Figure 2.6; Panels B and D). SMI#9 induced similar decreases in PCNA nuclear 
localization (Figure 2.6; Panel B and D). Immunofluorescence analysis of gH2AX showed a 
dramatic increase in gH2AX nuclear foci in cisplatin-treated MDA-MB-231 cells, which was 
strongly inhibited and replaced by diffuse cytoplasmic anti-gH2AX reactivity in SMI#9 treated 
cells (Figure 2.6, Panel C and D). These data are consistent with the results from subcellular 
fractionation analysis which showed SMI#9-induced selective decreases in nuclear gH2AX and 
monoubiquitinated FANCD2 and PCNA proteins (Figure 2.4), further corroborating a role for 
Rad6 in platinum-induced damage response. 
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FIGURE 2.6 Rad6 inhibition disrupts cisplatin-induced FANCD2, Rad6, PCNA and 
gH2AX nuclear foci formation in MDA-MB-231 cells. Immunofluorescence staining of (A) 
FANCD2 (green) and PCNA (red), (B) Rad6 (green) and PCNA (red), and (C) gH2AX (red) 
counterstained with DAPI (blue) nuclear stain. D) Quantification of foci positive (containing 
> 5 foci) cells. Approximately 30-75 cells from three to five fields and two independent 
experiments were scored. Data were analyzed by 2-tailed Student’s t test. Representative 
images are shown. Figure contributed by Matthew Sanders, Ph.D.. 
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2.3.4 Reinitiation of cisplatin-induced stalled replication forks is impeded by Rad6 
inhibition and silencing 
Our data from analysis of cisplatin-induced DNA damage response indicate the 
involvement of Rad6 in PCNA and FANCD2 monoubiquitinations, surrogate markers of TLS and 
FA pathway activation, respectively. To confirm whether the tolerance or intrinsic resistance of 
MDA-MB-231 breast cancer cells to cisplatin involves Rad6-mediated  TLS, we performed 
replication fork restart assays at the DNA fiber and intact cell level to compare the restart ability 
of cisplatin-induced stalled replication forks in cells with and without SMI#9 pretreatments [118]. 
Vehicle or SMI#9 pretreated MDA-MB-231 cells were first pulse-labeled with IdU, treated with 
cisplatin, and then washed and pulse-labeled with CldU (Figure 2.7; Panel A). Replication fork 
restart was quantified by determining the total number of IdU labeled replication foci colabeled 
with CldU. Control and cisplatin treated MDA-MB-231 cells showed DNA fibers with similar 
numbers of contiguous IdU and CldU signals indicating resumption of DNA synthesis or 
replication fork restart (Figure 2.7; Panels B and C). In SMI#9 treated cells, CldU signals were 
reduced when compared to control (P<0.05) and restart of cisplatin stalled replication forks were 
also significantly impaired in SMI#9 pretreated cells (P<0.01) (Figure 2.7; Panels B and C).  
The impact of Rad6 inhibition or silencing with SMI#9 or Rad6B siRNA, respectively, on 
global DNA replication restart was assessed in MDA-MB-231 cells after release from cisplatin 
treatment. Cells pretreated with SMI#9 or transfected with Rad6B siRNA (or the corresponding 
controls) were pre-labeled with IdU, treated with cisplatin and then post-labeled with CldU. Cells 
were fixed, and after denaturation cells were immunostained with IdU and CldU antibodies. 
Whereas vehicle treated or nontarget siRNA transfected cells demonstrated strong IdU/CldU 
contiguous labeling, SMI#9 treated or Rad6B siRNA transfected cells showed a significant  
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FIGURE 2.7 Rad6 inhibition or silencing impedes replication fork restart. (A) MDA-MB-
231 cell labeling and treatment scheme (cisplatin-CDDP) for DNA fiber (B) and global DNA 
replication (D and E) analysis. DNA fibers or cells were immunostained with IdU (red) and 
CldU (green) antibodies, and counterstained with DAPI (blue, D, E). Immunofluorescent 
validation of Rad6 knockdown is shown in panel E. Scale bar, 10 mm. 35-75 fibers or cells were 
analyzed for each experiment. Representative images and the average of three independent 
experiments is shown. C and F) Quantification of stalled, restarted, or newly fired forks (C) or 
nuclei labeled with IdU and CldU (F). In (C), *, ** P<0.01 indicate significant differences in 
restarted or stalled forks between CDDP and SMI#9 or SMI#9 + CDDP groups. 
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reduction in CldU labeled cells, which was exacerbated by cisplatin treatment (Figure 2.7; Panels 
D-F). In most of these cells, the stalled IdU labeled replication forks were not restarted as they 
showed negligible incorporation of CldU. Consistent with robust repair capacity of MDA-MB-231 
cells, cisplatin DNA adduct levels were decreased by ~60% by 72 h in control cells, which was 
compromised by pretreatment with SMI#9 (Figure 2.8). These data provide mechanistic support 
for the role of Rad6 in repair of cisplatin-induced ICLs and the enhanced sensitization of cells to 
platinum drugs by Rad6 inhibition.  
2.3.5 Rad6 inhibition prevents DNA synthesis in mid/late S phase   
As Rad6 is maximally expressed in late-S phase of the cell cycle [77] and our data from 
Figure 2.7 panels C and F show that Rad6 inhibition reduces replication fork restart, sequential 
IdU/CldU pulse-labeling experiments were performed on control or SMI#9 pretreated cells with 
or without cisplatin treatment to determine whether Rad6 deficiency affected DNA synthesis in 
early- and/or mid/late-S phase cells. Cells were fixed and stained with antibodies to IdU and CldU 
and analyzed by fluorescence microcopy. Representative cells showing the different patterns 
associated with DNA synthesis in early-and mid/late-S phases are shown in Figure 2.9 panel A. In 
early-S phase cells, numerous replication foci are evenly distributed throughout the nucleus 
whereas mid-S phase cells are characterized by distribution of replication foci around the periphery 
of nucleus and in the nucleolar regions [119]. Late-S phase cells have few large replication foci 
that correspond to the replication of heterochromatic regions [119]. Since the MDA-MB-231 cells 
used here contained only a very small population of late-S phase cells, and since late-S and mid-S 
labeling patterns are sometimes difficult to distinguish, they were scored together. Incorporation 
of CldU and Idu nucleotides was measured by ImageJ as the ratio of mean pixel densities of CldU 
to Idu for each cell (indicated by the numbers on the right in Figure 2.9; Panel A). No significant  
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FIGURE 2.8 Rad6 inhibition delays removal of cisplatin (CDDP) adducts. MDA-MB-
231 cells treated with 5 µM CDDP for 4 h with or without SMI#9 (5 µM) pretreatment were 
analyzed for CDDP-DNA adduct removal. Cells were rinsed and allowed to recover to 
facilitate repair of DNA adducts. Genomic DNA isolated from cells at the indicated recovery 
times were analyzed for cisplatin-DNA adducts by ELISA. Data are expressed mean ± S.D. 
from two independent experiments. 
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FIGURE 2.9 SMI#9 preferentially inhibits DNA synthesis in mid- to late-S-phase cells. 
MDA-MB-231 cells were treated, labeled and immunostained as in Figure 2.7, panel A. (A) 
Representative images of cells in early-(E) or mid- to late-S (M/L) phases. Mean integrated 
pixel intensities of CldU and IdU for cells in early-and mid- to late-S phases were measured by 
ImageJ and the ratios of CldU to IdU mean pixel intensity are shown. (B) The percent of IdU 
and CldU colabeled populations in each phase, and (C) percent of cells in each phase. Results 
are mean ± S.D. of approximately 20 cells counted for each treatment group from duplicate 
experiments. 
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differences in CldU incorporation into early-S or mid/late-S phase cells of cisplatin treated cells 
were observed as these cells showed comparable labeling intensities for both nucleotides in the 
merged images (Figure 2.9; Panels A and B). Pretreatment with SMI#9 significantly decreased 
CldU incorporation into replication foci of mid/late–S phase cells as compared to the control cells 
(control vs. SMI#9, P = 0.0331; control vs. SMI#9 + cisplatin, P = 0.0025) whereas DNA synthesis 
in early-S phase cells was minimally affected by SMI#9 treatment (Figure 2.9; Panels A and B). 
The decreases in mid/late-S phase DNA synthesis in SMI#9 treated cells were not due to decreases 
in the number of cells in mid/late-S phases as ~1.6-3.0 fold higher numbers of mid/late-S phase 
cells as compared to early-S phase cells were observed in the SMI#9 groups (Figure 2.9; Panel C). 
Approximately 20 cells for each parameter were analyzed, and our data show that SMI#9 
pretreatment preferentially impairs S phase progression in the mid/late-S phase.  
2.3.6 Loss of Rad6 impedes cisplatin-induced PCNA and FANCD2 colocalization with Pol h 
Our data from Figure 2.3 showed that treatment with SMI#9 or Rad6B siRNA results in a 
decrease in cisplatin-induced PCNA monoubiquitination and overall steady state levels of 
FANCD2. During repair of ICLs, FANCD2, PCNA and TLS DNA Pol h play important roles in 
restart of replicating forks at the damage site [120]. Formation of FANCD2 foci is suggested to 
mark the site of cisplatin damage in the chromatin and, in combination with PCNA and TLS 
polymerase Pol h, to play a role in resolution of stalled replication forks[104, 105]. To verify 
whether the failure to restart stalled replication forks in Rad6B-deficient cells is related to defective 
FANCD2, PCNA and/or Pol h foci formation, MDA-MB-231 cells were co-immunostained with 
anti-FANCD2 and anti-Pol h, or anti-Pol h and anti-PCNA antibodies. PCNA and Pol h foci 
formation and colocalization were strongly induced by cisplatin in nontarget siTNA control cells 
but exhibited diffuse immunoreactivities in Rad6B siRNA transfected cells (Figure 2.10; Panels   
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FIGURE 2.10 Rad6 depletion or inhibition disrupts cisplatin-induced recruitment and 
colocalization of DNA damage response proteins. MDA-MB-231 cells transiently 
transfected with nontarget (NT) or SMARTpool Rad6B siRNAs were treated overnight with 
cisplatin (CDDP), fixed and immunostained for (A) Pol h (green) and PCNA (red), (B) Rad6 
(green) or (C) Pol h (green) and FANCD2 (red). Cells were counterstained with DAPI (Blue). 
D) Percent of cells with >5 colocalized foci in NT and Rad6B siRNA transfected cells. E) 
Vehicle or SMI#9 pretreated MDA-MB-231 cells were exposed to CDDP followed by post-
labelling with CldU. Cells were fixed and immunostained for CldU (green) and gH2AX (red). 
F) Percent of cells with gH2AX/CldU foci colocalization. Representative images from a typical 
experiment are shown and cells were scored from ~ 30 cells in four to six fields with Image J. 
Data were analyzed by 2-tailed Student’s t test. 
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A and D). Similarly, untreated nontarget and Rad6B siRNA cells showed, albeit weakly, stained 
FANCD2 and Pol h foci (Figure 2.10; Panels C and D). Cisplatin treatment induced robust 
FANCD2 and Pol h foci formation and colocalization in nontarget siRNA control cells; however, 
this was impaired in Rad6B deficient cells (Figure 2.10; Panels C and D).  Immunofluorescence 
staining with anti-Rad6 antibody verified decrease in Rad6B caused by Smartpool Rad6B siRNAs 
(Figure 2.10; Panel B). Since phosphorylation of histone H2AX is required for FANCD2 
recruitment to the site of DNA damage [118] and our data showed that Rad6 inhibition attenuates 
FANCD2 and gH2AX foci formation (Figure 2.6; Panels A, C and D), we investigated the 
recruitment of gH2AX to sites of replication fork restart marked by CldU incorporation. MDA-
MB-231 cells exposed to cisplatin with or without SMI#9 pretreatments were post-labeled with 
CldU, and cells were immunostained with anti-gH2AX and anti-CldU antibodies followed by 
incubation with Texas Red- and FITC-conjugated secondary antibodies, respectively. Although 
control and cisplatin treated cells effectively incorporated CldU, only cisplatin treated cells 
exhibited discrete gH2AX/CldU foci colocalization (Figure 2.10; Panels E and F). SMI#9 
pretreatment reduced gH2AX/CldU foci formation and colocalization (Figure 2.10; Panels E and 
F). This effect was dramatically exacerbated with SMI#9+cisplatin treatment, suggesting the 
involvement of Rad6 in cisplatin-induced recruitment of DNA damage response proteins and 
repair. 
2.3.7 SMI#9 inhibits MDA-MB-231 tumor growth and enhances cisplatin sensitivity in vivo 
We have previously shown that SMI#9 decreases colony formation and survival of MDA-
MB-231 TNBC cells (Figure 2.2; Panel A) [78]. To determine whether SMI#9 pretreatment 
influences the ability of cancer cells to develop tumors, MDA-MB-231 cells were treated overnight 
with SMI#9, cisplatin, combination of SMI#9 and cisplatin, or vehicle, and 5 × 106 viable cells 
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assessed by trypan blue exclusion staining were implanted into the inguinal mammary fatpads of 
immunodeficient female nude mice. Tumors arising from SMI#9 treated cells were significantly 
growth inhibited as compared to vehicle controls (P<0.001) (Figure 2.11; Panels A and B). Cells 
treated with cisplatin prior to in vivo implantation were also significantly growth inhibited, and 
cells exposed to SMI#9 + cisplatin combination showed dramatic inhibition of tumor development 
(Figure 2.11; panels A and B). Consistent with these data, hematoxylin and eosin (H&E) staining 
showed increased angiogenesis (a factor causally associated with tumor progression) (Figure 2.11; 
Panel C control, arrow) and regional lymph node metastasis in control xenografts. H&E analysis 
of xenografts derived from SMI#9 and cisplatin-treated cells showed the presence of apoptotic 
(Figure 2.11; Panel C SMI#9, short arrow) and necrotic cells as well as cells with abnormal nuclear 
morphology that is characteristic of mitotic catastrophe (Figure 2.11; Panel C, SMI#9, long arrow). 
Immunohistochemical analysis showed robust nuclear staining for PCNA in control xenografts 
(Figure 2.11; Panel D) whereas PCNA immunoreactivity was reduced and diffusely localized in 
the cytoplasm of SMI#9 treated xenografts (Figure 2.11; Panel D). Rad6 staining was detected in 
both the nuclear and cytoplasmic compartments of control xenografts (Figure 2.11; Panel D) while 
it was detected predominantly in the cytoplasm of SMI#9 xenografts (Fig. 2.11; Panel D).   
To evaluate the therapeutic responses of MDA-MB-231 derived tumors to SMI#9, 
cisplatin, or SMI#9 + cisplatin, 5 × 106 MDA-MB-231 cells were implanted into the axillary or 
inguinal mammary fatpads of female nude mice, and treatments with vehicle, cisplatin, SMI#9 or 
SMI#9 + cisplatin were initiated when the lesions were ~150 mm3. Compared to controls, MDA-
MB-231 tumors responded poorly to cisplatin or SMI#9 given individually; however, in mice that 
received a combination of SMI#9 and cisplatin, tumor growth was significantly inhibited as 
compared to cisplatin, SMI#9, or vehicle controls (P <0.0001,one-way ANOVA) (Figure 2.12;  
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FIGURE 2.11 SMI#9 pre-treatment inhibits the ability of MDA-MB-231 cells to form 
tumors and enhances cisplatin (CDDP) sensitivity in vivo. (A-D) MDA-MB-231 cells were 
treated overnight with vehicle, SMI#9, cisplatin (CDDP), or SMI#9 + CDDP and 5 × 106 viable 
cells were implanted into the mammary fatpads of female nude mice. (A) Tumor volumes 
measured twice weekly (mean ± S.E.M), and (B) vertical scatter plots of mass of excised tumors 
at time of sacrifice. (C) H&E analysis of tumors. Arrow in control shows angiogenesis; long 
and short arrows in SMI#9 and SMI#9+CDDP indicate mitotic catastrophe and apoptosis, 
respectively. (D) Immunohistochemical staining of Rad6 and PCNA in control and SMI#9 
groups. Inset panels show enlarged images. (E-H) MDA-MB-231 cells (5 × 106) were 
implanted orthotopically and when the tumors reached ~ 150 mm3, mice were randomly 
assigned to vehicle control, CDDP (4 mg/kg body weight, once/week, intraperitoneal), SMI#9 
(2.5 mg/kg body weight, twice/week, intratumoral), or a combination of SMI#9 and CDDP 
groups. Data are analyzed by one way ANOVA and 2-tailed Student’s t test. Figure contributed 
by Matthew Sanders, Ph.D. 
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Panels A and B). H&E staining showed vascularized tumors in control and cisplatin treated 
animals. Tumors from the SMI#9 treated group showed the presence of apoptotic (Figure 2.11; 
Panel D, long arrow) and multinucleated giant cells (Figure 2.11; Panel D, short arrow), which 
was enriched in the tumors derived from SMI#9 and cisplatin combination treatments (Figure 2.11; 
Panel D, long and short arrows). Consistent with our data in Figures 2.3 and 2.4, western blot 
analysis of tumor lysates showed PCNA monoubiquitination in cisplatin treated mice but not in 
control or SMI#9 treated mice (Figure 2.12; Panel C).  Rad6 protein levels were marginally 
induced by cisplatin treatment, whereas Rad18 and FANCD2 protein levels were not consistently 
altered (Figure 2.12; Panel C). These in vivo data confirm in vitro data in Figures 2.1 – 2.3 and 
provide further support for an important role for Rad6 in tumor growth and progression and the 
therapeutic potential of SMI#9 in sensitizing cisplatin-resistant tumors and inhibiting tumor 
growth. 
2.4 Discussion 
In this chapter, we present evidence to support a critical role for Rad6 in repair of platinum 
compound-induced DNA damage and the potential therapeutic impact of SMI#9, a Rad6-selective 
small molecule inhibitor, in sensitization of TNBC cells to cisplatin. Using a mismatch repair 
deficient HCT116 colon cancer isogenic model of oxaliplatin resistance, we also show that the 
Rad6 pathway is constitutively upregulated in oxaliplatin-resistant cells and their oxaliplatin 
sensitivity is enhanced by Rad6 inhibition. This chemosensitization by SMI#9 or Rad6B siRNA 
is associated with attenuation in platinum-induced PCNA and FANCD2 ubiquitinations, surrogate 
markers of TLS and FA pathway activation, respectively, providing support for the importance of 
Rad6 catalytic activity in ICL repair and tolerance of platinum-based drugs. These data agree with 
hose of Song et al. who showed regulation of these events by the ubiquitin ligase Rad18 [112], an  
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FIGURE 2.12 SMI#9 enhances sensitivity to cisplatin (CDDP) and inhibits tumor growth 
in vivo. MDA-MB-231 cells (5 × 10
6
) were implanted orthotopically and when tumors reached 
~ 150 mm
3
, mice were randomly assigned to vehicle control, CDDP (4 mg/kg body weight, 
once/week, intraperitoneal), SMI#9 (2.5 mg/kg body weight, twice/week, intratumoral), or 
SMI#9+CDDP groups. A) Tumor volumes measured twice weekly (mean ± S.E.M). B) Vertical 
scatter plots of tumor masses at time of sacrifice. C) Tumor lysates from each treatment group 
were analyzed by western blot for indicated proteins. Arrow indicates monoubiquitinated 
PCNA. PCNA monoubiquitination was verified in the adjacent blot. * indicates nonspecific 
band recognized by anti-mouse antibodies. D) H&E analysis. Arrow in control shows 
angiogenesis; long and short arrows in SMI#9 and SMI#9 + CDDP indicate apoptosis and 
multinucleated giant cells, respectively. Data are analyzed by one way ANOVA and 2-tailed 
Student’s t test. 
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enzyme whose activity requires the ubiquitin conjugating catalytic activity of Rad6.  
gH2AX and FANCD2 participate in the same pathway in response to ICL damage [121]  
and gH2AX foci and FANCD2 activation provide an indirect measurement of DSBs [122]. Our 
data show that gH2AX, FANCD2 and PCNA ubiquitination are concurrently activated during 
cisplatin-induced damage response, and Rad6 inhibition attenuates all these events. This is further 
corroborated by not only the failure to form gH2AX and FANCD2 nuclear foci in SMI#9 treated 
cells but also by the localization of gH2AX, FANCD2 and Rad6 immunoreactivities in the nuclear 
periphery and cytoplasm of Rad6 inhibited cells. gH2AX is regarded as a canonical marker for 
DSBs; however, the decrease in gH2AX levels and foci noted in our study corresponds to a collapse 
rather than completion of repair as evidenced by decreased repair of cisplatin-DNA adducts in 
SMI#9 treated cells. This is further supported by our data that show Rad6 inhibition hampers 
cisplatin-induced colocalization of gH2AX with CldU-labeled replication fork restart sites, 
implicating a central role for Rad6 in assembly/recruitment of repair factors and ICL processing. 
Subcellular fractionation analysis showed that cisplatin-induced monoubiquitinated FANCD2 
peaks before monoubiquitinated PCNA, a key event for the recruitment of TLS polymerases [103, 
110, 112, 123]. SMI#9 decreased the levels of both cisplatin-induced FANCD2 and PCNA 
ubiquitinations, indicating that Rad6 catalytic activity is required for these modifications but that 
Rad6-induced PCNA monoubiquitination is not a prerequisite for FANCD2 activation. These 
findings agree with Fu et al. who demonstrated rise in monoubiquitinated FANCD2 prior to 
monoubiquitinated PCNA [105]. Studies using replication-competent Xenopus cell-free extracts 
similarly showed that TLS events occur distal to FANCD2-FANCI activation when replication 
forks converge on ICLs [102] but differ from others that showed PCNA ubiquitination is a 
prerequisite for Rad18-induced FANCD2 monoubiquitination [112].  
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  We have taken advantage of IdU and CldU thymidine analogs to analyze the effects of 
Rad6 inhibition or depletion on DNA replication during and after replication stalling with cisplatin 
[124] . Consistent with the intrinsic cisplatin resistance of BRCA1 wild type MDA-MB-231 cells, 
these cells efficiently resume DNA replication after exposure to cisplatin; however, this is strongly 
impeded by Rad6 inhibition or silencing. IdU and CldU incorporation experiments also revealed 
that the DNA replication inhibition by SMI#9 or Rad6B siRNA is selective to mid S/late-S phase 
cells. Replication of heterochromatin segments occurs in late-S phase [125], and inhibition of 
heterochromatin replication may be critical due to their temporal proximity to mitosis and 
increased susceptibility to mutagenic damage because of their location at the nuclear periphery 
[126]. The proportion of HR decreases as cells progress to late-S and G2 phases [127], whereas 
Rad6 is maximally expressed in late-S/G2 phases of the cell cycle [77]  and SMI#9 induces G2/M 
arrest in human breast cancer cells [78], providing further support for an important role for Rad6 
in synthesis of DNA in late-S phase. Although IdU was efficiently incorporated in initial DNA 
labeling, continuation of DNA synthesis as measured by CldU incorporation was reduced in both 
SMI#9 and Rad6B siRNA cells, albeit more severely in Rad6B siRNA cells. These data suggest 
that Rad6 is not required for initiation of DNA synthesis but is necessary for replication 
progression in heterochromatin. Since the impact on DNA replication progression was more severe 
with Rad6B siRNA as compared to SMI#9, it is plausible that Rad6 may have other roles that are 
independent of its catalytic activity. Our data also suggest that the intra-S checkpoint activated by 
cisplatin-induced DNA damage in BRCA1 wild type breast cancer cells is not robust but is 
strengthened in mid/late-S phase by the Rad6 inhibitor.  TLS occurs both in S and G2 phases of 
cell cycle [128], and is dependent upon the activity of damage-induced PCNA monoubiquitination 
by Rad6/Rad18 [110, 123]. Monoubiquitination of PCNA plays a critical role in switching 
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replicative polymerases with Y family TLS polymerases Pol h, Pol i, Pol k or Pol z [71]. We 
analyzed Pol h recruitment into foci formation as it has the highest affinity for PCNA and is the 
first TLS polymerase that is recruited to stalled replication forks to initiate nucleotide insertion at 
the damaged template [102]. Consistent with the decreases in cisplatin-induced PCNA and 
FANCD2 ubiquitinations in Rad6 inhibited or Rad6B depleted cells, the robust PCNA, FANCD2 
and Pol h foci signals induced by cisplatin in control cells were dramatically reduced in Rad6B 
siRNA cells. However, recently Hung et al. reported that monoubiquitination of histone H2B 
facilitates lesion bypass and fork recovery [129]. Since Rad6 catalytic activity is also required for 
Bre1 E3 ligase regulated histone H2B monoubiquitination, these data further substantiate the 
importance of Rad6 in fork recovery and gap filling repair following damage. 
 Clinical data suggest that patients with defects in BRCA1 and BRCA2 have better overall 
responses to platinum-based therapies because of the critical roles these proteins play in HR of 
cisplatin-induced DNA damage [130-133]. The augmentation of BRCA1 wild type breast cancer 
cell cisplatin sensitivity by Rad6 inhibition not only supports the important role of Rad6/TLS in 
platinum-induced ICL repair and tumor survival, but also brings to light the potential therapeutic 
advantage of leveraging this target for treatment of HR-competent TNBCs. 
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CHAPTER 3-THE RAD6 TRANSLESION SYNTHESIS PATHWAY PROMOTES 
HOMOLOGOUS RECOMBINATION MEDIATED REPAIR OF CISPLATIN INDUCED 
DNA CROSSLINKS IN BRCA1 WILD TYPE AND BRCA1 MUTANT TRIPLE 
NEGATIVE BREAST CANCERS 
 
3.1 Introduction 
As discussed in Chapter 2, the TLS and FA pathways crosstalk to repair ICLs, restart 
replication forks and enhance platinum resistance. In this chapter, we present data that demonstrate 
a role for Rad6-mediated TLS in promoting FA and HR pathways in repair of cisplatin induced 
damage in BRCA1 wild type and BRCA1 mutant TNBCs.  
The clinical benefit of platinum drugs in breast cancer was first demonstrated by Sledge et 
al. [134]. This study found that while only one of seven (14%) ER-positive patients responded to 
cisplatin, five of eight (63%) ER-negative patients responded to cisplatin, implicating a use for 
cisplatin in TNBC treatment [134]. Resurgence of interest in cisplatin use for TNBC treatment was 
driven by the fact that approximately 35% of TNBCs are BRCA1 mutated and most sporadic 
TNBCs manifest BRCAness features [7, 135]. This dysfunction in BRCA1 impairs HR capacity 
and is proposed to sensitize TNBC cells to DSBs inducing agents. In this context, use of platinum-
based compounds in BRCA1 mutant TNBCs invokes synthetic lethality as these agents induce 
DSBs which are left unrepaired due to impaired HR activity. Several clinical studies substantiate 
this observation and demonstrate patients with BRCA1 mutated TNBCs display improved 
response rates to cisplatin [133, 136-139].  However, cisplatin associated toxicity and acquired 
resistance to cisplatin are still of concern, particularly since resistance can arise from secondary 
mutations in BRCA1 that restore BRCA1 function [140, 141].  
In chapter 2, we showed a direct role for Rad6 ubiquitin-conjugating activity in 
coordinating activation of the FA and TLS pathways in cisplatin treated MDA-MB-231 TNBC 
cells. Given these cells are BRCA1 wild type, the ability of SMI#9 to sensitize these cells to 
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cisplatin suggests a role for Rad6 in coordinating crosstalk between TLS, FA and HR. Using 
BRCA1 wild type MDA-MB-468, and BRCA1 mutant SUM1315 and HCC1937 TNBC cell lines 
we show that inhibition of Rad6-mediated TLS with SMI#9 sensitizes them to cisplatin regardless 
of their BRCA1 status. Additionally, these cell lines represent the basal (MDA-MB-468 and 
HCC1937) and mesenchymal (SUM1315) subtypes of TNBCs, which are the most prevalent and 
aggressive. SMI#9 pretreatment attenuated cisplatin-induced monoubiquitination of PCNA, and 
reduced FANCD2 and gH2AX steady-state levels. Consistently, cisplatin-induced colocalization 
of gH2AX with Pol h, FANCD2, and Rad51 were diminished in cells treated with SMI#9. 
Evaluation of the restart of cisplatin-induced stalled replication forks showed that Rad6 inhibition 
blocked the restart of stalled replication forks in both BRCA1 wild type MDA-MD-468 and 
BRCA1 mutant SUM1315 TNBC cells.  To examine whether loss of Rad6 directly impacted HR, 
we used BRCA1 wild type HeLa cells stably transfected with the DR-GFP vector to measure DSB-
induced HR. Whereas cisplatin increased HR efficiency, SMI#9 pretreatment decreased DSB-
induced HR. Taken together, our data imply a critical role for Rad6-mediated TLS in promoting 
HR in the repair of cisplatin-induced DNA damage, and suggest that targeting Rad6 catalytic 
activity may be universally beneficial to both BRCA1 wild type and BRCA1 mutant TNBCs. 
3.2 Materials and methods 
3.2.1 Cell lines and cell culture 
BRCA1 wild type MDA-MB-468, and BRCA1 mutant SUM1315 and HCC1937 TNBC 
cell lines were purchased from ATCC and propagated as described in Chapter 2.  BRCA1 wild 
type HeLa cervical cancer cell line stably transfected with the DR-GFP vector containing an I-
SCE1 cut site was graciously provided by Dr. J. Parvin (Department of Biomedical Informatics at 
the Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus, OH, 
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USA).  HeLa cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)/F-12 
supplemented with 5% fetal bovine serum and 1.5 µg/mL of puromycin. All cells were retained at 
37°C with 5% CO2. Cell lines were expanded and multiple aliquots were cryopreserved. Cells 
were used within 10-15 passages. MDA-MB-468 and HCC1937 cells represent basal TNBCs and 
SUM1315 cells represent mesenchymal TNBCs. 
3.2.2 Patient survival and copy number data mining analysis 
Overall survival data analysis was performed using the PROGgene database 
( http://www.compbio.iupui.edu/proggene) [142]. PROGgene is a compilation of data from public 
repositories that include GEO, EBI Array Express and The Cancer Genome Atlas (TCGA). With 
64 patient series from 18 cancer types in this database, this tool provides the most comprehensive 
resource available for survival analysis to date. Copy number analysis was performed with 
Oncomine v4.5 database (https://www.oncomine.org/). Oncomine contains a total of 91,866 
samples from 729 datasets, 132 of which are breast cancer datasets with 14,277 samples. 
3.2.3 Cell viability assays 
Cell viability was measured using the standard MTT protocol. MDA-MB-468, HCC1937 
or SUM1315 TNBC cells (3.5-7 X 103) were seeded in 96-well plates. Cells were treated with 
vehicle, various concentrations of cisplatin (0.1-10 µM; Pharmaceutical grade, Sigma) or the 
Rad6-selective small molecular inhibitor SMI#9 (0.1-10 µM) [78]. For drug combination 
experiments, cells were pretreated with SMI#9 (0.1-10 µM) overnight and either treated with 
cisplatin (at equivalent concentrations) or vehicle. Phase contrast images of cells were collected 
on an Olympus IX71 microscope equipped with a Hamamatsu digital camera and viability was 
assessed at 72 h post cisplatin /SMI#9 treatment. Absorbance was read at 570 nm using a Synergy 
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2 microplate reader. Experiments were done with three replicates per dose and results presented 
are representative of at least three independent experiments. 
3.2.4 Colony formation assays 
SUM1315 cells were treated with vehicle, SMI#9 (5 µM dose) or cisplatin (1 µM dose). 
For combination treatment cells were pre-treated with SMI#9 overnight prior to cisplatin 
treatment. Cells were then replated at 100 single cells per well in 24-well plates for colony 
formation. Two to three weeks later, colonies were stained with 0.1% crystal violet in 20% 
methanol for 10 min. Colonies containing >50 cells were scored and colony forming efficiency 
was expressed relative to control cells. Experiments were done in quadruplicate and results 
expressed from at least two independent experiments.  
3.2.5 DNA damage response assays and protein analysis  
Cells (1 x 106) were plated in 100 mm plates and treated with vehicle or cisplatin (1µM for 
SUM1315, 2 µM for MDA-MB-468, and 25 µM for HCC1937) for 4 h. To assess the impact of 
Rad6 inhibition, cells were pretreated with SMI#9 (5 µM for SUM1315, 3 µM for MDA-MB-468, 
2 µM for HCC1937) overnight prior to cisplatin treatment.  Post cisplatin treatment, cells were 
washed with PBS and allowed to recover in drug free medium for 0-24 h. At the indicated time 
points, cells were lysed in Triton X-100 lysis buffer supplemented with protease inhibitors. Protein 
matched samples from each cell line were separated by SDS-PAGE and transblotted onto 
Immobilon P membranes. Blots were probed with anti-Rad6 [76], anti-PCNA (Dako, CA), anti-
FANCD2 (Novus Biologicals, CO), anti-b-actin (Sigma-Aldrich Chemicals, MO), anti-gH2AX 
(BioLegend, CA), anti-Rad18 (Imgenex Corp., CA), anti-Pol h (Abcam, MA), and anti-Rad51 
(Calbiochem, MA) antibodies. Proteins were visualized by chemiluminescence with anti-rabbit or 
anti-mouse secondary antibodies coupled to horseradish peroxidase. For PCNA ubiquitination 
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analysis, appropriate MDA-MB-468 and SUM1315 lysates were subjected to immunoprecipitation 
with anti-PCNA or corresponding normal IgG antibodies, and protein A/G captured immune 
complexes were analyzed by immunoblotting with anti-ubiquitin antibody. The membranes were 
stripped and reprobed with anti-PCNA antibody to verify efficiency of PCNA pulldown among 
samples. 
3.2.6 Replication fork restart assay   
MDA-MB-468 and SUM1315 TNBC cells were labeled and DNA fibers were spread and 
immunolabeled as described in Materials and Methods of Chapter 2. Briefly, cells were pulsed 
with 200 µM IdU( Sigma-Aldrich Chemicals, MO) for 45 min and washed with PBS prior to 
treatment with vehicle or cisplatin (1 µM for SUM1315 and 2 µM for MDA-MB-468) for 1 h. 
Cells were washed with PBS and allowed to recover for 1 h in drug free medium prior to being 
pulse labeled with 200 µM CldU (Sigma-Aldrich Chemicals) for 45 min [109]. To investigate the 
impact of Rad6 inhibition, cells were treated with vehicle or SMI#9 for 12 h prior to initial IdU 
labeling. After labeling, cells were trypsinzed, resuspended in PBS and spotted onto glass 
microscope slides. Cells were mixed with 7 µl of DNA lysis buffer and slides were tilted to allow 
spreading of DNA fibers. DNA was denatured in 1.5 N HCl for 45 min at room temperature prior 
to incubation with 5% BSA blocking solution. Slides were then immunoloabeled with anti-IdU 
and anti-CldU antibodies and respective Texas Red- or FITC-conjugated secondary antibodies. 
Images were taken from randomly selected fields of untangled DNA fibers and analyzed by Image 
J software. Approximately 35-75 individual fibers were analyzed for each experiment and the 
average of three independent experiments presented. 
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3.2.7 Immunofluorescence staining  
MDA-MB-468, SUM1315, and HeLa cells were grown on coverslips and treated for 12 h 
with vehicle or SMI#9 (1 µM). Cells were then treated with cisplatin (2.5 µM for MDA-MB-468, 
1 µM for SUM1315, and 0.04 µM for HeLa) for 4 h and allowed to recover in drug free medium 
for 6 h. Cells were fixed in 10% buffered formalin and permeabilized with methanol/acetone (1:1, 
v/v). Slides were incubated with anti-gH2AX/anti-FANCD2, anti-gH2AX/anti-Pol h (Abcam, 
MA), or anti-gH2AX/anti-Rad51 antibodies followed by corresponding Texas Red- and Orange 
Green-conjugated mouse and rabbit secondary antibodies (Molecular Probes, OR). Nuclei were 
counterstained with DAPI. Slides were also stained in the absence of primary antibody or with 
isotype matched nonimmune IgG to assess nonspecific reactions. Images were collected on an 
Olympus BX40 microscope equipped with a Sony high resolution/sensitivity CCD video camera 
and SlideBook software. The results shown are representative of data collected from ~ 75-100 cells 
in five to ten fields and two independent experiments. 
3.2.8 Homologous recombination assay	 
BRCA1 wild type HeLa cells were treated with 0.04 µM cisplatin for 4 h and incubated in 
drug free media for 3 h prior to I-SCE1 transfection. I-SCE1 plasmid was graciously provided by 
Dr. Tej Pandita (Department of Radiation Oncology at the Houston Methodist Research Institute, 
Houston, Texas). To assess the contribution of Rad6 to HR, cells were pretreated with 1 µM SMI#9 
for 12 h prior to cisplatin treatment. Transient transfections were done with the Metafectene Pro 
transfection reagent (Biontex Laboratories, Germany) per the manufacturer’s directions.  Cells 
were transfected with 0.7 µg I-SCE1 and 40 ng of the pRL-TK vector (Renilla luciferase reporter 
vector, Promega) to normalize transfection efficiency variations. Cell images were taken 72 h post-
transfection.  The percent of GFP+ cells was quantified with Image J and by flow cytometry. For 
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flow cytometry, cells were trypsinized and 1 x 106 viable cells, as assessed by trypan blue 
exclusion, were washed with PBS. Cells were suspended in 50 µl PBS with 0.5 µg/µl of propidium 
iodide. GFP expression was analyzed with Amnis ImageStreamX Mark II and quantified with the 
IDEAS software. Flow cytometry was performed at the Microscopy, Imaging, and Cytometry 
Resources Core at Wayne State University School of Medicine. Renilla luciferase activity was 
measured using Promega Dual Luciferase Assay system. HR efficiency was normalized against 
Renilla luciferase activity to correct for transfection efficiency variations. The results shown are 
representative of data collected from ~ 25-50 cells in three to five fields and two independent 
experiments.  
3.2.9 Statistical analysis 
Statistical analysis was performed with GraphPad Prism. Statistical comparisons between 
two groups were analyzed by two-tailed Student's t test and p < 0.05 was considered significant. 
3.3 Results 
3.3.1 Rad6 is overexpressed in BRCA1 wild type and BRCA1 mutant TNBC cell lines and 
clinical breast cancer tissues.   
We have previously shown that platinum response and acquisition of resistance is 
associated with overexpression of  TLS pathway proteins [143]. As Rad6 is a fundamental 
component of TLS, we examined steady state levels of Rad6 in four TNBC cell lines compared to 
the non-transformed MCF10A cells. Western blot analysis with an anti-Rad6 antibody [76] 
demonstrated overexpression of Rad6 in BRCA1 wild type (MDA-MB-231 and MDA-MB-468) 
and BRCA1 mutant (SUM1315 and HCC1937) TNBC cell lines compared to normal behaving 
MCF10A cells (Figure 3.1; Panel A).  Immunofluorescence staining verified western blot data and 
showed intense Rad6 cytoplasmic staining in both BRCA1 wild type and BRCA1 mutant TNBC 
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cell lines, whereas MCF10A cells displayed weak Rad6 immunoreactivity (Figure 3.1; Panel B). 
Immunohistochemical staining of clinical breast tissues showed weak Rad6 staining 
predominantly in the cytoplasm of cells in normal breast tissues (Figure 3.1; Panel Ca). In contrast, 
Rad6 staining was robustly detected in the cytoplasmic and nuclear compartments of the normal 
ducts of BRCA1 mutant tumors (Figure 3.1; panel Cb) as well as in BRCA1 wild type and BRCA1 
mutant infiltrating ductal carcinomas (Figure 3.1; Panels Cc and Cd, respectively). These data 
demonstrate Rad6 overexpression regardless of BRCA1 status.                                                                     
We have previously identified Rad6B, rather than Rad6A, to be overexpressed in breast 
cancer lines and tumor tissues, and that its expression correlates with breast cancer progression 
and chemoresistance [76, 77]. Oncomine analysis of Rad6A and Rad6B copy number gain in 
invasive lobular breast carcinomas compared to normal breast tissue revealed a 1.06 log2 fold 
increase in Rad6B (P = 1.31 X 10-4; Figure 3.2 Panel A). Similar analysis of Rad6A and Rad6B 
copy number gain in invasive ductal breast carcinomas with lymph node metastasis compared to 
invasive ductal carcinoma without lymph node infiltration, revealed a 1.02 log2 fold increase in 
Rad6B expression with lymph node infiltration (P = 0.048; Figure 3.2; Panel B). Neither analysis 
showed a significant correlation with Rad6A.  To evaluate the clinical association of Rad6 
expression with TNBC patient survival, we utilized The Cancer Genome Atlas (TCGA). TCGA 
datamining corroborated previous data and showed that TNBC patients with high Rad6B 
expression were 2.34 times more likely to die from their disease than those with low Rad6B 
expression (hazard ratio = 2.34 (5% CI, 1.6-3.43) P = 0.0001; Figure 3.2; Panel D).  This 
association was not evident with Rad6A (hazard ratio = 1.32 (95% CI, 0.75-2.35) P= 0.33;  
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FIGURE 3.1 Rad6 is overexpressed in breast cancer. A) Western blot analysis of Rad6 and 
b-actin from whole cell lysates collected from nontranformed MCF10A cells and TNBC cells. 
B) Immunofluorescence staining of Rad6 (green) in nontransformed MCF10A cells (panel a), 
in BRCA1 wild-type MDA-MB-231 and MDA-MB-468 cells (panels b and d, respectively), 
and in BRCA1 mutant SUM1315 and HCC1937 cells (panels c and e, respectively). 
Counterstained with DAPI (blue). C) Immunohistochemical staining of Rad6B in normal breast 
tissue (panel a), in the normal ducts of BRCA1 mutant tumor (panel b), and in BRCA1 wild 
type (panel c), and BRCA1 mutant infiltrating ductal carcinomas (panel d).  
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FIGURE 3.2 Rad6B is associated with aggressive breast cancer and decreased triple 
negative breast cancer patient survival.  A-B) Oncomine analysis of UBE2A/Rad6A and 
UBE2B/Rad6B copy number gain in invasive lobular breast carcinoma compared to normal 
(A) and in node negative invasive ductal breast carcinoma compared to node positive invasive 
ductal breast carcinoma (B). n=1,602 and 18,823 gene measured. C-D) TCGA analysis of 
Rad6A (C) and Rad6B (D) gene expression in correlation with TNBC patient survival. Hazard 
ratio (HR) (Red: high expression. Green: low expression. n= 297) 
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Figure 3.2; Panel C). These data verify the role of Rad6B in aggressive breast cancers regardless 
of their BRCA1 status, and suggest that Rad6B could be a potential therapeutic target in BRCA1 
wild type and BRCA1 mutant TNBCS. While our Rad6-selective inhibitor SMI#9 is not specific 
to Rad6B, utilization of this inhibitor would still elicit therapeutic benefit as it will target both 
Rad6A and Rad6B [78]. 
3.3.2 Inhibition of Rad6 sensitizes TNBC cells to cisplatin  
Clinical data suggest BRCA1 wild type TNBCs display enhanced resistance to cisplatin 
compared to their BRCA1 mutant counterparts, presumably due to a functional HR pathway [133, 
136-139, 144, 145]. To ascertain the responses of BRCA1 wild type and BRCA1 mutant TNBC 
cell lines to cisplatin, we performed cell viability assays with increasing doses of cisplatin (Figure 
3.3). Contrary to clinical data, we did not observe such a correlation. In our hands, the BRCA1 
mutant HCC1937 TNBC cell line showed the greatest resistance to cisplatin (IC50 = 25 µM, Figure 
3.3; Panels Ca and Cc) followed by the BRCA1 wild type MDA-MB-231 (IC50 10 µM; Chapter 
2), MDA-MB-468 (IC50 = 3.8 µM, Figure 3.3; Panels Aa and Ac), and BRCA1 mutant SUM1315 
(IC50 = 3.7 µM, Figure 3.3; Panels Ba and Bc) TNBC cell lines. These data are consistent with 
that of Lehmann et al. who also observed enhanced cisplatin resistance in the BRCA1 mutant 
HCC1937 cells compared to the BRCA1 wild type MDA-MB-468 TNBC cells [19]. To evaluate 
the impact of Rad6 inhibition on cisplatin response, TNBC cells were pretreated with SMI#9 prior 
to cisplatin treatment at equivalent doses. Regardless of the BRCA1 status and cisplatin sensitivity, 
pretreatment with SMI#9 sensitized cells to cisplatin treatment, albeit only marginally in the 
BRCA1 mutant SUM1315 cell lines (Figure 3.3; Panel B). To investigate the nature of this 
sensitization, isobolograms were constructed using the IC50 doses of each drug singly and in 
combination. SMI#9 and cisplatin showed synergy in all cell lines, except the BRCA1 mutant  
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FIGURE 3.3 Rad6 inhibition synergistically enhances TNBC cell lines to cisplatin 
(CDDP). MTT assays were performed using BRCA1 wild-type MDA-MB-468 (Aa) TNBC 
cells and BRCA1 mutant SUM1315 (Ba) and HCC1937 (Ca) TNBC cells. Cells were either 
treated with CDDP and SMI#9 alone or pretreated with SMI#9 followed by CDDP. Ab, Bb, 
and Cb) Isobolograms were constructed with the IC50 values of CDDP, SMI#9, and SMI#9 + 
CDDP.  Ac, Bc and Cc) Tabular representation of IC50 values for CDDP, SMI#9, and SMI#9 
+ CDDP treatments. All results are mean ± S.D. from three independent experiments.  
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FIGURE 3.4 SMI#9 inhibition diminishes clonogenic potential of SUM1315 TNBC cells 
in response to cisplatin (CDDP). A-B) SUM1315 cells treated with vehicle, SMI#9 (5µM), 
CDDP (1µM), or SMI#9 +CDDP were trypsinized and reseeded in triplicate at 100 cells per 
well. *P < 0.05, Student’s t-test comparing colony formation efficiency of treatment to 
control. B) Visual representation of colony forming potential.  All results are mean ± S.D. 
from three independent experiments.  
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SUM1315 cell line (Figure 3.3; Panels Ab, Bb and Cb). To investigate whether the lack of synergy 
resulted from cytostatic cell survival, the effect of SMI#9 pretreatment on cisplatin sensitivity in 
BRCA1 mutant SUM1315 cells was validated with clonogenic assays.  These assays showed that 
while treatments with SMI#9 or cisplatin alone significantly reduced the clonogenic potential of 
of SUM1315 cells by ~40% (P < 0.05), pretreatment with SMI#9 drastically reduced the 
clonogenic potential of cisplatin treated cells by >90% compared to control (Figure 3.4; Panels A 
and B). These data indicate that SMI#9 pretreatment synergistically enhances cisplatin sensitivity 
in TNBC cells regardless of BRCA1 status. 
3.3.3 Rad6 inhibition diminishes cisplatin induced TLS, FA and HR pathway activation  
Our data implicate a role for Rad6 in cisplatin response in both BRCA1 wild type and 
BRCA1 mutant TNBC cell lines. Previously, we have shown in the BRCA1 wild type MDA-MB-
231 cell line that SMI#9 associated cisplatin sensitivity results from attenuated TLS and FA 
activation as measured by decreases PCNA and FANCD2 monoubiquitinations, respectively 
[143]. To determine if this response was consistent across our panel of TNBC cell lines, the steady 
state levels of Rad6, Rad18, PCNA, FANCD2, gH2AX, pol h and Rad51 were analyzed by western 
blotting. BRCA1 wild type and BRCA1 mutant TNBCs were pretreated with vehicle or SMI#9 for 
12 h followed by treatment with cisplatin for 4 h. Whole cell lysates were collected at the indicated 
time points post-cisplatin washout. Whereas cisplatin treatment induced Rad6 expression in the 
BRCA1 mutant SUM1315 cells, there were no notable changes in BRCA1 wild type or BRCA1 
mutant MDA-MB-468 and HCC1937 cells, respectively (Figure 3.5). Further, cisplatin treatment 
did not affect the steady state levels of Rad18 or nascent PCNA in any of the cell lines examined. 
Similarly, to what was observed in the BRCA1 wild type MDA-MB-231 cells (Chapter 2, and 	
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FIGURE 3.5 Rad6 inhibition reduces PCNA ubiquitination and attenuates FANCD2 and 
Pol h expression. BRCA1 wild type MDA-MB-468 (A and D) and BRCA1 mutant SUM1315 
(B and E) and HCC1937 (D) TNBC cells were treated for 4 h with cisplatin (CDDP), with or 
without SMI#9 pretreatment. Whole cell lysates were then collected at the indicated time points 
post CDDP washout and subjected to western blot analysis for target proteins.  D and E) 
Extracts prepared from MDA-MB-468 (D) and SUM1315 (E) cells 0 h and 24 h post-CDDP 
washout, with or without SMI#9 pretreatment, were subjected to immunoprecipitation with 
anti-PCNA antibody. Extracts were then analyzed by western blot with anti-ubiquitin antibody. 
PCNA pulldown was verified by reprobing stripped blots with anti-PCNA antibody. E and G) 
Densitometry quantification of monoubiquitnated PCNA as compared to unmodified PCNA. 
To simultaneously analyze the indicate proteins, 4-20% and 4-12% (for PCNA IP) gradient 
gels were used. 
	
A C B 
D 
E 
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[146]), cisplatin treatment induced PCNA monoubiquitination, a surrogate marker of TLS pathway 
activation. This induction became apparent 4-6 h post cisplatin washout and peaked at 24 h post 
washout (Figure 3.5).  Addition of SMI#9 attenuated cisplatin-induced PCNA monoubquitination 
regardless of BRCA1 status. Higher molecular forms of PCNA potentially reflecting 
polyubiquitinated species of PCNA were induced by cisplatin and SMI#9 treatment did not 
influence their levels.  To verify PCNA monoubiquitination and its regulation by cisplatin and 
SMI#9, whole cell lysates prepared from control and treated MDA-MB-468 and SUM1315 cells 
were subjected to immunoprecipitation with anti-PCNA antibody and western blotting with anti-
ubiquitin antibody (Figure 3.5; Panels D and E, respectively). Efficacy of PCNA pulldown was 
confirmed by subsequent stripping of the membrane and immunoblotting with anti-PCNA 
antibody. As shown in Figure 3.5 panels D and E, PCNA associated ubiquitin immunoreactivity 
was present with cisplatin treatment and reduced by the addition of SMI#9 in the BRCA1 wild 
type MDA-MB-468 cells. This response was more robust in the BRCA1 mutant SUM1315 cells 
(Figure 3.5; Panels F and G). Analysis of FANCD2 revealed two immunoreactive bands, 
corresponding to unmodified and monoubiquitinated FANCD2, respectively [113].   Whereas, 
FANCD2 monoubiquitination was enhanced by cisplatin treatment, as monitored by induction of 
the upper band, pretreatment with SMI#9 reduced the overall steady state levels of FANCD2 
expression (Figure 3.5; compare 24 h post cisplatin washout with and without SMI#9 
pretreatment). Similar to PCNA and FANCD2, gH2AX protein expression was induced by 
cisplatin, and attenuated with SMI#9 pretreatment. 	
The TLS and FA pathways are intimately connected with the HR pathway. It has been 
shown that both PCNA and FANCD2 interact with Pol h,  facilitating its recruitment to sites of 
damage. In addition to its role in TLS, Pol h has also been reported to play a role in HR as loss of 
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Pol h caused a 10-fold decrease in HR [147, 148]. To investigate the impact of Rad6 inhibition on 
HR pathway proteins, we examined the regulation of Pol h and Rad51 (an integral HR protein 
required for strand invasion; Figure 3.5). While no significant changes in Rad51 levels were 
observed, pretreatment with SMI#9 drastically delayed cisplatin induced Pol h expression. SMI#9 
induced similar effects on Pol h regulation in both BRCA1 wild type and BRCA1 mutant TNBC 
cells, suggesting an important role for Rad6 in coordinating TLS, FA and HR mediated repair of 
cisplatin-induced damage. 
3.3.4 Rad6 inhibition prevents ICL repair by abrogating replication fork restart and the 
recruitment of DNA damage response proteins to sites of damage 
Our data thus far demonstrate SMI#9 sensitization is associated with diminished cisplatin-
induced activation of TLS and FA. Additionally, SMI#9 pretreatment delays Pol h expression 
suggesting potential disruption of pathway crosstalk between TLS, FA and HR. We have 
previously shown Rad6 inhibition abrogates replication fork restart in BRCA1 wild type MDA-
MB-231 TNBC cells (Chapter 2 and [146]). To investigate this mechanism further, BRCA1 wild 
type MDA-MB-468 and BRCA1 mutant SUM1315 cells were treated with vehicle or SMI#9 prior 
to being labeled with IdU. Cells were then treated with cisplatin, allowed to recover, and labeled 
with CldU (Figure 3.6; panel A). Replication fork restart was measured by quantifying the total 
number of Idu/CldU colabeled replication tracks. Whereas both MDA-MB-468 and SUM1315 
control cells efficiently incorporated IdU and CldU, cisplatin reduced replication fork restart in 
SUM1315 cells potentially reflecting its BRCA1 deficiency but not in MDA-MB-468 cells (Figure 
3.6; Panels B-E). Regardless of cisplatin sensitivity and BRCA1 status, treatment with SMI#9 
reduced replication fork restart and combining SMI#9 with cisplatin further decreased the ability 
of cells to restart stalled replication forks (Figure 3.6; Panels C and E; P < 0.0001).  
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FIGURE 3.6. SMI#9 prevents replication fork restart and recruitment of DNA damage 
response protein to sites of DNA damage. A) Labeling scheme for replication restart assay.  B-
C) BRCA1 wild-type MDA-MB-468 (B) and BRCA1 mutant SUM1315 (C) TNBC cells were 
IdU/CldU labeled. Cells were subjected to DNA combing and DNA fibers were immunolabeled 
with anti-IdU (red) and anti-CldU (green) antibodies.  Bar graphs display percent of replicating 
foci which have restarted (IdU/CldU), stalled (IdU) or been newly fired (CldU). Approximately 
35-75 individual cells or fibers were analyzed for replication fork restart and the average of three 
independent experiments presented. 
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To further investigate the crosstalk between TLS, FA and HR pathways in repair of 
cisplatin-induced DNA damage in TNBC cells, we analyzed the impact of Rad6 inhibition on 
repair protein recruitments to the sites of DNA damage. MDA-MB-468 and SUM1315 TNBC cells 
were grown on coverslips and treated with either vehicle, cisplatin for 4 h with or without SMI#9 
pretreatment, or SMI#9 alone. Cells recovered in drug free medium for 6 h prior to being fixed 
and were then subjected to dual immunofluorescence analysis of gH2AX/FANCD2, gH2AX/Pol 
h, or gH2AX/Rad51. Whereas cisplatin treatment enhanced colocalizations of FANCD2 and Pol 
h with gH2AX, SMI#9 treatment reduced this colocalization in both BRCA1 wild type MDA-MB-
468 cells (Figure 3.7; Panels A-D; P <0.0001 and P = 0.0385, respectively) and BRCA1 mutant 
SUM1315 cells (Figure 3.7; Panels G-J; P = 0.0008 and P = 0.0016, respectively). Additionally, 
SMI#9 treatment reduced gH2AX foci formation, similarly to the data presented for the BRCA1 
wild type MDA-MB-231 cells in Chapter 2 [146]. The reduction in gH2AX foci formation is 
consistent with the decrease in gH2AX observed in the western blots (Figure 3.5; Panels A and B). 
Although a slight increase in colocalized foci were seen in SMI#9 + cisplatin groups as compared 
to SMI#9 alone (Figure 3.7; Panels A-D and G-J), the levels were significantly lower than that in 
the cisplatin groups, indicating that loss of Rad6 can impede cisplatin-induced recruitment of 
FANCD2 and Pol h to the sites of DNA damage. Investigation into the association of Rad51 with 
gH2AX showed that in control MDA-MB-468 cells, Rad51 is sequestered into diffuse pools or 
compartments (Figure 3.7; Panel E Control, white arrow) but become mobilized into discrete foci 
that show colocalization with gH2AX when treated with cisplatin (Figure 3.7; Panel E CDDP).  
Treatment with SMI#9 had no impact upon cisplatin-induced Rad51 mobilization and foci 
formation but showed decreased colocalization with gH2AX (Fig. 3.4, Panel E; P = 0.0093).  
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FIGURE 3.7. SMI#9 prevents replication fork restart and recruitment of DNA damage 
response protein to sites of DNA damage.  MDA-MB-468 (A-F) and SUM1315 (G-K) cells 
were treated with control, cisplatin (CDDP) for 4 h with or without SMI#9 pretreatment, or 
SMI#9 alone. Cells were allowed to recover in drug free medium for 6 h and then subjected to 
co-immunolabeling with FANCD2 (A-B and G-H; green), Pol h (C-D and I-J; green) or 
Rad51 (E-F and K-L; green) and gH2AX (red). Bar graphs show the percent of cells with 
colocalization (> 5 foci). 
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Similar analysis of BRCA1 mutant SUM1315 cells showed diffuse Rad51 and gH2AX 
immunoreactivities in control cells that were not assembled into discrete foci following cisplatin 
treatment (Figure 3.7; Panel K). These data suggest that BRCA1, and not Rad6, is required for 
Rad51 activity. However, since Rad6 is necessary for assembly of gH2AX, inhibition of Rad6 
impedes recruitment of Rad51 to the damage sites. These data agree with Bhattacharyya et al. who 
reported that loss of BRCA1 results in defective Rad51 foci formation [149].  
In Chapter 2, we  showed that gH2AX colocalizes with CldU at sites of replication fork 
restart [143]. Thus, these data potentially suggest that in both BRCA1 wild type and BRCA1 
mutant TNBC cells, loss of Rad6 disrupts recruitment of these proteins to stalled replication forks 
impeding replication fork restart. 
3.3.5 Rad6 inhibition mitigates HR pathway activity.	 
Our data suggest that Rad6 participates in coordinating the activities of TLS, FA and HR 
in the restart of cisplatin stalled replication forks, as SMI#9 disrupts PCNA and FANCD2 
monoubiquitinations, delays Pol h expression and impedes protein recruitment to sites of damage. 
To establish a direct role for Rad6 in HR, we utilized the BRCA1 wild type HeLa cervical cancer 
cells carrying the DR-GFP vector (Figure 3.9; Panel A). In this system, expression of exogenous 
I-Sce1 introduces a single DSB, the repair of which by HR creates a functional GFP. To investigate 
the response of HeLa cells to cisplatin and SMI#9, cell viability assays were performed. 
Concordant with TNBC cells, SMI#9 pretreatment synergistically enhanced sensitivity of HeLa 
cells to cisplatin (Figure 3.8; Panel A). To verify a functional TLS, HeLa cells were treated with 
control, cisplatin for 4 h with or without SMI#9 pretreatment, or SMI#9 alone. Cells were allowed 
to recover for 6 h in drug free medium and fixed prior to co-immunolabeling with  
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FIGURE 3.8 Rad6 inhibition sensitizes BRCA1 wild type HeLa cells to cisplatin (CDDP). 
A) Cells were either treated with CDDP and SMI#9 alone or pretreated with SMI#9 followed 
by CDDP.  MTT assays were performed 72 h post CDDP treatment (Aa). Isobologram was 
constructed with the IC50 values of CDDP, SMI#9, and SMI#9 + CDDP (Ab).  Tabular 
representation of IC50 values for CDDP, SMI#9, and SMI#9 + CDDP treatments (Ac). B-G) 
Cells were fixed and co-stained for FANCD2 (B-C; green), Pol h (D-E; green) or Rad51 (F-G; 
green) with gH2AX (red). Accompanying bar graphs display the percentages of colocalized foci 
for each treatment condition.   
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anti-FANCD2/anti-gH2AX, anti-Pol h/anti-gH2AX, or anti-Rad51/anti-gH2AX antibodies. 
Whereas cisplatin treatment induced robust colocalization of FANCD2 and Pol h with gH2AX, 
inhibition of Rad6 reduced this colocalization (Figure 3.8; Panels B-E). Combination treatment of 
SMI#9 with cisplatin further reduced the colocalization of FANCD2 and Pol h with gH2AX 
(Figure 3.8; Panels B-E; P = 0.0006 and P = 0.0003, respectively). Interestingly, investigation into 
the colocalization of Rad51 with gH2AX in these cells did not show distinct Rad51 pools, as seen 
in the BRCA1 wild type MDA-MB-468 TNBC cells, but instead displayed dispersed Rad51 
staining throughout the nucleus (Figure 3.8; Panel F). Cisplatin treatment induced Rad51 
colocalization with gH2AX, which was diminished by SMI#9, and SMI#9 + cisplatin treatments 
(Figure 3.8; Panels F and G; P = 0.0006). These data demonstrate that HeLa cells respond similarly 
to cisplatin as TNBC cells in terms of FANCD2, Pol h, Rad51 and gH2AX foci formation and 
associations, and inhibition of Rad6 causes similar pathway disruptions. 
 To analyze the role of Rad6 in HR, HeLa-DR-GFP cells were treated with cisplatin for 4 
h with or without SMI#9 pretreatment, and then transiently transfected with the I-SCE1 plasmid 
(Figure 3.9; Panel A). At 72 h post transfection, cells were either imaged with an Olympus IX71 
microscope for visual scoring of GFP expression and analysis by Image J software or processed 
for flow cytometry analysis (Figure 3.9; panels B-C and D-G). Image J analysis of GFP expression 
showed a slight increase in HR efficiency in cisplatin group compared to control (4.2% vs 3.5%, 
Figure 3.9; Panel C). Treatment with SMI#9 drastically reduced HR efficiency to control and 
cisplatin (Figure 3.9; Panel C).  To verify Image J data, cells were subjected to flow cytometry 
with an ImageStream Mark II Imaging Flow Cytometer (Figure 3.9; Panels D-G).  The cytometry 
data corroborated the data from Image J analysis and showed ~2.2-fold decrease in HR efficiency 
between cisplatin and SMI#9 + cisplatin treatments (Figure 3.9; Panel H). Renilla expression was 
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measured and did not vary significantly vary between treatment conditions, indicating the 
differences observed in HR efficiency are not due to differences in transfection efficiency (Figure 
3.9; Panel H).  These data provide evidence for a direct role of Rad6 in HR. 
3.4 Discussion 
 In this chapter, we demonstrate the relevance of Rad6 in facilitating crosstalk between TLS, 
FA network and HR in repair of cisplatin-induced interstrand crosslinks and provide support for 
targeting Rad6 activity with SMI#9 for treating both BRCA1 wild type and BRCA1 mutant TNBC 
cells. Immunohistochemical analysis showed Rad6 overexpression in both BRCA1 wild type and 
BRCA1 mutant breast carcinomas and cell lines. Further, TCGA analysis correlated Rad6B (and 
not Rad6A) gene copy number and overexpression in invasive lobular and invasive ductal breast 
carcinomas with lymph node metastasis and decreased TNBC patient survival whereas no such 
association was observed with Rad6A expression. These data are in line with our previous data 
that showed overexpression of Rad6B mRNA in metastatic breast cancer cell lines and tissues as 
compared to nonmetastatic cells [76]. These data support an oncogenic role for Rad6 in breast 
cancer progression, metastasis and patient survival, regardless of their BRCA1 status. As BRCA1 
status is implicated in clinical response to cisplatin, we evaluated the sensitivities of BRCA1 wild 
type and BRCA1 mutant cell lines to cisplatin. MTT cell viability assays showed no correlation 
between BRCA1 status and cisplatin sensitivity, and Rad6 inhibition with SMI#9 enhanced 
cisplatin sensitivity  
We have previously shown that inhibition of Rad6 with SMI#9 sensitizes BRCA1 wild 
type MDA-MB-231 TNBC cells to cisplatin by attenuating TLS and FA network activation, as 
monitored by PCNA and FANCD2 monoubiquitinations, respectively.  To validate this 
mechanism of Rad6 inhibition in BRCA1 wild type and BRCA1 mutant TNBCS, we evaluated  
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FIGURE 3.9 Rad6 inhibition diminishes homologous recombination (HR). A) Plasmid 
construct for HR repair assay. B-C) HeLa cells stably transfected with the DR-GFP plasmid 
were treated with cisplatin (CDDP) for 4 h with or without SMI#9 pretreatment and then 
transiently transfected with the I-SCE1 plasmid. 72 h post transfection, cells were either imaged 
with an Olympus IX71 microscope and scored for GFP expression Image J analysis (B) or 
trypsinized and analyzed by ImageStream Mark II Imaging Flow Cytometry (C). D) Table of 
HR repair efficiency. Data expressed as mean ± S.E.M from at least 2 independent experiments. 
E) HR efficiency was normalized against Renilla luciferase activity to correct for transfection 
efficiency. 
	
C 
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PCNA and FANCD2 monoubiquitination in our panel of BRCA1 wild type and BRCA1 mutant 
TNBC cells. Similarly, to MDA-MB-231 TNBC cells cisplatin treatment induced PCNA and FA 
monoubiquitination in both BRCA1 wild type and BRCA1 mutated TNBCs and this response was 
attenuated with addition of SMI#9. While we have shown PCNA monoubiquitination is not a 
prerequisite for FANCD2 monoubiquitination (CITE), our data shows SMI#9 pretreatment 
reduces the steady state levels of FANCD2. These data corroborate previous findings which 
suggests that PCNA and FANCD2 interact via the FANCD2-PCNA interacting peptide (PIP)-box 
motif and that a mutation in this motif abrogates FANCD2 monoubiquitination35. FANCD2 and 
monoubiquitinated PCNA have been shown to interact with Pol h,  facilitating its recruitment to 
sites of damage [22, 25]. As Rad6 inhibition attenuates monoubiqutination of PCNA and reduces 
the steady states levels of FANCD2, we investigated the impact of Rad6 inhibition on Pol h 
expression and found severe delay in cisplatin -induced Pol h accumulation in BRCA1 wild type 
and BRCA1 mutant TNBC cells.  Due to the extensive crosstalk between monoubiqutinated 
PCNA, FANCD2 and Pol h, it is possible the loss of monoubiquitinated PCNA by Rad6 inhibition 
may affect the steady state levels of FANCD2 and Pol h by interfering with these interactions at 
stalled replication forks. Interestingly, regulation of Rad51 was unaffected by Rad6 inhibition. 
We performed IdU/CldU pulse-chase labeling to examine replication fork restart in 
BRCA1 wild type MDA-MB-468 and BRCA1 mutant SUM1315 cells. Whereas control cells 
efficiently incorporated both IdU and CldU, cisplatin treatment reduced the ability of SUM1315 
cells from restarting stalled replication forks while having only marginal effect in MDA-MB-468 
cells. Regardless of their BRCA1 status, SMI#9 and SMI#9 + cisplatin treatments decreased 
replication fork restart. To determine whether this is due to disruption of protein recruitment to the 
sites of DNA damage, we examined the colocalization of FANCD2, Pol h, and Rad51 with 
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gH2AX. We have previously shown that γH2AX foci localizes with restarted replication forks as 
measured by CldU incorporation [143]. Our data showed that cisplatin treatment enhanced 
colocalization of FANCD2, Pol h and Rad51 with gH2AX in BRCA1 wild type MDA-MB-468 
cells and SMI#9 pretreatment reduced this cisplatin-induced colocalization. Interestingly, SMI#9 
pretreatment only decreased cisplatin-induced FANCD2, Pol h and gH2AX foci formations, 
corroborating western blot data, but had no effect on Rad51. Although Rad51 foci formation was 
inhibited in BRCA1 mutant SUM1315 cells, it is interesting to note that FANCD2, Pol h and 
gH2AX activations were not compromised in these cells and SMI#9 similarly inhibited these 
protein associations as in BRCA1 wild type TNBC cells. However, since Rad51 localization to 
gH2AX was decreased by SMI#9 treatment and literature has shown Rad51 binding of D-loops 
facilitates Pol h mediated D-loop extension [148, 151, 152], our data imply that Rad6 activated 
TLS and FA pathways are critical for HR to occur.  
FANCD2 expression increases HR by 2-fold and the monoubiquitination of FANCD2 is 
required for this action [147]. Additionally, loss of Pol h has been shown to result in a 10-fold 
decrease in HR while overexpression of Pol h resulted in a 6-fold increase in HR frequency [153]. 
This effect is a result of the role of Pol h in extending the D-loop structures formed during HR 
strand invasion [151]. It has been shown that Pol h preferentially binds to D-loop structures 
compared to replication fork or single- or double- strand DNA structures [151]. To investigate the 
impact of Rad6 inhibition on the interaction of TLS and FA pathways with HR, we utilized the 
BRCA1 wild type HeLa cells stably carrying the DR-GFP vector.  Using this system, we showed 
that cisplatin induced HR. In line with our data examining recruitment of DDR proteins, SMI#9 
pretreatment decreased cisplatin-induced HR.  As both monoubiquitinated PCNA and FANCD2 
have been shown to interact with Pol h and SMI#9 disrupts the monoubiquitination and 
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localization of these proteins, we propose that Rad6 plays an important role in directing TLS, FA 
and HR crosstalk that culminates in recruitment of and polymerase switching to Pol h for TLS and 
subsequent initiation of HR via Pol h extension of D-loop structures. Our data suggest that Rad6 
may not be involved in D-loop formation as inhibition of Rad6 had minimal effect on Rad51 [107]. 
These data reveal an important role for Rad6 in coordinating activities of TLS, FA and HR in 
repair of cisplatin-induced ICLs, and implicate the potential therapeutic value of targeting Rad6 
for TNBC patient treatment. 
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CHAPTER 4-RAD6 INHIBITION ENHANCES PACLITAXEL SENSITIVITY OF 
BRCA1 WILD TYPE AND BRCA1 MUTANT TRIPLE NEGATIVE BREAST CANCER 
CELLS BY INDUCING MITOTIC SPINDLE DEFECTS 
 
4.1 Introduction 
In addition to the role of BRCA1 in DNA damage response and repair, BRCA1 plays a 
central role in centrosome function, particularly during mitosis, and loss of BRCA1 is implicated 
in resistance to taxane-based drugs.  Likewise, Rad6 is associated with centrosomes at all phases 
of cell cycle, implicating a potential role for Rad6 in centrosome function besides its role in DNA 
repair. In this chapter, we investigate the role of Rad6 at the centrosome and the impact of 
inhibiting Rad6 on taxane sensitivity. 
4.1.1 Taxane-based therapies and mechanism of action 
The taxane-based drugs paclitaxel (Taxol) and docetaxel (Taxotere) are microtubule (MT) 
stabilizing agents commonly used as first-line chemotherapies for various solid tumors, including 
TNBCs. MTs are composed of a- and b-tubulin subunits that dimerize to promote MT nucleation 
during mitosis [150, 154]. This nucleation is facilitated and stabilized by g-tubulin ring complexes 
(g-TuRCs) and their interaction with a-tubulin at the centrosome [150, 154]. During mitosis, it is 
essential that MTs nucleate and depolymerize to allow for chromosomal interaction and 
segregation, respectively. It is also essential that only two centrosomes are present during mitosis 
for equal chromosomal segregation to occur. Taxane drugs function during mitosis by binding to 
the b-subunit of assembled MTs and preventing depolymerization [155-158]. Thus, taxane 
treatment leads to mitotic arrest and subsequent mitotic catastrophe.  
While both paclitaxel (PTX) and docetaxel exert their cytotoxic effects in a similar manner, 
there are differences between these agents [136, 137]. Principally it has been found that docetaxel 
binds more efficiently to b-tubulin than PTX, resulting in increased potency [150, 159]. However, 
98	
	
this increased potency is also associated with increased toxicity when compared to PTX [160]. 
Additionally, while both PTX and docetaxel improve disease-free survival in combination therapy 
settings, increase in overall survival has been noted only  with PTX treatment [136, 137, 161]. 
Regardless of these differences, both drugs show initial anti-cancer activity; however, taxane 
associated cytotoxicity and acquired resistance to taxane-based therapies are major clinical 
challenges [145, 150].  
4.1.2 Regulation of taxane response by ubiquitination 
A proposed mechanism of taxane resistance is the mutation, methylation or loss of BRCA1 
[145, 162, 163]. During mitosis, BRCA1 in conjuction with BARD1 functions as an E3 ubiquitin-
ligase that facilitates the addition of a single ubiquitin moiety to Lys48 and Lys344 of g-tubulin, a 
major component of the g-TuRCs [13, 164, 165]. Monoubiquitinations of g-tubulin at Lys48 and 
Lys344 prevent its centrosomal localization, resulting in reduced MT nucleation [12, 166]. 
Additionally, monoubiquitination at Lys48 of g-tubulin also regulates centrosome amplification 
as this ubiquitination prevents centrosome reduplication [12, 14, 167-169]. Deubiquitination of g-
tubulin by BAP1 reverses these effects allowing for regulated MT polymerization, 
depolymerization and centrosome duplication replication [170]. Physiologically, this delicate 
balance between ubiquitination and deubiquitination of g-tubulin is critical during mitosis to 
regulate centrosome number and the rate at which MTs nucleate/depolymerize for proper 
chromosome segregation. Therapeutically, this regulation of the rates of MT polymerization and 
depolymerization, and centrosome amplification permits stable taxane binding and efficacy.  
In contrast to BRCA1 wild type cells, BRCA1 mutant cells show reduced g-tubulin 
monoubiquitination, which leads to increased rates of MT polymerization and depolymerization 
and centrosome number [13, 166-168, 171]. Consequently, MTs nucleate and depolymerize at 
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increased rates, which hinders binding of taxane to the MTs.  Corroborating this mechanism, it has 
been found clinically that BRCA1 wild type TNBCs are sensitive to taxanes, whereas BRCA1 
mutant TNBCs are resistant [22, 145, 162]. 
4.1.3 Rad6 and centrosome function 
We have previously shown that Rad6 is associated with centrosomes at all phases of cell 
cycle and, in contrast to BRCA1, constitutive overexpression of Rad6 in normal human breast cells 
induces centrosome amplification, multiple mitotic spindles and aneuploidy [76]. We have also 
shown that like PTX, SMI#9 treatment of MDA-MB-231 TNBC cells results in G2/M arrest and 
inhibition of MT depolymerization [78], providing further support for  a role of  Rad6 at the 
centrosome. A recent study reported gains in chromosome 5q31, a locus harboring the Rad6B 
gene, in MDA-MB-231 TNBC cells with acquired PTX resistance [172], suggesting the potential 
involvement of Rad6B in taxane resistance. 
In this chapter, we present data that demonstrate a role for Rad6 in centrosome function. 
We also show that PTX responses and centrosome numbers do not correlate with BRCA1 status 
in the TNBC models tested, and that inhibition of Rad6 with SMI#9 sensitizes TNBC cells to PTX 
regardless of their BRCA1 status. Our data demonstrate that addition of SMI#9 to PTX treatments 
affects cyclin B1 protein expression. Additionally, SMI#9 induced PTX sensitization is associated 
with reduced expression of 1N3R and 0N4R isoforms of tau, and increases in the proportion of 
cells with monopolar (abnormal) mitotic spindles, supporting a functional role for Rad6 in 
centrosome regulation.  Utilizing an isogenic MDA-MB-468 TNBC model of PTX resistance, we 
also demonstrate that SMI#9 treatment restores PTX sensitivity to these cells.   
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4.2 Material and methods 
4.2.1 Cell lines and cell culture 
BRCA1 wild type MDA-MB-231 and MDA-MB-468, and BRCA1 mutant SUM1315 and 
HCC1937 TNBC cell lines were obtained from ATCC and maintained as previously described. 
Cells were expanded and multiple aliquots were cryopreserved. Cells were used within 10-15 
passages. To generate an isogenic model of acquired PTX resistance, parental MDA-MB-468 cells 
were exposed to gradually increasing concentrations of PTX to select MDA-MB-468 cells capable 
of tolerating 15 nM PTX, and are referred as MDA-MB-468-PTXR cells. 
4.2.2 Cell viability assay 
Cell viability was measured using the standard MTT assay. MDA-MB-231, MDA-MB-
468, SUM1315, HCC1937 and MDA-MB-468-PTXR cells were seeded in triplicate at a density 
of 5-7 X 103 cells in a 96-well plate. Cells were treated with vehicle or increasing concentrations 
of clinical grade PTX (Hospira).  To assess the effect of Rad6 inhibition on PTX response, BRCA1 
wild type MDA-MB-468 and MDA-MB-468-PTXR and BRCA1 mutant HCC1937 cells were 
treated with 0.75 µM SMI#9 alone (corresponding to the IC10 dose of parental MDA-MB-468 
and HCC1937 cells) or along with PTX. Culture medium was removed at 72 h, replaced with drug 
free medium, and cells incubated with MTT reagent for 3 h at 37°C under 5% CO2. Formazan 
crystals were dissolved with 0.04 N HCl in isopropanol and absorbance was read at 570 nm using 
the Synergy 2 microplate reader. Phase contrast images were taken with the Olympus IX71 
microscope equipped with a Hamamatsu digital camera. 
4.2.3 Clonogenic assay 
MDA-MB-468 and HCC1937 cells were seeded in 24-well plates, and treated with PTX at 
the indicated doses for 24 h.  Cells were then trypsinized and 100 viable cells were replated per 
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well in triplicate. PTX treated cells were allowed to form colonies with ~ 50 cells and then treated 
with either vehicle or 0.75 µM SMI#9. Cultures were fixed and stained with 0.1% Crystal Violet 
in 20% methanol for 10 min. Colonies containing more than 50 cells were scored for colony 
forming efficiency and colony composition (presence of enlarged or multinucleated cells). Colony 
forming efficiency was expressed relative to control colonies. Results expressed as mean ± S.E.M 
from at least two independent experiments. 
4.2.4 Immunoblot analysis 
MDA-MB-468 and HCC1937 cells were treated with PTX at the indicated IC25 and IC50 
doses, 0.75 µM SMI#9, or a combination of PTX and 0.75 µM SMI#9. At 72 h, cells were washed 
with PBS and lysed in Triton X-100 lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris-
HCl pH 7.4 supplemented with protease inhibitor cocktail (Roche), 1 mM PMSF, sodium 
orthovanadate and sodium pyrophosphate). Protein-matched aliquots were subjected to SDS-
PAGE and immunoblot analysis with anti-Rad6 [76], anti-tau (Abcam, MA), anti-cyclin B1 
(Sigma-Aldrich Chemicals, MO), and anti–b-actin (Sigma-Aldrich Chemicals, MO) antibodies. 
4.2.5 Immunofluorescence staining	 
To assess centrosome number, MDA-MB-231, MDA-MB-468, SUM1315 and HCC1937 
cells were plated in 8-well chambers slides. Untreated cells were fixed in 10% buffered formalin 
and permeabilized with methanol/acetone (1:1, v/v). Slides were incubated with anti-pericentrin 
(Abcam, MA) antibody followed by FITC-conjugated rabbit secondary antibody. Nuclei were 
counterstained with DAPI and cells were scored for pericentrin labeled centrosomes. To evaluate 
tau localization and spindle orientation, MDA-MB-468 and HCC1937 cells were grown in 8-well 
chamber slides and treated for 24 h with 0.75 µM SMI#9, PTX (2.5 nM for MDA-MB-468 and 10 
nM for HCC1937) or a combination of 0.75 µM SMI#9 and PTX. Cells were fixed in 10% buffered 
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formalin as described above, and incubated with anti-a-tubulin (Sigma-Aldrich Chemicals, MO) 
and anti-tau antibodies followed by incubation with Texas Red- and FITC-conjugated mouse and 
rabbit secondary antibodies, respectively. Nuclei were counterstained with DAPI, and scored for 
tau positive cells and mitotic spindles. For all experiments, slides were also stained in the absence 
of primary antibody or with isotype matched nonimmune IgG to assess nonspecific reactions. 
Images were collected on an Olympus BX40 microscope equipped with a Sony high 
resolution/sensitivity CCD video camera. The results shown are representative of data collected 
from at least 40 cells in five-seven fields and two independent experiments.  
4.3 Results 
4.3.1. BRCA1 status does not correlate with centrosome number or PTX response 
BRCA1 function has been implicated in centrosome amplification and PTX resistance, 
with loss of BRCA1 resulting in increases in both these properties [167, 168, 171]. To determine 
whether BRCA1 wild type and BRCA1 mutant TNBC cells show variation in centrosome 
numbers, TNBC cells were immunostained for the centrosomal protein pericentrin (Figure 4.1; 
Panel A). Staining showed that TNBC cells exhibit amplified centrosomes regardless of their 
BRCA1 status as ~64% of MDA-MB-231 and ~20% of MDA-MB-468 BRCA1 wild type cells, 
and ~35% of SUM1315 and ~34% of HCC1937 BRCA1 mutant cells had ≥3 centrosomes (Figure 
4.1; Panel B).  
To assess BRCA1 wild type and BRCA1 mutant TNBC cell sensitivity to PTX, MTT 
assays were performed with increasing concentrations of PTX (Figure 4.1; Panels C-F). The results 
show no correlation between BRCA1 status and PTX sensitivity as the most resistant TNBC cell 
line is the BRCA1 wild type MDA-MB-231 cells(IC50 = 35 nM), followed by the BRCA1 mutant 
HCC1937 cells (IC50 = 25 nM), and the BRCA1 wild type MDA-MB-468 and BRCA1 mutant 
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FIGURE 4.1 BRCA1 status does not correlate with centrosome number or paclitaxel 
(PTX) response. A) TNBC cell lines were fixed and immunostained with anti-pericentrin 
(green) antibody. Nuclei were counterstained with DAPI. Accompanying bar graph (B) 
displays the percent of cells with indicated centrosome count.  Approximately 75 cells in four 
to six fields were scored for centrosome number. Data shown as mean ± S.E.M from at least 2 
independent experiments. C-F) MTT assays were performed in triplicate wells using the 
BRCA1 wild type MDA-MB-231 (C) and MDA-MB-468 (E) and BRCA1 mutant SUM1315 
(D) and HCC1937 (F) TNBC cell lines. Cells were treated with various concentrations of PTX 
for 72 h prior to cell surivival analysis. Results are expressed as mean ± S.E.M. of three 
independent experiments. 
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SUM1315 ( IC50 = 5 nM for both).  
4.3.2 Rad6 inhibition sensitizes BRCA1 wild type and BRCA1 mutant TNBC cells to PTX 
As the BRCA1 wild type MDA-MB-468 and BRCA1 mutant HCC1937 TNBC cells 
followed clinical trends with the HCC1937 cells showing heightened PTX resistance compared to 
MDA-MB-468 cells (Figure 4.1; Panels E and F), we utilized these cells to assess the impact of 
Rad6 inhibition on PTX response. Treatment with SMI#9 enhanced PTX sensitivity in both MDA-
MB-468 and HCC1937 cells (Figure 4.2; Panels A, B and D, E, respectively; P < 0.0001 for both). 
However, since single treatment with SMI#9 significantly decreased MDA-MB-468 cell 
proliferation compared to control or PTX alone (P < 0.01), the benefit seen in combination 
treatments in MDA-MB-468 cells appear to result from SMI#9 alone (Figure 4.2; Panel B). 
Furthermore, any cumulative benefit was masked as MDA-MB-468 cells exhibit enhanced PTX 
sensitivity as compared to HCC1937 cells (Figure 4.2, Panels D and E).  
4.3.3 SMI#9 diminishes colony survival and enhances mitotic catastrophe in BRCA1 wild 
type and BRCA1 mutant TNBC cells	 
MTT data was corroborated with colony survival assays (Figure 4.3). MDA-MB-468 and 
HCC1937 cells were treated with PTX at the indicated doses and then replated as 100 single cells. 
Colonies containing ~50 cells were allowed to form prior to treatment with 0.75 µM SMI#9. This 
approach parallels the therapeutic setting as cells capable of producing colonies represent a 
potential resistant outgrowth and allows for examination of the impact of Rad6 inhibition on PTX 
resistant cell populations. Colonies were scored 72 h after SMI#9 treatment for colony survival 
and the presence of enlarged/multinucleated cells (characteristics of mitotic arrest or mitotic 
catastrophe). SMI#9 treatment significantly reduced colony survival in both MDA-MB-468 
(Figure 4.3; Panels A; P = 0.0222) and HCC1937 (Figure 4.3; Panels D; P = 0.008). However,    
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FIGURE 4.2. SMI#9 synergistically enhances paclitaxel (PTX) sensitivity in BRCA1 wild 
type and BRCA1 mutant TNBC cell lines. MDA-MB-468 (A-B) and HCC1937 (C-D) cells 
were seeded and treated with PTX alone or along with 0.75 µM SMI#9 in triplicate wells. 
Results are expressed as mean ± S.E.M from three independent experiments. *P<0.01, 
**P<0.005.  
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SMI#9 significantly (P = 0.038) enhanced the proportion of cells containing enlarged or multiple 
nuclei only in the HCC1937 cells (Figure 4.3; Panels E and F). This significant increase was not 
seen in MDA-MB-468 colonies probably because of mitotic arrest lethally induced by PTX that 
masked further increases by SMI#9 (Figure 4.3; Panels B and C).  
4.3.4 PTX and SMI#9 induce alterations in tau and cyclin B1 protein levels in BRCA1 wild 
type and BRCA1 mutant TNBC cells	 
To assess the responses of MDA-MB-468 and HCC1937 cells to PTX at the protein level, 
MDA-MB-468 and HCC1937 cells were treated with 2.5 nM and 5 nM or 10 nM and 25 nM PTX 
(respectively), with or without 0.75µM SMI#9, SMI#9 alone or vehicle, and whole cell lysates 
were analyzed by western blotting for Rad6, tau, and cyclin B1. Whereas there was no discernable 
alteration in Rad6 protein levels with PTX, SMI#9, or combination treatments, tau and cyclin B1 
protein levels were affected.  
Tau is a MT-associated protein that functions to reversibly stabilize MT. This protein has 
six isoforms, resulting from alternative splicing, that are assigned to two groups based upon the 
number of MT binding repeats (3R vs. 4R). It has been previously shown that tau preferentially 
binds to assembled MTs in the same region as PTX [173, 174], setting off  a competition between 
tau and PTX for  binding to the  MTs [174-177].  To this end, tau overexpression has been 
associated with reduced PTX efficacy in the ZR75.1 breast cancer cell line and in metastatic breast 
cancer patients [175, 176, 178-180] Treatments with PTX or SMI#9 decreased the steady state 
levels of 1N3R and 0N4R tau isoforms in MDA-MB-468 cells as compared to control (Figure 4.4; 
Panel A). Consistent with SMI#9 induced PTX sensitization, PTX + SMI#9 treatment induced 
pronounced reduction of these tau isoforms that was noticeable at the lower (IC25) dose of PTX 
(Fig. 4.4; Panel A, compare 2.5 nM PTX with 2.5 nM PTX + SMI#9). In PTX resistant HCC1937 
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FIGURE 4.3 Rad6 inhibition induces multinucleation and enlarged nuclei.  MDA-MB-468 
(A-C) and HCC1937 (D-F) cells were treated with the indicated doses of paclitaxel (PTX) for 
24 h. 100 viable cells were replated as single cells in quadruplicates post PTX treatment. 
Colonies were allowed to form and were either left untreated or treated with 0.75 µM SMI#9. 
A and D) Graphical representation of the percent of surviving colonies compared to untreated 
colonies. B and E) Graphical representation of cells with enlarged and multiple nuclei 
(abnormal nuclei). Results are expressed as mean ±S.E.M. of replicates. C and F) 
Representative phase contrast images (enlarged nuclei, white arrow, and multinucleated cells, 
black arrow).  
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cells, only the 1N3R tau isoform was decreased by PTX or SMI#9 as compared to control, while 
the 0N4R isoform was only marginally affected requiring higher concentrations of PTX (Figure 
4.4; Panel B).  
We also analyzed cyclin B1, a marker of G2/M arrest, in MDA-MB-468 and HCC1937 
cells (Figure 4.4; Panels A and B, respectively). Western blot analysis showed modest increases 
in cyclin B1 steady state levels in PTX or SMI#9 treated MDA-MB-468 cells as compared to 
control, and PTX + SMI#9 treatment induced ~ 1.9-fold increase in cyclin B1 compared to control 
(Figure 4.4; Panel A). Interestingly, in HCC1937 cells, treatment with PTX, SMI#9, or PTX + 
SMI#9 caused loss of cyclin B1 as compared to control (Figure 4.4, Panel B). Premature 
degradation of cyclin B1 has been linked to mitotic slippage, which results from the release of 
G2/M arrested cells that have not satisfied the spindle assembly checkpoint [181-183]. Mitotic 
slippage can result in pseudo-G1 cells with increased DNA content/multinucleation that 
subsequently undergo cell death within G1 [181-183]. As our MTT and clonogenic survival assays 
show loss of cell viability and increased proportions of cells with enlarged or multiple nuclei with 
these treatments, it is likely that the observed degradation of cyclin B1 is suggestive of mitotic 
slippage that ultimately results in cell death. 
 4.3.5 Inhibition of Rad6 induces monopolar mitotic spindles 
To examine the localization of tau to mitotic spindles MDA-MB-468 and HCC1937 cells 
were treated with PTX, SMI#9, or PTX + SMI#9 and then immunostained with anti-tau and anti-
a-tubulin antibodies, to visualize mitotic spindles (Figure 4.5; Panels A-B and C-D, respectively). 
Immunofluorescence analysis showed intense tau staining selectively in mitotic cells and 
treatments with PTX, SMI#9, or PTX + SMI#9 did not affect localization of tau to the mitotic 
spindles. Instead SMI#9 treatment either alone or in combination with PTX, induced monopolar 
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FIGURE 4.4 Paclitaxel and SMI#9 alter tau and cyclin B1 protein levels. Whole cell lysates 
from MDA-MB-468 (A) and HCC1937 (B) cells treated with PTX, SM#9 or PTX + SMI#9 
were analyzed by western blot for indicated proteins. Protein levels were normalized to b-actin 
using Image J software.  
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mitotic spindles in both BRCA1 wild type (Figure 4.5; Panels A-B; P < 0.005) and BRCA1 mutant 
cells (Figure 4.5; Panels C-D; P < 0.05). Interestingly, BRCA1 wild type MDA-MB-468 cells 
treated with PTX alone did not display enhanced monopolar mitotic spindle formation compared 
to PTX+SMI#9 treatment (Figure 4.5; Panels A and B). It is possible that the increased PTX 
sensitivity seen in MDA-MB-468 cells prevents the accumulation of cells with disrupted mitotic 
spindles as these cells are experiencing increased cell death. Since MTT data demonstrate potent 
SMI#9 sensitization in MDA-MB-468 cells, this suggests that the SMI#9-induced sensitivity 
probably results from induction of monopolar mitotic spindles (indicative of inability to undergo 
mitosis), and provide additional support for a functional role for Rad6 in centrosome duplication 
and/or segregation. Concordant with the enhanced sensitivity observed with PTX + SMI#9 
treatment in HCC1937 cells (Figure 4.2; Panel C), both PTX and SMI#9 induced monopolar 
spindles and this was further enhanced with PTX+SMI#9 treatment (Figure 4.5; Panels C and D). 
4.3.6 SMI#9 reverts acquired paclitaxel resistance 
To determine if inhibition of Rad6 was capable of reverting acquired PTX resistance, an 
isogenic model of acquired PTX resistance was developed using the MDA-MB-468 cells, as these 
cells displayed increased PTX sensitivity (Figure 4.6). Compared to parental MDA-MB-468 cells, 
MDA-MB-468-PTXR cells demonstrated increased PTX resistance (Figure 4.6; panel A; IC50 = 
5 nM vs 50 nM, respectively).  Evaluation of MDA-MB-468-PTXR demonstrated a significantly 
increased proportion of multinucleated cells (Figure 4.6; Panel B; P = 0.017). As PTX induces 
G2/M arrest, it is likely that these resistant cells undergo a prolonged G2/M arrest resulting in 
multinucleation. To investigate the effect of Rad6 inhibition on these cells, MDA-MB-468-PTXR 
cells were treated with increasing concentrations of PTX with or without the addition of SMI#9 
(0.75 µM). MTT analysis demonstrated that combination treatment with PTX + SMI#9  (0.75 µM) 
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FIGURE 4.5 SMI#9 induces monopolar mitotic spindles. MDA-MB-468 (A) and HCC1937 
(C) TNBC cells were treated with paclitaxel (PTX; 2.5 nM and 10 nM, respectively), SMI#9 
(0.75 µM) or PTX + SMI#9. Cells were fixed and immunostained for tau (green) and a-tubulin 
(red). B and D) Graphs represent the percent of tau positive cells and cells with monopolar 
mitotic spindles. Results are expressed as mean ± S.E.M of replicates.  
	
A B 
C 
D 
112	
	
drastically reduced the IC50 of MDA-MB-468-PTXR (IC50= 4.4 nM, Figure 4.6; Panel Ca; P = 
0.0004), sensitizing MDA-MB-468-PTXR cells to that of parental MDA-MB-468 cells.  
4.4 Discussion 
The data presented in this chapter support a functional role for Rad6 in centrosome 
duplication/segregation and/or MT nucleation, and suggest that inhibition of Rad6 could help 
achieve taxane sensitivity in BRCA1 wild type and BRCA1 mutant TNBC cells. Here we show 
that BRCA1 status does not influence centrosome number in our panel of TNBC cell lines. We 
also examined the impact of BRCA1 status on PTX sensitivity and found that while BRCA1 status 
did not influence PTX response in mesenchymal (MDA-MB-231 and SUM1315) TNBC cells, 
basal (MDA-MB-468 and HCC1937) TNBC cells appeared to follow the clinical trend with 
BRCA1 mutant HCC1937 cells being more resistant as compared to the BRCA1 wild type MDA-
MB-468 cells. It has been previously found that basal TNBCs are more responsive to taxane drug 
treatment than mesenchymal TNBCs, possibly accounting for the BRCA1 dependent PTX 
response in this TNBC subtype [19]. As Rad6 has been found to be overexpressed in both BRCA1 
wild type and BRCA1 mutant TNBCs, we assessed the effect of Rad6 inhibition with SMI#9 on 
PTX sensitivity. SMI#9 treatment sensitized both MDA-MB-468 and HCC1937 cells to PTX. 
Colony survival assays confirmed the SMI#9 mediated reduction in survival of PTX resistant 
MDA-MB-468 and HCC1937 colonies. Examination of colony composition revealed PTX 
increased the proportion of cells with enlarged or multiple nuclei, a characteristic feature of mitotic 
catastrophe in both cell lines, and SMI#9 significantly enhanced these characteristics in the more 
PTX resistant HCC1937 cells. Additionally, utilizing MDA-MB-468-PTXR cells it was seen that 
SMI#9 treatment was able to revert PTX resistance to that of parental cells.  
Protein analysis revealed that PTX and SMI#9 treatments affected tau and cyclin B1 levels. 
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FIGURE 4.6 SMI#9 reverts paclitaxel (PTX) resistance. (A) Sensitivities of parental MDA-
MB-468 and isogenic MDA-MB-468 PTX-R cells to paclitaxel. (B) Quantification of enlarged 
and multinucleated cells in parental MDA-MB-468 and PTX resistant MDA-MB-468 PTX-R 
cells. Data expressed as mean ± S.E.M. Representative images are shown C) MDA-MB-468 
PTX-R cells were treated with increasing doses of PTX with or without SMI#9 (0.75 µM) in 
triplicate. MTT assay was used to measure cell proliferation. Data are expressed relative to 
control cells as mean ± S.E.M. (D) Representative images are shown.  
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In MDA-MB-468 cells, PTX or SMI#9 decreased the steady state levels of 1N3R and 0N4R tau. 
In PTX resistant HCC1937 cells, only the 1N3R tau isoform was visibly decreased by PTX. As 
the 0N4R tau isoform possesses more MT binding regions and has been shown to bind more 
efficiently to MTs [184], it is possible this tau isoform is tightly bound to HCC1937 MTs, 
promoting PTX resistance and requires higher drug concentrations for displacement.  Release of 
tau from MTs has been shown to result in increased protein misfolding and proteosomal 
degradation [185-187], supporting the possibility that PTX displacement of tau promotes its 
degradation and that this process may be enhanced by SMI#9. Immunostaining for tau did not 
indicate that PTX or SMI#9 affected tau binding. However, induction of monopolar mitotic 
spindles was observed. In this setting, tau is still able to bind to MTs, however the induction of 
monopolar mitotic spindles may reduce tau binding and consequently promote tau degradation. 
Additionally, the induction of monopolar mitotic spindles with SMI#9 treatment demonstrates a 
role for Rad6 in centrosome duplication and/or segregation. 
Analysis of cyclin B1 (a marker of G2/M arrest) in MDA-MB-468 cells showed modest 
increases in cyclin B1 levels with PTX treatment that were marginally enhanced by SMI#9. In 
HCC1937 cells, treatment with PTX, SMI#9, or SMI#9+PTX caused loss of cyclin B1, a 
characteristic linked to mitotic slippage [181, 183]. Mitotic slippage results in pseudo-G1 cells 
with increased DNA content/multinucleation that exit mitosis to either continue to cycling, 
undergo cell death within G1, or remain viable but reproductively dead [181-183]. Our clonogenic 
survival assays suggest that PTX may induce a leaky G2/M arrest in HCC1937 cells, that allows 
for cell cycle continuation. Addition of SMI#9 strengthens the durability of this arrest, as measured 
by increases in the proportion of cells with multiple or enlarged nuclei and loss of cell viability. 
As mitotic slippage results from the inability of cells to satisfy the mitotic spindle checkpoint, 
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induction of monopolar mitotic spindles by SMI#9 may contribute to mitotic slippage in these 
cells. In contrast, PTX may induce a stable G2/M arrest that is marginally enhanced by SMI#9 in 
MDA-MB-468 cells. 
In this chapter, we examine two TNBC cells with differential sensitivities to PTX. 
Interestingly, though these two cell lines respond differently to PTX there are commonalities. Both 
the MDA-MB-468 and HCC1937 cells produce cells with enlarged and/or multiple nuclei. 
However, the more PTX sensitive MDA-MB-468 cells are halted at this stage, while the more 
resistant HCC1937 cells are able to continue cycling. We have previously shown that Rad6 
colocalizes with g-tubulin at all phases of the cell cycle and constitutive overexpression of Rad6B 
results in centrosome amplification and aneuploidy [76]. Here we show that inhibition of Rad6 
results in monopolar mitotic spindles and consequently enhances the proportion of cells with 
enlarged and multiple nuclei. Our data suggest that the production of cells with enlarged and/or 
multiple nuclei, as noted in PTX resistant HCC1937 cells, may provide a resistance mechanism 
and treatment with SMI#9 enhances cell death by strengthen the durability of cell cycle arrest and 
/or mitotic catastrophe. Together, our data provide mechanistic support for the role of Rad6 in 
centrosome duplication and/or segregation and suggest that inhibition of Rad6 may be 
therapeutically beneficial for BRCA1 wild type and BRCA1 mutant TNBC patients treated with 
PTX.  
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CHAPTER 5- SYNTHESIS AND FUNCTIONAL CHARACTERIZATION OF RAD6 
INHIBITOR SMI#9 CONJUGATED GOLD NANOPARTICLES IN TRIPLE NEGATIVE 
BREAST CANCER CELLS 
 
5.1 Introduction 
We have shown that Rad6 is overexpressed in BRCA1 wild type and BRCA1 mutant 
TNBCs and that inhibition of Rad6 with SMI#9 sensitizes these cells to both cisplatin and 
paclitaxel.  Additionally, we have previously shown that SMI#9 treatment suppresses proliferation, 
migration, and induces apoptosis in TNBC cells but spares nontransformed MCF10A breast cells 
[78]. While these findings support the therapeutic significance of Rad6 inhibition in TNBCs, poor 
solubility of SMI#9 limits its in vivo therapeutic efficacy [78]. To overcome this challenge, we 
have chemically modified SMI#9 to permit its conjugation to gold nanoparticles (GNPs). 
GNPs have been shown to be nontoxic and demonstrate bio-stability [188-191]. 
Additionally, surface modifications of GNPs allow  easy  conjugation with multiple agents, 
including chemotherapies [192]. Due to their small size, typically 1-100 nm, GNPs can effectively 
enter and traffic in the cell. These characteristics make GNPs an ideal drug delivery platform to 
enhance drug efficacy, while reducing drug toxicity. Aurimmune, developed by Cytimmune, is a  
GNP delivery platform for TNF-a and has been shown to have enhanced therapeutic efficacy and 
minimized systemic toxicity [193-196].  
 In this chapter, we describe the chemical modification of SMI#9 for its conjugation to 
GNPs to facilitate intracellular drug uptake. GNP tethered SMI#9 (SMI#9-GNP) was characterized 
for purity, ligand conjugation and size by thermogravimetric analysis (TGA), atomic force 
microscopy (AFM), transmission electron microscopy (TEM), ultraviolet visible (UV-Vis) 
spectroscopy and zeta sizer, and for cellular uptake and drug release by Fourier transform infrared 
spectroscopy (FTIR) and liquid chromatography with tandem mass spectrometry (LC-MS/MS). 
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We compared the activities of SMI#9-GNP and free (parent) SMI#9 for cytotoxicity and 
intracellular localization in BRCA1 wild type and BRCA1 mutant TNBC cells, and in 
nontransformed MCF10A cells. Analysis of the responses to conjugated and free SMI#9 showed 
that SMI#9-GNP and SMI#9 elicit similar effects. However, whereas free SMI#9 was cytotoxic to 
both basal and mesenchymal TNBC subtypes, SMI#9-GNP demonstrated as good or better 
cytotoxicity than free SMI#9 only in mesenchymal TNBC cells. MCF10A cells were unaffected 
by both free and SMI#9-GNP. Consistent with cellular sensitivities, SMI#9-GNP is efficiently 
endocytosed and processed in lysosomes of mesenchymal TNBC cells, while uptake into basal 
TNBC cells is compromised by cell microenvironment induced SMI#9-GNP aggregation. Similar 
to free SMI#9, SMI#9-GNP treatment induces mitochondrial dysfunction, stabilization and 
hyperactivation of PARP-1, and autophagy. Loss of Rad6 [197] and PARP-1 hyperactivation have 
been associated with mitochondrial dysfunction, and since inhibition of Rad6 induces both 
mitochondrial dysfunction and PARP-1 activation, our data suggest a novel role for Rad6 in 
linking these processes.  
5.2 Materials and methods 
5.2.1 Synthesis of gold nanoparticle (GNP) and conjugation of Rad6 inhibitor SMI#9 to GNP 
      Briefly, ice-cold 0.1 M NaBH4 solution was added with vigorous stirring to a solution of 
0.25 mM HAuCl4·3H2O and 0.25 mM trisodium citrate. The pH was adjusted to 11, and 50 mg 
MSA was added. The final solution was concentrated to 2.5 g (gold)/L by centrifugation using 
10,000 MW Amicon filters. SMI#9 was modified to enable GNP conjugation via an ester bond. 
To modify SMI#9, 1.5 mg SMI#9 was dissolved in 0.5 ml tetrahydrofuran (THF; 50%, v/v) 
followed by addition of 10 mg of NaHCO3 and 2.6 mg di-tert-butyl dicarbonate (Boc)2O. After 30 
min reaction, 5 µl of HCHO and 5 µl of triethylamine (Et3N) were added and the 
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hydroxymethylation reaction was allowed to proceed for 48 h. The solution was then added to 
GNP (2.5 g/L gold concentration) solution. The pH of the solution was adjusted to 4.7 with MSA, 
and 2 mg 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 0.2 mg 4-
dimethylaminopyridine (DMAP), and 2 ml dimethyl sulfoxide (DMSO) were added to catalyze 
the esterification reaction. After 40 h, the final solution was concentrated to 0.2 g/ml by 
centrifugation using 10,000 MW Amicon filters and desalted by exchanges with deionized water 
[198].  
5.2.2 Characterization of GNP and GNP-drug conjugates 
        SMI#9-GNP was characterized on a SDT-Q600 Thermo-Gravity Analyser by TGA. The 
air flow rate was maintained at 100 ml/min, and samples were heated from 25ºC to 800°C at a rate 
of 10°C/min. GNP size was determined by UV-vis spectroscopy with a Varian Cary® 50 
spectrometer in 2 mm optical path cells, and by TEM at 200 kV with a JEOL JEM-2010 
microscope equipped with a Gatan multiscan CCD camera. Dynamic light scattering (DLS) and 
zeta potential were measured using a Malvern Nano-ZS. The Z-average hydrodynamic diameter 
(HD), polydispersity index (PDI), and zeta potential were measured at 25°C. 15 scans were 
performed in each measurement. The backscattering angle Θ was fixed at 172° with a laser 
wavelength λ = 633 nm. The size measurement range was set between 1 nm and 6 µm. HD is a 
function of the diffusion coefficient (D), temperature (T), and viscosity (η) according to the Stokes-
Einstein equation: D
kTHD
ph3
=
, k is Boltzmann constant, T is 25 °C, and D was obtained from 
autocorrelation function via the cumulant fitting. AFM imaging was conducted using a Dimension 
3100 AFM from VEECO. AFM tapping mode in liquid was used and the nanoconjugate was 
deposited on mica by spin coating.  
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5.2.3 Cell survival assay 
       MDA-MB-231, SUM1315, MDA-MB-468, and HCC1937 TNBC cells were purchased 
from American Type Culture Collection (ATCC). Cells were maintained in Dulbecco’s Minimal 
Essential Medium/F12 (DMEM/F12; Invitrogen, Carlsbad, CA) supplemented with 5% fetal 
bovine serum as described before. Nontransformed MCF10A human breast cells were maintained 
in DMEM/F12 supplemented with 5% horse serum, 20 ng/ml epidermal growth factor, 10 µg/ml 
insulin, 0.5 µg/ml hydrocortisone and 0.10 µg/ml cholera toxin [76]. SMI#9-GNP sensitization of 
TNBC cells was assessed by MTT assay. Cells (5-7 X 103) were seeded in 96-well plates and 
treated with vehicle, SMI#9, SMI#9-GNP, or blank-GNP at various concentrations in triplicates. 
Amounts of SMI#9-GNP used were calculated based on the amounts of SMI#9 conjugated to the 
GNP. Blank-GNPs were used at similar amounts as drug loaded GNP. To assess their use in 
combination treatment, cells were treated with 0.1-10 µM cisplatin with or without SMI#9-GNP, 
and cell viability was assessed at 72 h by MTT assay. MCF10A sensitivity to SMI#9-GNP was 
assessed by trypan blue exclusion and counted with Biorad TC10 automatic cell counter. At least 
three independent experiments were performed for each cell line.   
5.2.4 SMI#9 and SMI#9-GNP uptake and intracellular release of the free drug from GNP 
conjugate 
       MDA-MB-231 (3 X 105) cells were treated with vehicle or various doses of SMI#9-GNP 
for 24-48 h. Cultures were rinsed and lysed in cold hypotonic buffer by freeze-thawing. Aliquots 
of clarified whole cell lysates were analysed by FTIR spectroscopy and compared with control cell 
lysates that were spiked with free SMI#9 as reference. To determine intracellular release of 
modified SMI#9 from the nanoparticles, SUM1315 (2 X 106) cells were treated with 5 µM free 
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SMI#9, 5 µM SMI#9-GNP or the corresponding amount of blank-GNP, or vehicle for 8 or 24 h. 
Cultures were rinsed in ice-cold PBS, lysed with cold 80% methanol and clarified by centrifugation 
at 10,000 g for 10 min at 4oC. Supernatants were subjected to high performance liquid 
chromatography (HPLC) coupled with tandem mass spectrometry (LC-MS/MS) analysis. 
Chromatography was performed with Waters Model 2695 system and Waters Xterra MS C18 
column (50 x 2.1 mm i.d., 3.5 µm) using an isocratic mobile phase of methanol/0.45% formic acid 
in water (60:30, v/v) at a flow rate of 0.2 mL/min.  The column effluent was monitored using a 
Waters Quattro MicroTM triple quadrupole mass-spectrometric detector. Multiple reactions 
monitoring at positive ionization mode were chosen for the analyte detection. For SMI#9 detection, 
the spectrometer was programmed to monitor transition of the parent ion m/z 366.69 ([M+H]+) to 
the major daughter ion with m/z 150.1 (Fig. 5.3; Panel Ab). For the detection of modified SMI#9 
released from GNP, the spectrometer was programmed to monitor transition of the parent ion m/z 
397.3 to the major daughter ion m/z 150.1. We monitored 14 MS transitions m/z 366.69 > 150.1, 
368.86 > 150.7, 381.3 > 150.1, 381.3 > 150.7, 381.3 > 232.3, 381.3 > 248.3, 397.3 > 150.1, 397.3 
> 150.7, 397.3 > 232.3, 397.3 > 248.3, 379.4 > 150.1, 379.4 > 150.7, 379.4 > 232.3, and 379.4 > 
248.3 to determine release of modified SMI#9 from the GNP conjugates. All the chosen parent 
ions were selected in the first quadrupole and allowed to pass into the collision cell filled with 
argon gas with a pressure of 0.00172 mBar. The dwell time per channel was set to 0.01s for data 
collection. 
5.2.5 Acridine orange/ethidium bromide staining. 
SUM1315 and HCC1937 cells (10 x 103) were seeded on cover slips and treated with vehicle, free 
SMI#9, blank-GNP or SMI#9-GNP for 24-48 h. Cover slips were rinsed with PBS and stained with 
ethidium bromide/acridine orange (each 25 µg/mL). Images were captured immediately after staining with 
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an Olympus BX40 fluorescence microscope. A minimum of six fields with at least 50 cells/field were 
scored for determination of dye uptake [78], and experiments were repeated at least three times.  
5.2.6 Mitochondrial assay 
       The mitochondrial membrane potential (Dym) of SUM1315 and HCC1937 TNBC cells 
was assessed using JC-1 (Mitocapture, Biovision, Mountainview, CA), a potentiometric green 
fluorescent dye that shifts to red fluorescence within mitochondria with a normal negative Dym. 
Cells treated with vehicle, SMI#9, blank-GNP or SMI#9-GNP were incubated with the 
MitoCapture reagent for 15 min at 37°C and imaged by fluorescence microscopy [199]. The 
percent of cells showing >5 punctate J-aggregates were scored by counting three-five fields with 
50-100 cells/field. To quantitate mitochondrial membrane potential changes, SUM1315 or 
HCC1937 (20 X 103) cells were seeded in 96-well plate, and treated for 48 h with 5 µM SMI#9-
GNP or blank-GNP. Cells were then incubated with 10 µM JC-1 for 30-60 min, and the red and 
green fluorescence intensities of JC-1 were measured at Excitation/Emission = 490/525 nm and 
490/590 nm with a Synergy 2 fluorescence reader. Results were expressed as the ratio of red to 
green fluorescence.  
5.2.7 Intracellular uptake of SMI#9-GNP 
  SUM1315 or HCC1937 cells were seeded on sterile coverslips and treated with blank- or 
SMI#9-GNP. Cultures were rinsed and incubated with 75 nM of LysoSensor Green DND-189 for 
30-60 min at 37oC. [200] Cells were counterstained with DAPI to localize the nucleus and images 
were acquired with an Olympus BX40 fluorescence microscope equipped with a Sony high 
resolution/sensitivity camera. 
5.2.8 Western blot and immunofluorescence analysis 
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       Breast cancer cells were treated with vehicle, free SMI#9, blank- or SMI#9-GNP (1-5 µM) 
for 24-96 h and lysed by freeze-thaw cycles in cold passive lysis buffer [78]. Aliquots of whole 
cell lysates containing 25 µg of protein were subjected to SDS-PAGE and western blot analysis of 
PARP-1 (Cell Signaling), Rad6 [76], LC3-I/II (Cell Signaling), p62 (Cell Signaling) and b-actin 
(Sigma). LC3 or p62 subcellular localization was determined by treating cells with vehicle or 
SMI#9-GNP and fixing cells with ice cold methanol:acetone (1:1, v/v). Cells were then stained 
with anti-LC3 or anti-p62 antibodies and incubated with FITC- or Texas Red-conjugated anti-
rabbit secondary antibodies. Cells were counterstained with DAPI and analyzed by fluorescence 
microscopy. Slides were also stained in the absence of primary antibody or with isotype matched 
nonimmune IgG to assess nonspecific reactions. Images were collected on an Olympus BX40 
microscope equipped with a Sony high resolution/sensitivity CCD video camera and SlideBook 
software.  
5.2.9 Statistical analysis 
Each experiment was performed in triplicate and reproduced at least three times. Data are 
expressed as mean ± S.E.M. Statistical significance (P <0.05) was determined by Student’s t-test. 
5.3 Results 
5.3.1 Nanoparticle synthesis and characterization 
To conjugate SMI#9 to GNPs, citrate-reduced GNPs were synthesized from HAuCl4.3H20 and 
subsequently capped by MSA. Modified SMI#9 was attached to the MSA-GNP surface via ester bond 
(Figure 5.1). The chemical compositions of GNP and SMI#9-GNP were determined by TGA. Figure 5.2 
panel A shows the TGA curves of MSA-GNP (blank-GNP) and MSA-GNP conjugated SMI#9 (SMI#9-
GNP) with weight loss of 6.15% and 13%, respectively, at 800°C. Figure 5.2 panel B shows the UV-vis 
spectra of GNPs before and after conjugation with modified SMI#9. The surface plasmon resonance (SPR) 
absorption peak of freshly prepared GNPs is 508 nm, which corresponds to GNP diameter range of 3-5 nm. 
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However, upon conjugation with modified SMI#9, the SPR absorption peak broadened and shifted to 524 
nm, which is indicative of particle aggregation. The size of SMI#9-GNPs was also determined by TEM 
(Figure 5.2; Panel C) and AFM (Figure 5.2; Panel D) which showed a size of 32 nm and 40.2 ± 1.4 nm, 
respectively, that is consistent with aggregation. DLS further verified the average size of SMI#9-GNP 
nanoconjugate at 41 nm as compared to 4.8 nm for GNP. The zeta potential of MSA-capped GNP changed 
from -41 mV to -16.2 mV after conjugation with SMI#9. The decrease in surface charge is the result of 
SMI#9 conjugation to highly charged MSA. Particle aggregation could also contribute to surface charge 
reduction.  
5.3.2 Characterization of SMI#9-GNP intracellular uptake and release 
To determine SMI#9-GNP uptake and intracellular release of the conjugated SMI#9, 
MDA-MB-231 cells were exposed to SMI#9-GNP, blank-GNP, SMI#9 or vehicle, and cell lysates 
analyzed by FTIR or LC-MS/MS. Results were compared to control cell lysates spiked with 
(parent) SMI#9 as a reference. FTIR analysis of SMI#9 (Figure 5.2; Panel E; red line) showed the 
characteristic nitro group banding at ~ 1550 cm-1, indicative of SMI#9 presence. Analysis of lysates 
prepared from SMI#9-GNP treated MDA-MB-231 cells or MDA-MB-231 control lysates also 
showed this spike indicating the intracellular uptake of SMI#9 in SMI#9-GNP treated cells (Figure 
5.2; Panel F). Hydroxymethylation of SMI#9 enabled its conjugation to GNP via an ester bond 
(Figures 5.1 and 5.3; Panel Aa).  Intracellular hydrolysis would result in the release of modified 
SMI#9 with the molecular weight of 396.3, which would then produce parent ions at 397.3 
([M+H]+) and product ions at 150.1 (Figure 5.3; Panels Ab and Ac).  LC-MS/MS analysis of 
SUM1315 cells treated with SMI#9-GNP detected a strong peak under m/z 381.3 > 150.1 transition 
(but not under 397.3 > 150.1) at both 8 and 24 h that was not detected in blank-GNP or untreated 
control cultures (Figure 5.3; Panel C). Release of drug with 381.3 molecular mass could arise by 
dehydroxylation of hydroxymethylated-SMI#9. The precise structure of intracellularly released  
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FIGURE 5.1 Gold nanoparticle (GNP) synthesis. GNPs were capped with mercaptosuccinic 
acid (MSA) capping to promote SMI#9 binding. SMI#9 was hydroxymethylated to enable 
conjugation via a hydrolyzable ester bond to gold nanoparticles GNP. GNP synthesis and SMI#9 
conjugation were performed by our collaborators Yanhua Zhang, Ph.D. and Guangzhao Mao, 
Ph.D.  
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FIGURE 5.2 SMI#9-GNP characterization. (A) thermogravimetric analysis; (B) UV-vis 
spectroscopy; (C) transmission electron microscopy; (D) Atomic force microscopy (AFM). Da) 
AFM height of SMI#9-GNP, Z-range = 5 nm. Inset in Da shows a white line from where the 
AFM sectional height profile in Db was taken, and shows 39 nm particle width (two arrows). 
(E) Fourier transform infrared spectroscopy (FTIR) spectra of chloroform/methanol (11:1, v/v) 
without (green) and with SMI#9 (red). (F) FTIR spectra of SMI#9-GNP treated and control 
MDA-MB-231 lysates spiked with parent SMI#9. Arrow indicates nitro banding. Gold 
nanoparticle characterization was performed by our collaborators Yanhua Zhang, Ph.D. and 
Guangzhao Mao, Ph.D.  
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drug and its metabolic processing is under investigation. As the peak signals were stronger at 8 h 
as compared to 24 h, this may suggest rapid intracellular processing. The positive control cells 
treated with SMI#9 showed the expected peak under m/z 366.69 > 150.1 transition (Figure 5.3; 
Panel B). These results suggest efficient uptake and rapid intracellular processing of the chemically 
modified SMI#9-GNP conjugates.  
5.3.3 Cellular response to SMI#9-conjugated GNP 
To compare the sensitivities of MDA-MB-231, SUM1315, HCC1937, and MDA-MB-468 TNBC 
cells to SMI#9-GNP, MTT cell viability assays were performed. Whereas all TNBC cell lines are 
growth inhibited by free SMI#9 with IC50s for MDA-MB-231, SUM1315, HCC1937 and MDA-
MB-468 of 5 µM, 6 µM, 1.8 µM and 3 µM, respectively (Chapters 2 and 3), these cell lines display 
variable sensitivities to SMI#9-GNP (Figure 5.4; Panels A-D). Blank-GNP added at amounts 
equivalent to 1 or 10 µM SMI#9-GNP demonstrated negligible cytotoxicity in all four lines.  
MCF10A cells were unaffected by SMI#9-GNP (Figure 5.4; Panel E). Among the TNBC lines, 
SUM1315 cells displayed the greatest sensitivity to SMI#9-GNP with an GI50 (based on 
conjugated SMI#9 concentration) of ~0.5 µM as compared to 8.2 µM for MDA-MB-231 cells. 
Both the basal type HCC1937 and MDA-MB-468 cells were unaffected by SMI#9-GNP. 
Simultaneous phase-contrast imaging showed drug-induced morphologic transformations in the 
sensitized cells, corroborating MTT data (Figure 5.4; Panel G). Phase-contrast images of 
HCC1937 cells which are unaffected by SMI#9-GNP, showed aggregation of GNPs at the cell 
surface (Figure 5.4; Panel G). However, when combined with cisplatin, SMI#9-GNP 
synergistically increased cisplatin sensitivity of MDA-MB-468 and HCC1937 cells (Figure 5.4; 
Panel F), similar to free SMI#9 (Chapter 3). These data suggest that once imported into the cells, 
SMI#9-GNP is therapeutically active in basal subtype TNBC cells.   
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FIGURE 5.3. LC-MS/MS analysis of SMI#9 release. Aa) Chemical structures of parent 
SMI#9 (MW = 366.1), and GNP-conjugated hydroxymethylated SMI#9 (MW = 396.3). Ab) 
Predicted fragmentation of SMI#9 under the MS condition. Ac) Proposed mechanism of SMI#9 
release from GNP conjugate. B and C) Chromatograms of SUM1315 extracts prepared at 8 or 
24 h from untreated (control), or cells treated with blank-GNP (blank NP), 5 µM SMI#9 (B), 
or 5 µM SMI#9-GNP (C, 9-NP). Samples were monitored at m/Z 366.69 → 150.1 for SMI#9 
(B) or m/Z 381.3 → 150.1 for SMI#9 released from GNP (C). LC-MS/MS was performed by 
Jing Li, Ph.D. 
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5.3.4 SMI#9-GNP induces apoptosis 
  To verify whether the variable sensitivities of TNBC cells to SMI#9-GNP result from 
cytostatic or cytotoxic responses, cells were stained with the fluorescent DNA binding dyes 
acridine orange and ethidium bromide. With this assay, early stage apoptosis is marked by 
intercalated acridine orange within fragmented DNA [201] and late stage apoptosis is marked by 
apoptotic body separation and presence of reddish-orange color due to acridine orange binding to 
fragmented DNA [202].  Consistent with MTT data (Figure 5.4; Panel A), SUM1315 cells treated 
with SMI#9 and SMI#9-GNP underwent morphological changes consistent with apoptosis while 
cells treated with blank-GNP (at amounts equivalent to 5 µM SMI#9-GNP) were minimally 
affected (Figure 5.5; Panels A and C). In contrast, HCC1937 cells showed morphological 
alterations consistent with apoptosis in SMI#9 treated but not SMI#9-GNP treated, confirming 
SMI#9-GNP insensitivity of HCC1937 cells (Figure 5.5; Panels B and D).  
5.3.5. SMI#9-GNP alters mitochondrial membrane potential in responsive TNBC cells 
						 To test whether SMI#9-GNP-induced apoptosis occurred via the mitochondria we 
examined mitochondrial membrane potential (Dym). Dym is a marker of mitochondrial function 
and is thus used to monitor loss of mitochondrial function. SUM1315 and HCC1937 cells treated 
with free SMI#9, blank-GNP, or SMI#9-GNP were stained with the JC-1(5,5’,6,6’-tetrachloro-
1,1’,3,3’-tetraethylbenzimidazolylcarbocynane iodide) reagent. JC-1 is a lipophilic cationic dye 
which depending upon Dym accumulates in the cytoplasm as a green monomer or as punctate red 
aggregates in hyperpolarized mitochondria. The negative charge established by the mitochondrial 
membrane potential allows the lipophilic cationic dye to enter mitochondria where it accumulates 
[203]. When a critical concentration is exceeded, J-aggregates form, which fluoresces red. In 
apoptotic cells, Dym collapses, and the JC-1 is unable to accumulate in mitochondria. JC-1 thus 
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FIGURE 5.4 SMI#9-GNP is cytotoxic to TNBC cells. A-D) BRCA1 wild type MDA-MB-
231(A) and MDA-MB-468 (C) and BRCA1 mutant SUM1315 (B) and HCC1937 (D) TNBCs 
were treated with blank nanoparticles, SMI#9 or SMI9-GNP for 72 h. MTT assay was used to 
measure cell survival. E) MCF10A cells were treated with blank-GNP or SMI#9-GNP. Cells 
were trypsinized and viability was measure by trypan blue exclsion. Data are mean ± S.E.M. 
F) MDA-MB-468 and HCC1937 TNBCs were treated with cisplatin (CDDP), SMI#9-GNP or 
SMI#9-GNP + CDDP for 72 h. MTT assay was used to measure cell survival. GI50 values for 
cisplatin and SMI#9-GNP combination treatments. G) Representative phase contrast 
micrographs. Note the presence of internalized GNPs in SMI#9-GNP treated SUM1315 cells 
(inset), and GNP aggregates on HCC1937 cell surface.  
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remains in the cytoplasm as a green fluorescent monomer. SUM1315 and HCC1937 cells left 
untreated or treated with blank-GNP show heterogeneous punctate red and green fluorescence 
(Figure 5.5; Panels E and F). Overnight treatment with 1 µM free SMI#9 reduced J-aggregate 
formation in both SUM1315 and HCC1937 cells (Figure 5.5; Panels E and F). Additionally, 
occasional cells with mislocalized punctate red signals were observed in SMI#9-treated HCC1937 
cells (Figure 5.5; Panel F). However, consistent with MTT and acridine orange/ethidium bromide 
staining data, Dym of HCC1937 cells were unaffected by SMI#9-GNP treatment (Figure 5.5; 
Panel F). In contrast, the mitochondrial integrities of SUM1315 cells treated with free SMI#9 and 
SMI#9-GNP were similarly and dramatically compromised (Figure 5.5; Panel E; P < 0.5 for both). 
Quantitation of mitochondrial activity by manual scoring of J-aggregates (Figure 5.5; Panels G 
and H) and fluorescence measurements of red and green forms of JC-1 (Figure 5.5; Panel I) further 
confirmed that SMI#9-induced cell death occurs from loss of mitochondrial function, and 
importantly free and conjugated SMI#9 behave similarly to inhibit mitochondrial function and cell 
viability.  
5.3.6 SMI#9-GNP associates with lysosomes in mesenchymal TNBC cells  
We used SUM1315 and HCC1937 cells, as they were the most and least responsive to 
SMI#9-GNP respectively, to evaluate intracellular uptake of SMI#9-GNP. Internalization of 
nanoparticles is accomplished by endocytosis, transfer of cargo to early and mature endosomes, 
and fusion to become late endosomes/lysosomes [204-206]. To examine lysosomal uptake, 
SUM1315 or HCC1937 cells were left untreated or treated with SMI#9-GNP and stained with 
LysoSensor Green DND-189. LysoSensor Green DND-189 is an acidotropic dye that accumulates 
in intracellular acidic organelles, such as lysosomes, because of protonation and has a fluorescence 
intensity that is proportional to acidity [207, 208]. SUM1315 cells showed efficient SMI#9-GNP 
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FIGURE 5.5 SMI#9-GNP induces apoptosis and disrupts mitochondrial potential. A-B) 
SUM1315 (A) and HCC1937 (B) cells were treated with vehicle, SMI#9, blank-GNP or SMI#9-
GNP for 24 h and then stained with acridine orange/ethidium bromide. C-D) Quantitation of 
apoptotic/necrotic cells. E-F) JC-1 staining (red, J-aggregates; green, monomers) of SUM1315 
cells (E) and HCC1937 (F) cells. G-H) Quantitation of mitochondrial potential by manual 
scoring of SUM1315 (G) or HCC1937 (H) cells containing >5 J-aggregates, and by 
spectrofluorometery (I). Data are mean ± S.E.M. *P<0.05.  
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internalization as GNP aggregates were seen in lysosomes marked by the LysoSensor Green DND-
189 dye (Figure 5.6; Panel B). The overlapping of lysosomes with GNP aggregates and the strong 
sensitivity of SUM1315 cells to SMI#9-GNP suggest potential hydrolysis of the ester bond linked 
SMI#9-GNP and release of conjugated SMI#9 as supported by LC-MS/MS data (Figure 5.3). 
Though both control and SMI#9-GNP treated SUM1315 cells showed robust lysosomal staining 
(Figure 5.6; Panels A and B), formation of “acidic vesicles” (potentially indicative of 
autolysosome formation, a key feature of autophagy), was observed only in SMI#9-GNP treated 
SUM1315 cells (compare Figure 5.6 Panels A’ and B’). In contrast, HCC1937 cells showed weak 
staining with LysoSensor Green (Figure 5.6; Panels. C and D) suggesting weak acidification.  
5.3.7 SMI#9 and SMI#9-GNP induced cell death is associated with PARP-1 
stabilization/hyperactivation 
Since SMI#9 treatment induces apoptosis by causing mitochondrial dysfunction, we analyzed the 
steady-state levels of PARP-1 protein in TNBC cells treated for 24 h with vehicle, free SMI#9, 
blank-GNP or SMI#9-GNP. As shown in Figure 5.7 panel A, each cell line displayed unique 
PARP-1 processing, which was unaffected by blank-GNP and SMI#9-GNP. However, treatment 
with free SMI#9 resulted in PARP-1 stabilization/hyperactivation. Accumulation of PARP-1 
containing heterogeneous chain lengths of poly ADP-ribose (PARylated PARP-1) was observed 
in all cell lines, and appear to result from alterations in PARP-1 processing (Figure 5.7; Panel A). 
Since 24 h treatment with SMI#9-GNP did not evoke similar changes in PARP-1, we examined 
PARP-1 expression in SUM1315 cells treated with SMI#9-GNP for 24-96 h. Similar to free 
SMI#9, SMI#9-GNP also induces PARP-1 activation in these cells (Figure 5.7; Panel B ) These 
data suggest that both free and conjugated SMI#9 exert similar molecular effects on PARP-1 
activation; however, GNP-conjugated SMI#9 requires longer time to elicit this effect.  
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FIGURE 5.6 SMI#9-GNP is endocytosed by mesenchymal TNBC cells. Representative 
images of SUM1315 (A, A’, B, B’) and HCC1937 (C, D) cells treated with SMI#9-GNP (B, B’, 
D) or untreated (A, A’, C). Inset in B, enlarged view of GNP association with lysosomes (arrow). 
A’, B’, corresponding phase contrast micrographs of A and B, respectively. Arrow in B’ shows 
acidic vacuoles colocalizing with lysosomes. Scale bar, 5 mm. 
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A hallmark of autophagy is the conversion of the soluble form of LC3 (LC3-I) to the lipidated and 
autophagosome-associated form (LC3-II) [209]. High basal levels of LC3-I and LC3-II were 
observed in MDA-MB-231 cells compared to SUM1315 cells, suggesting the involvement of 
autophagic flux in normal survival of these cells (Figure 5.7; Panel B). Treatment for 24 h with 
free SMI#9 but not SMI#9-GNP downregulated both LC3-I and LC3-II in MDA-MB-231 cells 
(Figure 5.7; Panel B). Although changes in LC3-I processing was not immediately evident in 
SUM1315 cells treated for 24 h with free SMI#9 or SMI#9-GNP, a dramatic increase in LC3-I to 
LC3-II conversion was observed after 48 and 96 h of treatment that was commensurate with 
PARP-1 hyperactivation (Figure 5.7; Panel B). These effects are selective for SMI#9-GNP since 
treatment with blank-GNP for up to 96 h produced no changes in LC-3-I/II ratios or PARP-1 
activation (Figure 5.7; Panel B). Another marker of autophagy is p62. p62 is degraded through the 
autophagy-lysosomal pathway, a process that is mediated by its interaction with LC3 (37,38). 
Consistent with western blot data, LC3-positive foci were detected by immunofluorescence 
staining only in SMI#9-GNP treated SUM1315 cells (Figure 5.7 Panel D, arrow), whereas strongly 
stained p62-positive bodies were detected in control cells but not in SMI#9-GNP treated cells 
(Figure 5.7; Panel E). The coincident increases in PARP-1 hyperactivation, LC-I to LC3-II 
conversion, and p62 decrease in SMI#9-GNP treated cells signify cell death that is further 
supported by MTT assays (Figure 5.4; Panel A), phase-contrast micrographs (Figures 5.4; Panel 
G and 5.7; Panel C), and the presence of lysosome-associated acidic vesicles (Figures 5.6 Panel 
B’, arrows) in SMI#9-GNP treated but not control cells. As Rad6 activity is inhibited under these 
conditions, these data suggest an important role for Rad6 activity in assuring survival of cancer 
cells. 	
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FIGURE 5.7 SMI#9 and SMI#9-GNP induce PARP-1 stabilization/hyperactivation. A-B) 
Whole cell lysates collected from MDA-MB-231, SUM1315, and HCC1937 cells treated with 
control, blank-GNP, SMI#9 or SMI#9-GNP were subjected to western blot analysis of indicated 
proteins. Arrows in A and the bracket in B show high molecular weight PARP-1. Blot below B, 
longer exposure of PARP-1 blot in B. C) Representative phase-contrast images of SUM1315 
cells. D-E) SUM1315 cells treated with control or SMI#9-GNP were fixed and immunostained 
for LC3 (D; green) or p62 (E; red) Cells were stained with DAPI (blue) to locate the nucleus. 
LC-positive dots indicated by arrow. Panels D contributed by Sarah Petit, B.S. 
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5.4 Discussion 
In this chapter, we have expounded upon the therapeutic benefit of SMI#9 through its 
conjugation to a GNP-based vehicle for delivery. We demonstrated that upon uptake, the GNP 
tethered chemically modified SMI#9 is released from GNP and the released SMI#9 acts similarly 
to that of free parent SMI#9. Whereas SMI#9-GNP sensitized both BRCA1 wild type and BRCA1 
mutant TNBCs, we did observe subtype dependent responses to SMI#9-GNP. Unlike the 
mesenchymal TNBC subtype (SUM1315 and MDA-MB-231) cells, which show sensitivity to 
SMI#9-GNP, the basal TNBC subtype (MDA-MB-468 and HCC1937) cells are refractory to 
SMI#9-GNP. We show that the higher efficacy of SMI#9-GNP in SUM1315 and MDA-MB-231 
cells results from efficient endocytosis and lysosomal processing of SMI#9-GNP. SMI#9-GNP 
uptake and cellular response are compromised in HCC1937 and MDA-MB-468 cells due to 
aggregation at the cell surface. Theoretical models predict the optimal diameter for GNP uptake to 
be ~50 nm in receptor-mediated endocytosis [210-214]. The larger aggregates found in HCC1937 
and MDA-MB-468 cells may require more interactions to enable wrapping of membrane around 
the aggregates [212, 214, 215]. It should be noted that although all TNBC cells were cultured under 
similar conditions and with similar amounts of SMI#9-GNP, SMI#9-GNP aggregation occurred 
only in the basal subtype, suggesting local microenvironment involvement in particle aggregation.  
      Reduced cellular uptake in basal cells was verified by LysoSensor Green DND-189 staining 
which accumulates in intracellular acidic organelles due to protonation and has a fluorescence 
intensity that is proportional to acidity [207, 208]. In SUM1315 cells, SMI#9-GNP localized in 
strongly fluorescing lysosomes, whereas similar staining of HCC1937 cells showed weak 
LysoSensor Green fluorescence. Ma et al. [216] recently reported a GNP size-dependent 
alkalinization of lysosomes, which is consistent with the presence of large SMI#9-GNP aggregates 
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and weak fluorescence of LysoSensor Green DND-189 dye in HCC1937 cells. On a broad scale, 
we observed that in the mesenchymal TNBC subtype where SMI#9-GNP exists in a 
monodispersed or lower order of aggregation, SMI#9-GNP is endocytosed efficiently and 
hydrolyzed to release the conjugated drug. Although SMI#9-GNP uptake is impaired in basal 
subtype TNBC cells, when combined with cisplatin treatment SMI#9-GNP is effectively imported 
as it synergistically enhances cisplatin sensitivity. These data implicate the universal applicability 
of SMI#9-GNP in treatment of TNBCs as treatment regimens generally employ combination 
therapies. Since MCF10A cells are unaffected by both free and GNP-conjugated SMI#9, suggests 
that SMI#9-GNP may be used to deliver therapy to cancer cells while sparing normal cells. 
     Our mechanistic studies show that both SMI#9 and SMI#9-GNP induce apoptosis by affecting 
mitochondrial integrity. Cellular staining with JC-1, a potentiometric stain used to assess 
mitochondria membrane potential, showed pools of healthy mitochondria in SMI#9-GNP 
refractory HCC1937 cells whereas SMI#9-GNP sensitive SUM1315 cells showed enhanced 
mitochondrial depolarization after SMI#9-GNP treatment. Further, both free SMI#9 and SMI#9-
GNP drastically altered mitochondrial structure in SUM1315 cells. A role for Rad6 in the 
maintenance of healthy mitochondria was recently reported [197]. Here the authors showed that 
the UBC activity of Rad6A in combination with Parkin E3 ubiquitin ligase ubiquitinates 
mitochondrial proteins to facilitate autophagic clearance of dysfunctional mitochondria [197]. 
Patient derived human Rad6A mutant cells with defective UBC activity had accumulation of 
defective mitochondria [197]. Since SMI#9 targets Rad6 UBC activity and cells treated with free 
or GNP-tethered SMI#9 show accumulation of dysfunctional mitochondria, these data not only 
corroborate the role of Rad6 in mitochondrial function but also provide mechanistic evidence for 
SMI#9-GNP functionality. Treatment of TNBC cells with SMI#9 induces apoptosis, autophagy 
138	
	
and necrosis. Based on our data, we have formulated a model (Figure 5.8) that could explain cell 
death caused by Rad6 inhibition in this context. Rad6 along with Parkin facilitates the removal of 
dysfunctional mitochondria by autophagy. Thus, the low levels of autophagy in control cells 
promote cell survival by eliminating damaged organelles and preventing apoptosis. SMI#9 
treatment causes accumulation of damaged mitochondria which triggers upregulation of 
autophagy, an attempt by the cells to clear damaged organelles and rescue cell survival. However, 
excessive autophagy combined with mitochondrial permeabilization induces apoptosis as it 
promotes the release of apoptogenic factors involved in caspase-dependent or caspase-independent 
cell death. Our study showed that in both SMI#9- and SMI#9-GNP-induced apoptosis, PARP-1 
cleavage is not observed. Rather PARP-1 is stabilized/hyperactivated indicating caspase-
independent apoptosis [217, 218]  and necrosis from energy depletion [219, 220]. Since both Rad6 
loss [197] and PARP-1 hyperactivation [221] are associated with mitochondrial dysfunction, and 
inhibition of Rad6 by SMI#9 induces both mitochondrial dysfunction and PARP-1 activation, our 
data implicate a potential novel role for Rad6 linking these processes. 
      In summary, the data presented in this chapter show that GNPs are suitable vehicles for 
delivering SMI#9 and that the chemically modified SMI#9 released from GNPs functions similarly 
to the free parent SMI#9. Our data also show distinct differences in uptake and tolerability of 
SMI#9-GNP between basal and mesenchymal subtypes of TNBC cells that emanate from cell-
specific microenvironment-induced effects on SMI#9-GNP aggregation. Although the SMI#9-
GNP aggregates are nontoxic, these data are significant because it illustrates how cell 
microenvironments can induce alterations in the physical properties of GNP-drug conjugates and 
influence their anti-cancer efficacies. However, our data shows combination treatment with 
inhibition of Rad6 by SMI#9 induces both mitochondrial dysfunction and PARP-1 activation, our  
139	
	
  
FIGURE 5.8 Model of SMI#9-induced cell death. Dysfunctional mitochondria are removed 
by Rad6 mediated autophagy. Damage mitochondria accumulate with the loss of Rad6 activity, 
triggering escalation of autophagy to clear damaged organelles and rescue cell survival. 
Excessive autophagy combined with mitochondrial permeabilization promotes caspase-
dependent or caspase-independent apoptosis. SMI#9 induces PARP-1 
stabilization/hyperactivation. Combined with mitochondrial dysfunction, PARP-1 
stabilization/hyperactivation contributes to NAD+ and ATP depletion and necrosis.  
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data implicate a potential novel role for Rad6 linking these processes. 
       In summary, the data presented in this chapter show that GNPs are suitable vehicles for 
delivering SMI#9 and that the chemically modified SMI#9 released from GNPs functions similarly 
to the free parent SMI#9. Our data also show distinct differences in uptake and tolerability of 
SMI#9-GNP between basal and mesenchymal subtypes of TNBC cells that emanate from cell-
specific microenvironment-induced effects on SMI#9-GNP aggregation. Although the SMI#9-
GNP aggregates are nontoxic, these data are significant because it illustrates how cell 
microenvironments can induce alterations in the physical properties of GNP-drug conjugates and 
influence their anti-cancer efficacies. However, our data shows combination treatment with 
cisplatin overcomes reduced efficacy seen with SMI#9-GNP aggregation, possibly due to 
cisplatin-induced disruption of the cellular membrane resulting in SMI#9-GNP uptake. As many 
therapies are given in combination, aggregation of SMI#9-GNP does not limit its potential as a 
therapeutic option for both BRCA1 wild type and BRCA1 mutant TNBCs. 
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CHAPTER 6-CONCLUSIONS 
	
This body of work aims to define the role of Rad6 in TNBC drug response. As TNBCs lack 
the therapeutic targets estrogen receptor, progesterone receptor, and Her2/neu receptor 
amplification they are difficult to treat clinically. Cisplatin, a DNA damaging agent, is currently 
under clinical investigation for treatment of TNBCs, and paclitaxel, a mitotic spindle poison, is a 
first-line treatment option for this disease. While both of these compounds show therapeutic 
efficacy, BRCA1 mutation status, toxicity, and resistance are limiting factors.  
Rad6 functions as an E2 ubiquitin-conjugating enzyme and its enzymatic activity is 
required for its cellular functions. While Rad6 has two isoforms, Rad6A and Rad6B, encoded by 
distinct genes in humans, our laboratory has previously shown that Rad6B overexpression 
contributes to breast cancer development and progression.  Rad6 plays an integral role in DNA 
damage tolerance and its ubiquitin-conjugating activity is critical for this function as mutations in 
the Rad6 catalytic site induces hypersensitivity to ionizing and UV radiations, as well as alkylating 
and DNA crosslinking agents. Our laboratory has previously shown that Rad6 is associated with 
centrosomes at all phases of the cell cycle and that constitutive overexpression of Rad6B results 
in centrosome amplification, multiple mitotic spindles and aneuploidy. As the major molecular 
targets of cisplatin and paclitaxel are DNA and mitotic spindles, respectively, we hypothesized 
that Rad6 expression influences drug response of TNBCs to DNA damaging agents and 
microtubules stabilizing agents by regulating DNA damage repair pathways and centrosome 
function. Therefore, targeting Rad6 could offer sustained therapeutic benefit to TNBC patients. To 
evaluate the role of Rad6 in these processes, we utilized a novel Rad6-selective small molecular 
inhibitor, SMI#9, developed and characterized by our laboratory. SMI#9 inhibits the ubiquitin-
conjugating activity of Rad6. Additionally, SMI#9 induces G2/M arrest, and inhibits cell 
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proliferation and migration of MDA-MB-231 TNBC cells, while having no effect on normal 
behaving MCF10A cells.  
The first portion of this dissertation focuses on analyzing the functional role of Rad6 in the 
repair of cisplatin-induced DNA lesions (chapter 2) and its relevance in BRCA1 wild type and 
BRCA1 mutant TNBC cells (Chapter 3).  In these chapters, we show a direct role for the Rad6 
ubiquitin-conjugating activity in coordinating the activities of TLS, FA and HR in response to 
cisplatin. We demonstrate that Rad6 is overexpressed in TNBC cells lines, regardless of BRCA1 
status, and that Rad6B expression rather than Rad6A correlates with decreased TNBC patient 
survival, and breast cancer progression. We also show that BRCA1 status does not impact cisplatin 
response, and SMI#9 synergistically enhances cisplatin sensitivities in these cells. This 
sensitization is associated with suppression of cisplatin-induced FANCD2 and PCNA 
monoubiquitinations, as well as cisplatin-induced foci formation of critical TLS, FA, and HR 
proteins including gH2AX, PCNA, Pol h, FANCD2, Rad51 and Rad6. Additionally, the 
colocalization of PCNA/FANCD2, PCNA/Pol h, PCNA/Rad6, and FANCD2/Pol h is disrupted 
by SMI#9 treatment. We also demonstrate that SMI#9 diminishes colocalization of FANCD2, Pol 
h and Rad51 with gH2AX, a surrogate marker of replication fork restart. We show a requirement 
for Rad6 in overcoming cisplatin-induced replication fork stalling and clearing of cisplatin-
induced lesions as Rad6 inhibition blocked replication fork restart and removal of cisplatin 
adducts. Consistent with these results, in vivo assays showed that SMI#9 treatment inhibits 
proliferation and tumor growth of MDA-MB-231 TNBC cells, and enhances their sensitivity to 
cisplatin. Additionally, our data from an isogenic colon cancer model of oxaliplatin resistance 
showed that oxaliplatin induces PCNA and FANCD2 monoubiquitinations in the parental HCT116 
colon cancer cells whereas these proteins are constitutively monoubiquitinated in their oxaliplatin-
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resistant (HCT116-OxR) counterpart indicating upregulated Rad6/TLS activity in oxaliplatin 
resistance. SMI#9 treatment restores sensitivity of HCT116-OxR cells to oxaliplatin. To directly 
link Rad6 to the HR pathway, we used BRCA1 wild type HeLa cells stably transfected with a DR-
GFP vector which requires HR at the I-Sce1 induced double strand break site to generate a 
functional GFP. Whereas cisplatin induced HR, SMI#9 pretreatment reduced HR efficiency in 
these cells. Taken together, our data from chapters 2 and 3 of this dissertation imply a critical role 
for Rad6 in promoting the activities of TLS, FA and HR in the repair of cisplatin-induced DNA 
damage and suggest that inhibition of Rad6 catalytic activity may be clinically beneficial for 
sensitizing BRCA1 wild type and BRCA1 mutant TNBCs to platinum-based therapies. 
In Chapter 4 of this dissertation, we focused on the role of Rad6 at the centrosome. Our 
data showed that while BRCA1 status did not impact PTX response, SMI#9 treatment 
synergistically enhanced PTX sensitivity in both BRCA1 wild type and BRCA1 mutant TNBC 
cell lines. Additionally, it appears that this sensitization is related to the ability of SMI#9 to 
enhance PTX-induced G2/M arrest and mitotic catastrophe. Additionally, we found that SMI#9 
alters cyclin B1 protein expression, with cyclin B1 accumulation in PTX sensitive MDA-MB-468 
cells and cyclin B1 loss in PTX resistant HCC1937 cells. Further, SMI#9-induced PTX 
sensitization is associated with reduced expressions of 1N3R and 0N4R isoforms of tau (a protein 
whose overexpression is associated with PTX resistance), and increases in the proportion of cells 
with monopolar mitotic spindles.  Utilizing an isogenic model of PTX resistance, we also 
demonstrated the ability of Rad6 inhibitor to restore PTX sensitivity in MDA-MB-468-PTXR 
cells. The data presented in chapter 4 establish a role for Rad6 in centrosome duplication and/or 
segregation, and the potential therapeutic benefit of inhibiting Rad6 in PTX combination 
treatments of TNBCs. 
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The final chapter of this dissertation focused on overcoming the solubility limitations of 
SMI#9. To this end, we modified SMI#9 to allow for its conjugation to GNPs via an ester bond to 
facilitate intracellular drug delivery. SMI#9-GNPs were characterized for purity, ligand 
concentration, and efficiency of ligand conjugation (TGA), size (AFM, TEM, UV-Vis 
spectroscopy, and zeta sizer), and cellular uptake and drug release (FTIR and mass spectrometry).  
The activities of SMI#9-GNP and free SMI#9 for cytotoxicity and intracellular localization were 
compared in BRCA1 wild type and BRCA1 mutant TNBC cells, and in nontransformed MCF10A 
cells. We showed that while SMI#9-GNP and SMI#9 exhibited similar effects regardless of the 
BRCA1 status, differences in responses to SMI#9-GNP occurred between the mesenchymal and 
basal subtypes of TNBC cells with mesenchymal TNBC cells being more effective. However, we 
show that this lack of efficacy can be reversed with cisplatin co-treatment. MCF10A cells were 
unaffected by both free and SMI#9-GNP. Consistent with cellular sensitivities, we showed that 
SMI#9-GNP is efficiently endocytosed and processed in lysosomes in mesenchymal TNBC cells, 
while uptake into basal TNBC cells is compromised by cell microenvironment induced SMI#9-
GNP aggregation. Additionally, SMI#9-GNP treatment induces apoptosis, triggered by disruption 
of the mitochondrial membrane potential, in mesenchymal TNBC cells but not basal TNBCs. 
Commensurate with these effects, SMI#9-GNP treatment induced stabilization of PARP1 and 
autophagy. Free SMI#9 induced similar effects on mitochondria and PARP1 stabilization. These 
data support a novel role for Rad6 in linking mitochondrial dysfunction and PARP1 stabilization 
as well as demonstrate that conjugation of SMI#9 to GNPs does not disrupt its therapeutic function, 
as SMI#9-GNP can sensitize mesenchymal and basal TNBC cells to cisplatin regardless of their 
BRCA1 status. 
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Taken together, the data presented in this dissertation demonstrate an integral functional 
role for Rad6 in the repair of platinum-induced DNA damage, through its function in coordinating 
TLS, FA and HR repair pathways, and in centrosome duplication and/segregation. Due to the 
important role of Rad6 in these processes, inhibition of Rad6 with SMI#9 could be leveraged to 
enhance therapeutic benefits of cisplatin and PTX in treatment of BRCA1 wild type and BRCA1 
mutant TNBCs.   
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ABSTRACT 
 
FUNCTIONAL ANALYSIS OF RAD6 IN BRCA1 WILD TYPE AND BRCA1 MUTANT 
TRIPLE NEGATIVE BREAST CANCER DRUG RESPONSE 
by 
BRITTANY MICHELLE HAYNES 
December 2017 
Advisor: Dr. Malathy Shekhar 
Major: Cancer Biology 
Degree: Doctor of Philosophy 
TNBCs account for 15-20% of all breast and are unsuitable for common targeted therapies 
as they lack expression of estrogen, progesterone, and Her2/neu receptors. Cisplatin, a DNA 
damaging agent, is currently under clinical investigation for treatment of TNBCs and paclitaxel, a 
mitotic spindle poison, is a first-line treatment option for this disease. While both agents elicit 
therapeutic benefit BRCA1 mutation status, toxicity, and resistance are limiting factors. Rad6 
functions as an E2 ubiquitin conjugating protein and its enzymatic activity is critical for its cellular 
function. Rad6 is known to play a critical role in the translesion synthesis (TLS) damage response 
pathway and we have shown constitutive Rad6 overexpression induces aneuploidy and multiple 
mitotic spindles. Our laboratory has recently reported the development of a novel Rad6 small 
molecular inhibitor, SMI#9, shown to inhibit Rad6 enzymatic activity and elicit cytotoxic affects 
in TNBC cells while having no effect on normal behaving MCF10A breast cells. In this 
dissertation, we show Rad6 is overexpressed in both BRCA1 wild type and BRCA1 mutant 
TNBCs. Data presented here show that treatment with SMI#9 enhances sensitivity and reverts 
resistance of TNBC cells to both cisplatin and paclitaxel, regardless of BRCA1 status. We show 
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that SMI#9 mediated cisplatin sensitivity is associated with inhibition of the Rad6 TLS and 
attenuation of cisplatin-induced activation of FA network and HR repair pathway, implicating a 
central role for Rad6 in coordinating activities of these pathways. We also demonstrate that SMI#9 
induced paclitaxel sensitivity corresponds with monopolar mitotic spindle formation and mitotic 
catastrophe, establishing a role for Rad6 in centrosome duplication/segregation and/or mitotic 
spindle nucleation. To overcome SMI#9 solubility limitations, we conjugated SMI#9 to gold 
nanoparticles. We present data to show similar efficacies and cellular responses in TNBC cells 
between unconjugated and gold nanoparticle conjugated SMI#9. These data implicate Rad6 as a 
potential regulator of TNBC drug response and provide support for the therapeutic benefit of 
SMI#9.  
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